AU2016204968B2

AU2016204968B2 - FGF21 mutants and uses thereof

Info

Publication number: AU2016204968B2
Application number: AU2016204968A
Authority: AU
Inventors: Edward John Belouski; Murielle Marie Ellison; Agnes Eva Hamburger; Randy Ira Hecht; Yue-Sheng Li; Mark Leo Michaels; Jeonghoon Sun; Jing Xu
Original assignee: Amgen Inc
Current assignee: Amgen Inc
Priority date: 2008-06-04
Filing date: 2016-07-15
Publication date: 2018-03-01
Anticipated expiration: 2029-06-03
Also published as: AU2014201837A1; AU2014201837B2; AU2011253868A1; AU2016204968A1

Abstract

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such 5 nucleic acids, polypeptides, or pharmaceutical compositions.

Description

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

2016204968 15 Jul2016

FGF21 MUTANTS AND USES THEREOF

The present application is a divisional application of Australian Application No. 2014201837, which is incorporated in its entirety herein by reference.

BACKGROUND OF THE INVENTION

1. Field of the invention

The invention relates to nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

2. Background of the Invention

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

FGF21 is a secreted polypeptide that belongs to a subfamily of fibroblast growth 15 factors (FGFs) that includes FGF19, FGF21, and FGF23 (Itoh et at., 2004, Trend

Genet. 20: 563-69). FGF21 is an atypical FGF in that it is heparin independent and functions as a hormone in the regulation of glucose, lipid, and energy metabolism. FGF21 was isolated from a liver cDNA library as a hepatic secreted factor. It is highly expressed in liver and pancreas and is the only member of the FGF family to be primarily expressed in liver. Transgenic mice overexpressing FGF21 exhibit metabolic phenotypes of slow growth rate, low plasma glucose and triglyceride levels, and an absence of age-associated type 2 diabetes, islet hyperplasia, and obesity. Pharmacological administration of recombinant FGF21 protein in rodent and primate models results in normalized levels of plasma glucose, reduced triglyceride and cholesterol levels, and improved glucose tolerance and insulin sensitivity. In addition, FGF21 reduces body weight and body fat by increasing energy expenditure, physical activity, and metabolic rate. Experimental research provides support for the

2016204968 13 Sep 2016

- 2 pharmacological administration of FGF21 for the treatment of type 2 diabetes, obesity, dyslipidemia, and other metabolic conditions or disorders in humans.

Human FGF21 has a short half-life in vivo. In mice, the half-life of human FGF21 is 1 to 2 hours, and in cynomolgus monkeys, the half-life is 2.5 to 3 hours. In developing an FGF21 protein for use as a therapeutic in the treatment of type 2 diabetes, an increase in half-life would be desirable. FGF21 proteins having an enhanced half-life would allow for less frequent dosing of patients being administered the protein. Such proteins are described herein.

SUMMARY OF THE INVENTION

According to a first aspect, the present invention provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 4, further comprising substitution of the amino acid at position 180 with a glycine, proline, serine or glutamic acid residue.

According to a second aspect, the present invention provides a fusion polypeptide comprising the isolated polypeptide according to the first aspect, fused to a heterologous amino acid sequence.

According to a third aspect, the present invention provides a multimer comprising two or more polypeptides according to the second aspect.

According to a fourth aspect, the present invention provides a pharmaceutical composition comprising the polypeptide according to the first or second aspect and a pharmaceutically acceptable formulation agent.

According to a fifth aspect, the present invention provides an isolated nucleic acid encoding a polypeptide according to the first or second aspect.

According to a sixth aspect, the present invention provides a vector comprising the nucleic acid according to the fifth aspect.

According to a seventh aspect, the present invention provides a host cell comprising the nucleic acid according to the fifth aspect, or the vector according to the sixth aspect.

2016204968 13 Sep 2016

- 2aAccording to an eighth aspect, the present invention provides a method for:

(a) treating type 2 diabetes in a subject;

(b) reducing triglyceride levels in a subject;

(c) improving glucose tolerance in a subject;

(d) lowering body weight in a subject; or (e) lowering insulin levels in a subject, the method comprising administering to the subject the polypeptide according to the first or second aspect or the pharmaceutical composition according to the fourth aspect.

According to a ninth aspect, the present invention provides use of the polypeptide according to the first or second aspect for the manufacture of a medicament for:

(a) treating type 2 diabetes in a subject;

(b) reducing triglyceride levels in a subject;

(c) improving glucose tolerance in a subject;

(d) lowering body weight in a subject; or (e) lowering insulin levels in a subject.

Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise”, “comprising”, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”.

The present disclosure provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO:4, further comprising the substitution of any amino acid for: the alanine residue at position 45, the leucine residue at position 86, the leucine residue at position 98, the alanine residue at position 111, the alanine residue at position 129, the glycine residue at position 170, the proline residue at position 171 or the serine residue at position 172, and combinations thereof. In one embodiment the isolated polypeptide comprises the substitution of any amino acid for: the leucine residue at position 98, the proline residue at 171 or both the leucine residue at position

98 and the proline residue at position 171. In another embodiment the isolated polypeptide comprises the substitution of any amino acid for both the leucine residue at position 98 and the proline residue at position 171.

The present disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 4 having: (a) at least one amino acid substitution that is: (i) a glutamine, isoleucine, or lysine residue at position 19; (ii) a histidine, leucine, or phenylalanine residue at position 20; (iii) an isoleucine, phenylalanine,

2016204968 13 Sep 2016

-2btyrosine, or valine residue at position 21; (iv) an isoleucine, phenylalanine, or valine residue at position 22; (v) an alanine or arginine residue at position 150; (vi) an alanine or valine residue at position 151; (vii) a histidine, leucine, phenylalanine, or valine residue at position 152; (viii) an alanine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, proline, or serine residue at position 170; (ix) an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, lysine,

2016204968 15 Jul2016 tryptophan, or tyrosine residue at position 171; (x) a leucine or threonine residue at position 172; or (xi) an arginine or glutamic acid residue at position 173; and (b) at least one amino acid substitution that is: (i) an arginine, glutamic acid, or lysine residue at position 26; (ii) an arginine, glutamic acid, glutamine, lysine, or threonine residue at position 45; (iii) a threonine residue at position 52; (iv) a cysteine, glutamic acid, glycine, or serine residue at position 58; (v) an alanine, arginine, glutamic acid, or lysine residue at position 60; (vi) an alanine, arginine, cysteine, or histidine residue at position 78; (vii) a cysteine or threonine residue at position 86; (viii) an alanine, arginine, glutamic acid, lysine, or serine residue at position 88; (ix) an arginine, cysteine, glutamic acid, glutamine, lysine, or threonine residue at position 98; (x) an arginine, aspartic acid, cysteine, or glutamic acid residue at position 99; (xi) a lysine or threonine residue at position 111; (xii) an arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, or lysine residue at position 129; or (xiii) an arginine, glutamic acid, histidine, lysine, or tyrosine residue at position 134; and combinations thereof. In one embodiment the residue at position 98 is arginine and the residue at position 171 is proline, and in another embodiment the polypeptide can comprise an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO; 4, but wherein the at least one amino acid substitution of (a)(i)-(xi) and (b)(i)-(xiii) is not further modified.

The present disclosure additionally provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 4 having at least one amino acid substitution that is: (a) a glutamine, lysine or isolcucinc residue at position 19; (b) a histidine, leucine, or phenylalanine residue at position 20; (c) an isoleucinc, phenylalanine, tyrosine, or valine residue at position 21; (d) an isoleucinc, phenylalanine, or valine residue at position 22;

(c) an alanine or arginine residue at position 150; (f) an alanine or valine residue at position 151; (g) a histidine, leucine, phenylalanine, or valine residue at position 152; (h) an alanine, aspartic acid, cysteine, or proline residue at position 170; (i) an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, lysine, serine, threonine, tryptophan, or tyrosine residue at position 171; (j) a leucine residue at position 172; or (k) an arginine or glutamic acid residue at position 173; and combinations thereof. In one embodiment the residue at position 171 is proline, and in another embodiment the polypeptide can comprise an amino acid sequence that is at least

2016204968 15 Jul2016 percent identical to the amino acid sequence of SEQ ID NO: 4, but wherein the at least one amino acid substitution of (a)-(k) is not further modified.

The present disclosure further provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 4 having at least one amino acid substitution that is:

(a) an arginine, glutamic acid, or lysine residue at position 26; (b) an arginine, glutamic acid, glutamine, lysine, or threonine residue at position 45; (c) a threonine residue at position 52; (d) a glutamic acid, glycine, or serine residue at position 58; (c) an alanine, arginine, glutamic acid, or lysine residue at position 60; (f) an alanine, arginine, or histidine residue at position 78; (g) an alanine residue at position 88; (h) an arginine, glutamic acid, glutamine, lysine, or threonine residue at position 98; (i) an arginine, aspartic acid, cysteine, or glutamic acid residue at position 99; (j) a lysine or threonine residue at position 111; (k) an arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, or lysine residue at position 129; or (1) an arginine, glutamic acid, histidine, lysine, or tyrosine residue at position 134; and combinations thereof. In one embodiment, the residue at position 98 is arginine and in another embodiment the polypeptide can comprise an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 4, but wherein the at least one amino acid substitution of (a)-(l) is not further modified.

In various embodiments, the polypeptides disclosed herein can further comprise at least one amino acid substitution that is: (a) a phenylalanine, proline, alanine, serine or glycine at position 179; (b) a glutamic acid, glycine, proline, or serine at position 180; or (c) a lysine, glycine, threonine, alanine, leucine, or proline at position 181 and can further comprise 1 to 10 amino acid residues fused to the C-terminus of the polypeptide, and can be any amino acid, for example, one or more residues selected from the group consisting of glycine, proline and combinations thereof.

In various embodiments, the polypeptides disclosed herein can comprise (a) an amino-terminal truncation of no more than 8 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; (b) a carboxyl-terminal truncation of no more than 12 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; or (c) an amino-terminal truncation of no more than 8 amino acid residues and a carboxyl-terminal truncation of no more than 12 amino

2016204968 15 Jul2016 acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal.

In some embodiments, the polypeptides disclosed herein can be covalently linked to one or more polymers, such as PEG. In other embodiments, the polypeptides of the present invention can be fused to a heterologous amino acid sequence, optionally via a linker, such as GGGGGSGGGSGGGGS (SEQ ID NO: 23), The heterologous amino acid sequence can be an IgG constant domain or fragment thereof, such as the amino acid sequence of SEQ ID NO: 13. Such fusion polypeptides disclosed herein can also form multimers.

The present disclosure also provides pharmaceutical compositions comprising the polypeptides disclosed herein and a pharmaceutically acceptable formulation agent. Such pharmaceutical compositions can be used in a method for treating a metabolic disorder, and the method comprises administering to a human patient in need thereof a pharmaceutical composition of the present invention. Metabolic disorders that can be treated include diabetes and obesity.

Also provided arc isolated nucleic acid molecules encoding the polypeptides of disclosed herein, as well as vectors comprising such nucleic acid molecules and host cells comprising such nucleic acid molecules.

Truncated forms of the polypeptide of SEQ ID NO:4 arc also disclosed. In various embodiments the polypeptide can comprise: (a) an amino-terminal truncation of no more than 8 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; (b) a carboxyl-terminal truncation of no more than 12 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; or (c) an amino-terminal truncation of no more than 8 amino acid residues and

5 a carboxyl-terminal truncation of no more than 12 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal.

The present disclosure additionally provides an isolated fusion protein that can comprise: (a) an IgG constant domain; (b) a linker sequence fused to the IgG constant domain; and (c) an FGF21 mutant fused to the linker sequence and comprising the amino acid sequence of SEQ ID NO: 4 wherein the an arginine residue has been substituted for the leucine residue at position 98 and a glycine residue has been substituted for the

2016204968 15 Jul2016 proline residue at position 171. In one embodiment, the linker sequence can comprise GGGGGSGGGSGGGGS (SEQ ID NO:23) and in another the lgG constant domain can comprise SEQ ID NO: 13. In another embodiment, the linker sequence comprises GGGGGSGGGSGGGGS (SEQ ID NO:23) and the IgG constant domain comprises the amino acid sequence of SEQ ID NO: 13. In still another embodiment the N terminus of the linker is fused to the C terminus of the IgG constant domain and the N terminus of the FGF21 mutant is fused to the C terminus of the linker. The disclosed fusion proteins can form multimers.

In various embodiments of the fusion protein, the FGF21 mutant component can 10 comprise at least one amino acid substitution that is: (a) a phenylalanine, proline, alanine, serine or glycine at position 179; (b) a glutamic acid, glycine, proline, or serine at position 180; or (c) a lysine, glycine, threonine, alanine, leucine, or proline at position 181 and can further comprise 1 to 10 amino acid residues fused to the C-terminus of the FGF21 mutant, and the 1 to 10 amino acid residues, and can be any amino acid, for example, one or more residues selected from the group consisting of glycine, proline and combinations thereof.

In still other embodiments of the fusion protein, the FGF21 mutant component can comprise: (a) an amino-terminal truncation of no more than 8 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; (b) a carboxyl-terminal truncation of no more than 12 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; or (c) an amino-terminal truncation of no more than 8 amino acid residues and a carboxyl-terminal truncation of no more than 12 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal. In another embodiment, the FGF21 mutant component of a fusion protein can comprise an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 4, but wherein the arginine and glycine residues arc not further modified.

The present disclosure also provides pharmaceutical compositions comprising the fusion protein disclosed herein and a pharmaceutically acceptable formulation agent.

Such pharmaceutical compositions can be used in a method for treating a metabolic disorder, the method comprising administering to a human patient in need thereof a

2016204968 15 Jul2016 pharmaceutical composition of the present invention. Metabolic disorders that can be treated include diabetes and obesity.

Also provided are isolated nucleic acid molecules encoding the fusion protein disclosed herein, as well as vectors comprising such nucleic acid molecules and host cells comprising such nucleic acid molecules.

Specific embodiments of the present invention will become evident from the following more detailed description of certain embodiments and the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures I A-IB show the results of an ELK-lucifcrasc activity assay performed on the FGF21 truncation mutants 7-181 and 8-181 (Figure 1A) and the FGF21 truncation mutants 1-172, 1-171, 1-169, and 1-164 (Figure IB); each panel shows the results obtained for a human FGF21 control.

Figure 2 shows the results of an ELK-lucifcrasc activity assay performed on a human FGF21 control and the FGF21 truncation mutants 3-181, 4-181, 5-181, 7-181, 8181, 1-180, 1-178, 1-177, 1-176, 1-175, 1-174, 1-173, 1-172, 9-181, and 1-149.

Figure 3 shows the blood glucose levels measured in mice injected with PBS (solid bar), human FGF21 control (open bar), or the FGF21 truncation mutants 8-181 (gray bar) and 9-181 (stippled bar),

Figure 4 shows the percent change in blood glucose levels measured in mice injected with PBS (solid circles), an Fc-FGF21 control (WT) (open circles), or truncated Fc-FGF21 fusion proteins comprising amino acid residues 5-181 (solid triangles) or 7181 (open triangles).

Figure 5 shows the percent change in blood glucose levels measured in mice injected with PBS (solid circles), an FGF21-Fc control (WT) (open circles), a truncated FGF21-Fc fusion protein comprising residues 1-175 (solid triangles), or a truncated FcFGF21 protein comprising amino acid residues 1-171 (open triangles).

Figures 6A-6D show the results of liquid chromatography-mass spectrometry (LC-MS) analysis of a human Fc(5)FGF21 control sample (Figure 6A) and samples of

Fc(5)FGF2l drawn from mice at 6 hours (Sample D6; Figure 6B), 24 hours (Sample D24; Figure 6C), and 48 hours (Sample D48; Figure 6D) after injection.

2016204968 15 Jul2016

Figures 7A-7D show the r esuits if LC-MS analysis of a mammalian-derived human FGF21(3)Fc control sample (Figure 7A) and samples of FGF21(3)Fc drawn from mice at 6 hours (Sample E6; Figure 7B), 24 hours (Sample E24; Figure 7C), and 48 hours (Sample E48: Figure 7D) after injection.

Figures 8A-8D show the results of LC-MS analysis of an Fc(15)FGF21 control sample (Figure 8A) and samples of Fc(15)FGF21 drawn from mice at 6 hours (Figure 8B), 24 hours (Figure 8C), and 48 hours (Figure 8D) after injection.

Figures 9A-9D show the results of LC-MS analysts of an FGF21(15)Fc control sample (Figure 9A) and samples of FGF21(15)Fc drawn from mice at 6 hours (Figure

9B), 24 hours (Figure 9C), and 48 hours (Figure 9D) after injection.

Figures 10A-10B show the cleavage sites identified by LC-MS analysis of

Fc(15)FGF21 (Figure Ι0Α, SEQ ID NO:38) and FGF2I(I5)Fc (Figure 10B, SEQ ID NO:25) fusion proteins injected into mice.

Figure 11 shows the blood glucose levels measured in mice injected with PBS 15 (solid bar), Fc(15)FGF21 (open bar), or the Fc(15)FGF21 mutants Fc(15)FGF21 G170E (gray bar), Fc(15)FGF21 PI71A (stippled bar), Fc(15)FGF21 S172L (open diagonally crosshatched bar), Fc(I5)FGF21 G170E/P171A/S172L (solid horizontally crosshatched bar), or Fc(15)FGF21 G151A (open diagonally crosshatched bar).

Figure 12 shows the percent change in blood glucose levels measured in mice

0 injected with PBS (solid circles), Fc(15)FGF21 (open circles), or the Fc(15)FGF21 mutants Fc(15)FGF21 G170E (solid triangles), Fc(15)FGF21 Pl71A (open triangles), Fc(15)FGF21 S172L (solid diamonds), Fc(I5)FGF21 G170E/P171A/S172L (open diamonds), or Fc( 15)FGF21 G151A (solid squares).

Figure 13 shows the blood glucose levels measured in mice injected with PBS 25 (solid bar), Fc(15)FGF2I (open bar), or the Fc(15)FGF21 mutants Fc(I5)FGF21 P150A/G151A/I152V (gray bar), Fc(15)FGF21 G170E (open diagonally crosshatched bar), Fc(15)FGF21 G170E/P171A (gray diagonally crosshatched bar), or Fc(I5)FGF2!

G170E/S172L (open diagonally crosshatched bar).

Figure 14 shows the percent change in blood glucose levels measured in mice

0 injected with PB S (solid squares), Fc(15)FGF21 (open squares), or the Fc(15)FGF21 mutants Fc(15)FGF21 P150A/G151 A/Π52V (solid inverted triangles), Fc(15)FGF2i

2016204968 15 Jul2016

G170E (open inverted triangles), Fc(15)FGF2i G170E/P171A (solid circles), or Fc( 15)FGF21 G170E/S172L (open circles).

Figure 15 shows the blood glucose levels measured in mice injected with PBS (solid bar) or the Fc(15)FGF21 mutants Fc( I5)FGF21 G170E (open bar), Fc(15)FGF21

G170A (gray bar), Fc( 15)FGF21 G170C (open crosshatched bar), Fc( 15)FGF21 G170D (gray and white bar), Fc(15)FGF21 GI70N (solid crosshatched bar), or Fc(15)FGF21 G170S (open crosshatched bar).

Figure 16 shows the percent change in blood glucose levels measured in mice injected with PBS (solid circles) or the Fc(15)FGF21 mutants Fc(15)FGF21 G170E (open circles), Fc(15)FGF21 G170A (solid triangles), Fc(15)FGF21 G170C (open triangles), Fc(15)FGF21 G170D (solid diamonds), Fc(15)FGF21 G170N (open diamonds), or Fc(15)FGF21 G170S (inverted solid triangles).

Figure 17 shows the blood glucose levels measured in mice injected with PBS (solid bar) or the Fc(15)FGF21 mutants Fc(15)FGF21 G170E (open bar), Fc(15)FGF21

P171E (gray bar), Fc(15)FGF21 Pl71H (solid crosshatched bar), Fc(I5)FGF21 P171Q (open crosshatched bar), Fc(15)FGF21 P171T (stippled bar), or Fe(15)FGF21 P171Y (gray crosshatched bar).

Figure 38 shows the percent change in blood glucose levels measured in mice injected with PBS (solid circles) or the Fc(15)FGF21 mutants Fc(15)FGF21 G170E (open circles), Fc(15)FGF21 P171E (solid triangles), Fc(15)FGF2t P171H (open triangles), Fc(15)FGF21 P17IQ (solid diamonds), Fc(15)FGF21 P171T (open diamonds), or Fc(15)FGF21 P171Y (solid squares).

Figures 39A-19D show the results of LC-MS analysis of an Fc(15)FGF21 control sample (Figure 19A) and samples drawn from mice at time 6 hours (Figure 19B), 24 hours (Figure 19C), and 48 hours (Figure 19D) after injection.

Figures 20A-20D show the results of LC-MS analysis of an Fc(15)FGF21 G37OE control sample (Figure 20A) and samples of Fc(15)FGF21 G170E drawn from mice at 6 hours (Figure 20B), 24 hours (Figure 20C), and 48 hours (Figure 20D) after injection.

Figures 21A-21D show the results of LC-MS analysis of an Fc(15)FGF21 P17IA control sample (Figure 21 A) and samples of Fc(15)FGF21 P171A drawn from mice at 6 hours (Figure 21B), 24 (Figure 21C), and 48 hours (Figure 2ID) after injection.

2016204968 15 Jul2016

Figures 22A-22D show the results of LC-MS analysis of an Fc(15)FGF21 S172L control sample (Figure 22A) and samples of Fc(I5)FGF21 SI72L drawn from mice at 6 hours (Figure 22B). 24 hours (Figure 22C), and 48 hours (Figure 22D) after injection.

Figures 23A-23D show the cleavage sites identified by LC-MS analysis of 5 Fc(15)FGF21 (Figure 23A, SEQ ID NO:38), Fc(15)FGF21 G170E (Figure 23B, SEQ ID

NO:39), Fc(15)FGF2I P171A (Figure 23C, SEQ ID NO:40), and Fc(15)FGF21 S172L (Figure 23D, SEQ ID NO:41) fusion proteins injected in mice.

Figures 24A-24C show the results of an ELK-luciferase activity assay performed on the FGF21 mutants FGF21 L99R, FGF21 L99D, and FGF21 Al 1 IT (Figure 24A); the

FGF21 mutants FGF21 A129D, FGF21 A129Q, and FGF21 A134K (Figure 24B); and the FGF21 mutants FGF21 A134Y, FGF21 A134E, and FGF2I A129K (Figure 24C); each panel shows the results obtained for a human FGF21 control.

Figures 25A-25D show the results of an ELK-luciferase activity assay performed on the Fc-FGF21 mutants Fc-FGF21 P171G, Fc-FGF21 P171S, and Fc-FGF21 P171T (Figure 25A); the Fc-FGF21 m utants Fc-FGF21 P171Y, Fc-FGF21 PI71W, and FcFGF2I P171C (Figure 25B); Fc(15)FGF21, Fc(I5)FGF21 A45K/G170E, and FGF21 A45K (Figure 25C); and Fc(15)FGF21, Fc(15)FGF21 P17IE, and Fc(15)FGF2I A45K/GI70E (Figure 25D); each panel shows the results obtained fora human FGF21 control.

Figures 26A-B show the aggregation as a function of time for wild type mature

FGF21 and various FGF21 mutants; Figure 26A shows the change in percent aggregation for an FGF21 control (WT, solid diamonds) and FGF21 A45K (solid circles) following incubation of 65 mg/mL protein at 4°C for 1, 2, and 4 days, while Figure 26B shows the change in percent aggregation for an FGF21 control (WT) and FGF21 P78C, P78R,

L86T, L86R, L98 C, L98R, All IT, A129D, A129Q, A129K, A134K, A13 4Y, and

A134E (all labeled on the plot) following incubation of 65 mg/mL protein at4oC for 1, 6, and 10 days.

Figure 27 shows the results of an ELK-luciferase activity assay performed on a human FGF2I control and the FGF21 mutants FGF2I A45K, FGF21 L52T, and FGF21

L58E.

Figure 28A is a plot show the change in aggregation levels for the Fc(15)FGF21

2016204968 15 Jul2016 mutants Fc(15)FGF2I 6-181/G170E (solid diamonds), Fc(15)FGF21 A45K/G170E (open squares), Fc(15)FGF21 P171E (solid triangles), Fc(15)FGF21 P171A (crosses), Fc(15)FGF21 G170E (open triangles) ,and an FGF21 control (solid circles) following incubation at 4°C for 1, 4, and 8 days, and Figure 28B is a bar graph also showing the results of the incubation.

Figure 29 shows the blood glucose levels measured in mice injected with PBS (vehicle) (solid circles) or the Fc(15)FGF21 mutants Fc(15)FGF21 A45K/G170E (open circles), Fc(15)FGF21 A45K/P171G (solid triangles), or Fc(15)FGF21 L98R/P171G (open triangles).

Figure 30 is a plot showing the results of an ELK-luciferase activity assay performed on human FGF21 (solid circles, solid line), Fc-FGF21 (open circles, solid line) and Fc-FGF21 L98R/PI71G (solid triangles, dotted line).

Figure 31 is a plot showing the percent high molecular weight aggregates observed after nine days at room temperature (Figure 31 A) and at 4°C (Figure 3IB) for

FGF21 (solid c ircles, solid line), Fc-FGF21 (open circle, solid line) and Fc-FGF21 L98R/P171G (solid triangles, dotted line).

Figure 32 is a seri es of MALDI mass spectrometry traces showing observed changes in Fc-FGF21 L98R/P171G at various points over a 168 hour time period.

Figure 33 is a plot showing the percent change in blood glucose levels in ob/ob mice for each of a PBS ve hide control (open circles), wild-type mature FGF21 (solid squares), and the FGF21 mutants L98R, P171G (inverted solid triangles); L98R, P171G,

182P (open diamonds), and L98R, P171G, 182G (solid circles).

Figure 34 is a plot showing the percent change in blood glucose levels in db/db mice for each of a PBS vehicle control (solid circles), and the FGF21 mutants L98R,

P171G (solid triangles); L98R, P171G, 182G, I83G (open triangles), L98R, P171G,

182G (solid diamonds) and L98R, P171G, 182P (open diamonds).

Figure 35 is a plot showing the percent change in blood glucose levels in db/db mice for each of a PBS vehicle control (open circles), and the FGF21 mutants L98R, P171G (solid squares); L98R, P171G, Y179S (open triangles), L98R, P171G, Y179A (inverted solid triangles), L98R, P171G, 180S (open diamonds) and L98R, P171G, A180G (solid circles).

2016204968 15 Jul2016

Figure 36 is a plot showing the percent change in blood glucose levels in db/db mice for each of a PBS vehicle control (solid circles), and the FGF21 mutants L98R, P171G (open squares); L98R, P171G, Y179F (solid triangles), and L98R, P171G, A180E (open diamonds).

Figure 37 is a diagram graphically depicting the study design for a six-week dose escalation study performed in Rhesus monkeys; in the figure shaded symbols indicate blood draws in the fasted state and stippled symbols indicated blood draws in the fed state.

Figures 38A-D is a series of plots depicting how the rhesus monkeys were 10 randomized on OGTT profiles, OGTT AUCs and body weight; Figure 38A depicts baseline glucose levels in OGTT1, solid square corresponds to group A, solid circle, solid line corresponds to group B and open circle, dashed line corresponds to group C before compounds or vehicle were assigned to each group; Figure 38B depicts baseline glucose levels in OGTT2, solid square corresponds to group A, solid circle, solid line corresponds to group Band open circle, solid line corresponds to group C before compounds or vehicle were assigned to each group; Figure 38C shows baseline glucose levels for OGTTs 1 and 2 shown in terms of AUC, the stippled bar corresponds to group A, the shaded bar corresponds to group B and the open bar corresponds to group C; and Figure 38D shows baseline body weight, the stippled bar corresponds to group A, the shaded bar corresponds to group B and the open bar corresponds to group C.

Figure 39 is a plot showing the effects of vehicle, FGF21 and Fc-FGF21(RG) on body weight in Rhesus monkeys; shaded bars 1 and 2 correspond to weeks 1 and 2 at the low dose, open bars 3 and 4 correspond to weeks 3 and 4 at the mid dose, solid bars 5 and 6 correspond to weeks 5 and 6 at the high dose and stippled bars 7, 8 and 9 correspond to weeks 7-9 during the washout period.

Figure 40 is a plot showing the percent change in fasted insulin relative to baseline of vehicle, FGF21 and Fc-FGF21(RG) on fasted insulin levels in Rhesus monkeys; shaded bars 1 and 2 correspond to weeks 1 and 2 at the low dose, open bars 3 and 4 correspond to weeks 3 and 4 at the mid dose, solid bars 5 and 6 correspond to weeks 5 and 6 at the high dose and stippled bars 7 and 8 correspond to weeks 7 and 8 during the washout period.

2016204968 15 Jul2016

Figure 41 is a plot showing the effects of vehicle, FGF21 and Fc-FGF21(RG), given at the high dose, on fed insulin levels of Rhesus monkeys acquired during weeks 5 and 6 of the study; solid bars correspond to week 5 and shaded bars correspond to week 6.

Figure 42 is a plot showing the glucose profiles of OGTT5 performed at the end of the two week high-dose treatment with Fc-FGF2I(RG); solid circle, solid line corresponds to vehicle, open square, dotted line corresponds to FGF23 and solid triangle, solid line corresponds to Fc-FGF21(RG).

Figure 43 is a plot showing the insulin profiles of OGTT5 performed at the end of 10 the two week high-dose treatment with Fc-FGF21(RG); solid circle, solid line corresponds to vehicle, open square, dotted line corresponds to FGF21 and solid triangle, solid line corresponds to Fc-FGF21(RG),

Figure 44 is a plot showing the glucose OGTT AUC1-3 determined at the end of each dose period (low, mid and high dose) of the Rhesus monkeys; open bars correspond to AUC3 calculated from glucose measurements during OGTT3, solid bars correspond to AUC4 calculated from glucose measurements during OGTT4 and shaded bars correspond to AUC5 calculated from glucose measurements during OGTT5.

Figure 45 is a graph showing the effects of vehicle, FGF21 and Fc-FGF21(RG) on percent change from baseline of the fasted plasma triglyceride levels from each group of

Rhesus monkeys; shaded bars 1 and 2 correspond to weeks 1 and 2 at the low dose, open bars 3 and 4 correspond to weeks 3 and 4 at the mid dose, solid bars 5 and 6 correspond to weeks 5 and 6 at the high dose and stippled bars 7, 8 and 9 correspond to weeks 7-9 during the washout period..

Figure 46 is a graph showing fed plasma triglyceride levels from each group of the Rhesus monkeys; as measured during the fifth and sixth weeks of treatment with vehicle, FGF21 or Fc-FGF21(RG) at the high dose; shaded bars correspond to week 5 and solid bars correspond to week 6.

Figure 47 is a plot showing individual monkey FGF21 levels measured at predose, and 5, 12, 19, and 26 days, with samples acquired at approximately 21 hours after each injection.

Figure 48 is a plot showing individual monkey Fc-FGF21(RG) levels measured at

2016204968 15 Jul2016 prc-dosc, and 5, 12, 19, and 26 days, with samples acquired approximately 5 days after each injection.

Figure 49 is a plot showing mean concentrations of FGF21 and Fc-FGF21(RG) levels measured from the three OGTTs performed following each of the low, mid and high doses; shaded bars correspond to OGTT3 at the low dose, solid bars correspond to OGTT4 at the mid dose and open bars correspond to OGTTS at the high dose.

DETAILED DESCRIPTION OF THE INVENTION

A human FGF21 protein having enhanced properties such as an increased half-life and/or decreased aggregation can be prepared using the methods disclosed herein and standard molecular biology methods. Optionally, the half-life can be further extended by fusing an antibody, or portion thereof, to the N-terminal or C-tcrminal end of the wildtype FGF21 sequence, it is also possible to further extend the half-life or decrease aggregation of the wild-type FGF21 protein by introducing amino acid substitutions into the protein. Such modified proteins arc referred to herein as mutants, or FGF21 mutants, and form embodiments of the present invention.

Recombinant nucleic acid methods used herein, including in the Examples, arc generally those set forth in Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) or Current Protocols in Molecular Biology (Ausubel etai., eds., Green Publishers Inc. and Wiley and Sons 1994), both of which are incorporated herein by reference for any purpose.

1. General Definitions

The term “isolated nucleic acid molecule” refers to a nucleic acid molecule of the invention that (1) has been separated from at least about 50 percent of proteins, lipids, carbohydrates, or other materials with which it is naturally found when total nucleic acid is isolated from the source cells, (2) is not linked to all or a portion of a polynucleotide to which the “isolated nucleic acid molecule” is linked in nature, (3) is operably linked to a polynucleotide which it is not linked to in nature, or (4) does not occur in nature as part of a larger polynucleotide sequence. Preferably, the isolated nucleic acid molecule of the

2016204968 15 Jul2016 present invention is substantially free from any other contaminating nucleic acid molecules or other contaminants that are found in its natural environment that would interfere with its use in polypeptide production or its therapeutic, diagnostic, prophylactic or research use.

The term “vector” is used to refer to any molecule (e.g., nucleic acid, plasmid, or virus) used to transfer coding information to a host cell.

The term “expression vector” refers to a vector that is suitable for transformation of a host cell and contains nucleic acid sequences that direct and/or control the expression of inserted heterologous nucleic acid sequences. Expression includes, but is not limited to, processes such as transcription, translation, and RNA splicing, if introns are present.

The term “operably linked” is used herein to refer to an arrangement of flanking sequences wherein the flanking sequences so described are configured or assembled so as to perform their usual function. Thus, a flanking sequence operably linked to a coding sequence may be capable of effecting the replication, transcription and/or translation of the coding sequence. For example, a coding sequence is operably linked to a promoter when the promoter is capable of directing transcription of that coding sequence. A flanking sequence need not be contiguous with the coding sequence, so long as it functions correctly. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked” to the coding sequence.

The term “host cell” is used to refer to a cell which has been transformed, or is capable of being transformed with a nucleic acid sequence and then of expressing a selected gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent, so

5 tong as the selected gene is present.

The term “isolated polypeptide” refers to a polypeptide of the present invention that (1) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates, or other materials with which it is naturally found when isolated from the source cell, (2) is not linked (by covalent or noncovalent interaction) to all or a portion of a polypeptide to which the “isolated polypeptide” is linked in nature, (3) is operably linked (by covalent or noncovalent interaction) to a polypeptide with which it is not

2016204968 15 Jul2016 linked in nature, or (4) does not occur in nature. Preferably, the isolated polypeptide is substantially free from any other contaminating polypeptides or other contaminants that are found in its natural environment that would interfere with its therapeutic, diagnostic, prophylactic or research use.

The term “naturally occurring” when used in connection with biological materials such as nucleic acid molecules, polypeptides, host cells, and the like, refers to materials which are found in nature and are not manipulated by man. Similarly, “non-naturally occurring” as used herein refers to a material that is not found in nature or that has been structurally modified or synthesized by man. When used in connection with nucleotides, the term “naturally occurring” refers to the bases adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U). When used in connection with amino acids, the term “naturally occurring” refers to the 20 amino acids alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucinc (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), serine (S), threonine (T), valine (V), tryptophan (W), and tyrosine (Y).

The term “FGF21 polypeptide” refers to a naturally-occurring wild-type polypeptide expressed in humans. For purposes of this disclosure, the term “FGF21 polypeptide” can be used interchangeably to refer to any full-length FGF21 polypeptide, e.g., SEQ ID NO:2, which consists of 209 amino acid residues and which is encoded by the nucleotide sequence of SEQ ID NO: 1; any mature form of the polypeptide, e.g., SEQ ID NO:4, which consists of 181 amino acid residues and which is encoded by the nucleotide sequence of SEQ ID NO: 3, and in which the 28 amino acid residues at the amino-terminal end of the full-length FGF21 polypeptide (i.e., which constitute the signal peptide) have been removed, and variants thereof.

5 The terms “FGF2I polypeptide mutant” and “FGF21 mutant” refer to an FGF21 polypeptide variant in which a naturally occurring FGF21 amino acid sequence has been modified. Such modifications include, but are not limited to, one or more amino acid substitutions, including substitutions with non-naturally occurring amino acid analogs, and truncations. Thus, FGF21 polypeptide mutants include, but are not limited to, site30 directed FGF21 mutants, truncated FGF21 polypeptides, proteolysis-resistant FGF21 mutants, aggregation-reducing FGF21 mutants, FGF21 combination mutants, and FGF21

2016204968 15 Jul2016 fusion proteins, as described herein. For the purpose of identifying the specific truncations and amino acid substitutions of the FGF21 mutants of the present invention, the numbering of the amino acid residues truncated or mutated corresponds to that of the mature 181-residue FGF21 polypeptide,

In other embodiments of the present invention, an FGF21 polypeptide mutant comprises an amino acid sequence that is at least about 85 percent identical to the amino acid sequence of SEQ ID NO: 4, but wherein specific residues conferring a desirable property to the FGF21 polypeptide mutant, e.g., proteolysis-resistance, increased half life or aggregation-reducing properties and combinations thereof, have not been further modified. In other words, with the exception of residues in the FGF21 mutant sequence that have been modified in order to confer proteolysis-resistance, aggregation-reducing, or other properties, about 15 percent of all other amino acid residues in the FGF21 mutant sequence can be modified. For example, in the FGF21 mutant Q173E, up to 15 percent of all amino acid residues other than the glutamic acid residue, which was substituted for glutamine at position 173, could be modified. In still other embodiments, an FGF21 polypeptide mutant comprises an amino acid sequence that is at least about 90 percent, or about 95, 96, 97, 98, or 99 percent identical to the amino acid sequence of SEQ ID NO: 4, but wherein the specific residues conferring the FGF21 polypeptide mutant's proteolysis-resistance or aggregation-reducing properties have not been further modified.

Such FGF21 polypeptide mutants possess at least one activity of the wild-type FGF21 polypeptide.

The present invention also encompasses a nucleic acid molecule encoding an FGF21 polypeptide mutant comprising an amino acid sequence that is at least about 85 percent identical to the amino acid sequence of SEQ ID NO: 4, but wherein specific residues conferring a desirable property to the FGF21 polypeptide mutant, e.g., proteolysis-resistance, increased half life or aggregation-reducing properties and combinations thereof have not been further modified. In other words, with the exception of nucleotides that encode residues in the FGF21 mutant sequence that have been modified in order to confer proteolysis-resistance, aggregation-reducing, or other properties, about 15 percent of all other nucleotides in the FGF21 mutant sequence can be modified. For example, in the FGF21 mutant Q173E, up to 15 percent of all nucleotides

2016204968 15 Jul2016 other than the nucleotides encoding the glutamic acid residue, which was substituted for glutamine at position 173, could be modified. The present invention further encompasses a nucleic acid molecule encoding an FGF21 polypeptide mutant comprising an amino acid sequence that is at least about 90 percent, or about 95, 96, 97, 98, or 99 percent identical to the amino acid sequence of SEQ ID NO: 4, but wherein the specific residues conferring the FGF21 polypeptide mutant's proteolysis-resistance or aggregationreducing properties have not been further modified. Such FGF21 mutants possess at least one activity of the wild-type FGF21 polypeptide.

The present invention also encompasses a nucleic acid molecule comprising a 10 nucleotide sequence that is at least about 85 percent identical to the nucleotide sequence of SEQ ID NO: 3, but wherein the nucleotides encoding amino acid residues conferring the encoded FGF21 polypeptide mutant's proteolysis-resistance, aggregation-reducing or other properties have not been further modified. In other words, with the exception of residues in the FGF21 mutant sequence that have been modified in order to confer proteolysis-resistance, aggregation-reducing, or other properties, about 15 percent of all other amino acid residues in the FGF21 mutant sequence can be modified. For example, in the FGF21 mutant Q173E, up to 15 percent of all amino acid residues other than the glutamic acid residue, which was substituted for glutamine at position 173, could be modified. The present invention further encompasses a nucleic acid molecule comprising a nucleotide sequence that is at least about 90 percent, or about 95, 96, 97, 98, or 99 percent identical to the nucleotide sequence of SEQ ID NO: 3, but wherein the nucleotides encoding amino acid residues conferring the encoded FGF21 polypeptide mutant's proteolysis-resistance or aggregation-reducing properties have not been further modified. Such nucleic acid molecules encode FGF21 mutant polypeptides possessing at

5 least one activity of the wild-type FGF21 polypeptide.

The term “biologically active FGF21 polypeptide mutant” refers to any FGF2I polypeptide mutant described herein that possesses an activity of the wild-type FGF21 polypeptide, such as the ability to lower blood glucose, insulin, triglyceride, or cholesterol; reduce body weight; and improve glucose tolerance, energy expenditure, or insulin sensitivity, regardless of the type or number of modifications that have been introduced into the FGF21 polypeptide mutant. FGF21 polypeptide mutants possessing a

2016204968 15 Jul2016 somewhat decreased level of FGF21 activity relative to the wild-type FGF21 polypeptide can nonetheless be considered to be biologically active FGF21 polypeptide mutants.

The terms “effective amount” and “therapeutically effective amount” each refer to the amount of an FGF21 polypeptide mutant used to support an observable level of one or more biological activities of the wild-type FGF21 polypeptide, such as the ability to lower blood glucose, insulin, triglyceride, or cholesterol levels; reduce body weight; or improve glucose tolerance, energy expenditure, or insulin sensitivity.

The term “pharmaceutically acceptable earner” or “physiologically acceptable carrier” as used herein refers to one or more formulation materials suitable for accomplishing or enhancing the delivery of an FGF21 polypeptide mutant.

The term “antigen” refers to a molecule or a portion of a molecule that is capable of being bound by an antibody, and additionally that is capable of being used in an animal to produce antibodies that arc capable of binding to an epitope of that antigen. An antigen may have one or more epitopes.

The term “native Fc” refers to molecule or sequence comprising the sequence of a non-antigen-binding fragment resulting from digestion of whole antibody or produced by other means, whether in monomeric or multimcric form, and can contain the hinge region. The original immunoglobulin source of the native Fc is preferably of human origin and can be any of the immunoglobulins, although IgGl and IgG2 arc preferred.

Native Fc molecules arc made up of monomeric polypeptides that can be linked into dimeric or multimcric forms by covalent (i.e., disulfide bonds) and non-covalcnt association. The number of intermolccular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgGl, IgG2, IgG3, IgAl, and IgGA2). One example of a native Fc is a

5 disulfide-bonded dimer resulting from papain digestion of an IgG (see Ellison et a!., 1982, Nucleic Acids Res. 10: 4071-9). The term “native Fc” as used herein is generic to the monomeric, dimeric, and multimeric forms. An example of an Fc polypeptide sequence is presented in SEQ ID NO: 13.

The term “Fc variant” refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn (neonatal Fc receptor), international Publication Nos. WO 97/34631 and WO 96/32478 describe

2016204968 15 Jul2016 exemplary Fe variants, as well as interaction with the salvage receptor, and arc hereby incorporated by reference. Thus, the term “Fe variant” can comprise a molecule or sequence that is humanized from a non-human native Fe, Furthermore, a native Fe comprises regions that can be removed because they provide structural features or biological activity that are not required for the fusion molecules of the FGF21 mutants of the present invention. Thus, the term “Fc variant” comprises a molecule or sequence that lacks one or more native Fc sites or residues, or in which one or more Fc sites or residues has be modified, that affect or arc involved in: (1) disulfide bond formation, (2) incompatibility with a selected host cell, (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC). Fc variants are described in further detail hereinafter.

The term “Fc domain” encompasses native Fc and Fc variants and sequences as defined above. As with Fc variants and native Fc molecules, the term “Fc domain” includes molecules in monomeric or multimeric form, whether digested from whole antibody or produced by other means. In some embodiments of the present invention, an Fc domain can be fused to FGF21 or a FGF21 mutant (including a truncated form of FGF21 or a FGF21 mutant) via, for example, a covalent bond between the Fc domain and the FGF21 sequence. Such fusion proteins can form multimcrs via the association of the

Fc domains and both these fusion proteins and their multimcrs arc an aspect of the present invention.

2._Site-specific FGF21 Mutants

The term “site-specific FGF21 mutant” or “substituted FGF21 mutant” refers to an FGF21 mutant polypeptide having an amino acid sequence that differs from the amino acid sequence of a naturally occurring FGF21 polypeptide sequence, e.g., SEQ ID NOs:2 and 4 and variants thereof. Site-specific FGF21 mutants can be generated by introducing amino acid substitutions, either conservative or non-conscrvative and using naturally or non-naturally occurring amino acids, at particular positions of the FGF21 polypeptide.

“Conservative amino acid substitution” can involve a substitution of a native amino acid residue (i.e., a residue found in a given position of the wild-type FGF21

2016204968 15 Jul2016 polypeptide sequence) with a normative residue (i.e., a residue that is not found in a given position of the wild-type FGF2i polypeptide sequence) such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Conservative amino acid substitutions also encompass non-naturally occurring amino acid residues that are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include pcptidomimetics, and other reversed or inverted forms of amino acid moieties.

Naturally occurring residues can be divided into classes based on common side chain properties:

(1) hydrophobic: norleucine, Met, Ala, Val, Leu, lie;

(2) neutral hydrophilic: Cys, Ser, Thr;

(3) acidic: Asp, Glu;

(4) basic: Asn, Gin, His, Lys, Arg;

(5) residues that influence chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe.

Conservative substitutions can involve the exchange of a member of one of these classes for another member of the same class. Non-conservative substitutions can involve the exchange of a member of one of these classes for a member from another class.

Desired amino acid substitutions (whether conservative or non-conservative) can be determined by those skilled in the art at the time such substitutions are desired. An exemplary (but not limiting) list of amino acid substitutions is set forth in Table 1.

Table 1

Amino Acid Substitutions

Original Residue	Exemplary Substitutions
Ala	Val, Leu, He
Arg	Lys, Gin, Asn
Asn	Gin
Asp	Glu
Cys	Ser, Ala
Gin	Asn
Glu	Asp
Gly	Pro, Ala
His	Asn, Gin, Lys, Arg

2016204968 15 Jul2016

He	Leu, Val, Met, Ala, Phc
Leu	He, Val, Met, Ala, Phe
Lys	Arg, Gin, Asn
Met	Leu, Phe, He
Phc	Leu, Val, lie, Ala, Tyr
Pro	Ala
Ser	Thr, Ala, Cys
Thr	Scr
Trp	Tyr, Phe
Tyr	Trp, Phe, Thr, Scr
Val	He, Met, Leu, Phe, Ala

3. Truncated FGF21 Polypeptides

One embodiment of the present invention is directed to truncated forms of the mature FGF21 polypeptide. This embodiment of the present invention arose from an effort to identify truncated FGF21 polypeptides that arc capable of providing an activity that is similar, and in some instances superior, to untruncated forms of the mature FGF21 polypeptide.

As used herein, the term “truncated FGF21 polypeptide” refers to an FGF21 polypeptide in which amino acid residues have been removed from the amino-terminal (or N-tcrminal) end of the FGF21 polypeptide, amino acid residues have been removed from the carboxyl-terminal (or C-tcrminal) end of the FGF21 polypeptide, or amino acid residues have been removed from both the amino-terminal and carboxyl-terminal ends of the FGF21 polypeptide. The various truncations disclosed herein were prepared as described herein Examples 3 and 6.

The activity of N-tcrminally truncated FGF21 polypeptides and C-terminally truncated FGF21 polypeptides can be assayed using an in vitro ELK-lucifcrasc assay as described in Example 4. Specific details of the in vitro assays that can be used to examine the activity of truncated FGF21 polypeptides can be found in Example 4.

The activity of the truncated FGF21 polypeptides of the present invention can also be assessed in an in vivo assay, such as ob/ob mice as shown in Examples 5 and 7. Generally, to assess the in vivo activity of a truncated FGF21 polypeptide, the truncated FGF21 polypeptide can be administered to a test animal intrapcritoneally. After a desired incubation period (e.g., one hour or more), a blood sample can be drawn, and blood glucose levels can be measured. Specific details of the in vivo assays that can be used to

2016204968 15 Jul2016 examine the activity of truncated FGF21 polypeptides can be found in Examples 5 and 7.

a. N-terminal Truncations

In some embodiments of the present invention, N-terminal truncations comprise 5 1, 2, 3, 4, 5, 6, 7, or 8 amino acid residues from the N-terminal end of the mature FGF21 polypeptide. As demonstrated in, for example, Example 5 and Figure 3, truncated FGF21 polypeptides having N-terminal truncations of fewer than 9 amino acid residues retain the ability of the mature FGF21 polypeptide to lower blood glucose in an individual. Accordingly, in particular embodiments, the present invention encompasses truncated forms of the mature FGF21 polypeptide or FGF21 polypeptide mutants having Ntcrminal truncations of 1, 2, 3, 4, 5, 6, 7, or 8 amino acid residues.

b. _C-tcrminal Truncations

In some embodiments of the present invention, C-tcrminal truncations comprise 1, 15 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues from the C-tcrminal end of the mature FGF21 polypeptide. As demonstrated in, for example. Example 4 and Figure IB, truncated FGF21 polypeptides having C-tcrminal truncations of fewer than 13 amino acid residues exhibited an efficacy of at least 50% of the efficacy of wild-type FGF21 in an in vitro ELK-lucifcrase assay, indicating that these FGF21 mutants retain the ability of the mature FGF21 polypeptide to lower blood glucose in an individual. Accordingly, in particular embodiments, the present invention encompasses truncated forms of the mature FGF21 polypeptide or FGF21 polypeptide mutants having C-terminal truncations of I, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues.

c. N-terminal and C-terminal Truncations

In some embodiments of the present invention, truncated FGF21 polypeptides can have a combination of N-terminal and C-tcrminal truncations. Truncated FGF21 polypeptides having a combination of N-tcrminal and C-tcrminal truncations share the activity of corresponding truncated FGF21 polypeptides having either the N-terminal or

C-terminal truncations alone. In other words, truncated FGF21 polypeptides having both N-terminal truncations of fewer than 9 amino acid residues and C-terminal truncations of

2016204968 15 Jul2016 fewer than 13 amino acid residues possess similar or greater blood glucose-lowering activity as truncated FGF21 polypeptides having N-terminal truncations of fewer than 9 amino acid residues or truncated FGF21 polypeptides having C-terminal truncations of fewer than 13 amino acid residues. Accordingly, in particular embodiments, the present invention encompasses truncated forms of the mature FGF2I polypeptide or FGF21 polypeptide mutants having both N-terminal truncations of 1, 2, 3, 4, 5, 6, 7, or 8 amino acid residues and C-terminal truncations of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues.

As with all FGF21 mutants of the present invention, truncated FGF21 10 polypeptides can optionally comprise an amino-terminal methionine residue, which can be introduced by directed mutation or as a result of a bacterial expression process.

The truncated FGF21 polypeptides of the present invention can be prepared as described in Examples 3 and 6. Those of ordinary skill in the art, familiar with standard molecular biology techniques, can employ that knowledge, coupled with the instant disclosure, to make and use the truncated FGF21 polypeptides of the present invention. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, tissue culture, and transformation (e.g., electroporation, lipofcction). See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, supra, which is incorporated herein by reference for any purpose. Enzymatic reactions and purification techniques can be

0 performed according to manufacturer’s specifications, as commonly accomplished in the art, or as described herein. Unless specific definitions arc provided, the nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein arc those well known and commonly used in the art. Standard

5 techniques can be used for chemical syntheses; chemical analyses; pharmaceutical preparation, formulation, and delivery; and treatment of patients.

The truncated FGF21 polypeptides of the present invention can also be fused to another entity, which can impart additional properties to the truncated FGF21 polypeptide. In one embodiment of the present invention, a truncated FGF21 polypeptide can be fused to an Fc sequence. Such fusion can be accomplished using known molecular biological methods and/or the guidance provided herein. The benefits of such

2016204968 15 Jul2016 fusion polypeptides, as well as methods for making such fusion polypeptides, arc discussed in more detail herein.

4. Protcoivsis-resistant FGF21 Mutants

As described in Example 8, mature FGF21 was found to be undergoing in vivo degradation, which was ultimately determined to arise from proteolytic attack. The in vivo degradation of mature FGF21 was found to lead to shorter effective half-life, which can adversely affect the therapeutic potential of a molecule. Accordingly, a directed study was performed to identify FGF21 mutants that exhibit a resistance to proteolysis.

As a result of this investigation, the sites in the mature FGF21 polypeptide that were determined to be particularly susceptible to proteolysis include the peptide bond between the amino acid residues at positions 4-5, 20-21, 151-152, and 171-172.

A broad but focused and directed study was performed to identify particular substitutions that eliminate the observed proteolytic effect while not affecting the activity of the protein to an unacceptable degree. Tables 8 and 11 highlight some of the mutants that were prepared and tested. As described in, for example, Examples 13 and 14, not all FGF21 mutants exhibited an ideal profile; some mutants conferred proteolysis resistance but at the cost of compromised FGF21 activity. Other mutations retained FGF21 activity but did not confer proteolysis resistance. Several mutants, including, for example,

FGF21 P171G, retained a simitar level of activity as wild-type FGF21 while also exhibiting resistance to proteolytic degradation.

One selection criteria for identifying desirable proteolysis-resistant FGF21 mutants was that the activity of the FGF21 mutant be essentially the same as, or greater than, the activity of wild-type FGF21. Therefore, another embodiment of the present invention is directed to FGF21 mutants that are resistant to proteolysis and still retain activity that is essentially the same as, or greater than, wild-type FGF21. Although less desirable in some cases, FGF21 mutants that are resistant to proteolysis but exhibit somewhat decreased activity form another embodiment of the present invention. In some cases it can be desirable to maintain a degree of proteolysis, and consequently, FGF21 mutants that allow some degree of proteolysis to occur also form another embodiment of the present invention.

2016204968 15 Jul2016

As with all FGF21 mutants of the present invention, the proteolysis-resistant FGF2I mutants of the present invention can be prepared as described herein. Those of ordinary skill in the art, for example, those familiar with standard molecular biology techniques, can employ that knowledge, coupled with the instant disclosure, to make and use the proteolysis-resistant FGF21 mutants of the present invention. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, tissue culture, and transformation (e.g., electroporation, lipofection). See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, supra, which is incorporated herein by reference for any purpose. Enzymatic reactions and purification techniques can be performed according to manufacturer's specifications, as commonly accomplished in the art, or as described herein. Unless specific definitions are provided, the nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein arc those well known and commonly used in the art. Standard techniques can be used for chemical syntheses; chemical analyses; pharmaceutical preparation, formulation, and delivery; and treatment of patients.

The proteolysis-resistant FGF21 mutants of the present invention can be fused to another entity, which can impart additional properties to the proteolysis-resistant FGF21 mutant. In one embodiment of the present invention, a proteolysis-resistant FGF21 mutant can be fused to an IgG Fc sequence, e.g., SEQ ID NO: 13. Such fusion can be accomplished using known molecular biological methods and/or the guidance provided herein. The benefits of such fusion polypeptides, as well as methods for making such fusion polypeptides, arc known and are discussed in more detail herein.

5, Aggregation-reducing FGF21 Mutants

As described in Example 15, one property of the wild-type FGF21 polypeptide is its propensity to aggregate. At concentrations over about 5 mg/mL, the aggregation rate is high at room temperature. As shown and described herein, the aggregation rate for the wild-type FGF21 polypeptide is both concentration and temperature dependent.

Aggregation can prove to be a challenge when working with wild-type FGF21 at these concentrations, such as in the context of a therapeutic formulation. Accordingly, a

2016204968 15 Jul2016 directed study was performed to identify FGF21 mutants that exhibit reduced FGF21 aggregation. The resulting FGF21 mutants were then tested for the propensity to aggregate at various concentrations.

A broad but focused and directed study was performed to identify particular 5 substitutions that eliminate or reduce the observed aggregation effect of wild-type FGF21 while not affecting the activity of the protein to an unacceptable degree. The approach for identifying suitable aggregation-reducing mutants is described in Example 15. Table 16 highlights some of the mutants that were prepared and tested. As described in, for example, Example 17, not all FGF2I mutants exhibited an ideal profile. Some mutants, such as FGF2I L58E had compromised FGF21 activity and were not studied further. Other mutations, such as FGF21 AI34E, retained FGF2I activity but did not confer reduced aggregation properties. Several mutants, such as FGF2I L98R, retained FGF21 activity and also exhibited reduced aggregation. One mutant, FGF21 A45K, surprisingly exhibited increased FGF21 activity while also exhibiting reduced aggregation properties.

One selection criteria for identifying desirable aggregation-reducing FGF21 mutants was that the activity of the FGF21 mutant be essentially similar to, or greater than, the activity of wild-type FGF21. Therefore, another embodiment of the present invention is directed to FGF21 mutants having reduced aggregation properties while still retaining an FGF21 activity that is similar to, or greater than, wild-type FGF21.

Although less desirable in some cases, FGF21 mutants having reduced aggregation properties but exhibiting somewhat decreased FGF21 activity form another embodiment of the present invention. In some cases it may be desirable to maintain a degree of aggregation, and consequently, FGF21 mutants that allow some degree of aggregation to occur also form another embodiment of the present invention.

As with all FGF23 mutants of the present invention, the aggregation-reducing

FGF21 mutants of the present invention can be prepared as described herein. Those of ordinary skill in the art, familiar with standard molecular biology techniques, can employ that knowledge, coupled with the instant disclosure, to make and use the aggregationreducing FGF21 mutants of the present invention. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, tissue culture, and transformation (e.g., electroporation, lipofection). See, e.g., Sambrook et a!., Molecular Cloning: A

2016204968 15 Jul2016

Laboratory Manual, supra, which is incorporated herein by reference for any purpose. Enzymatic reactions and purification techniques can be performed according to manufacturer’s specifications, as commonly accomplished in the art, or as described herein. Unless specific definitions are provided, the nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein arc those well known and commonly used in the art. Standard techniques can be used for chemical syntheses; chemical analyses; pharmaceutical preparation, formulation, and delivery; and treatment of patients.

The aggregation-reducing FGF2I mutants of the present invention can be fused to another entity, which can impart additional properties to the aggregation-reducing FGF21 mutant. In one embodiment of the present invention, an aggregation-reducing FGF21 mutant can be fused to an IgG Fc sequence, e.g., SEQ ID NO:13. Such fusion can be accomplished using known molecular biological methods and/or the guidance provided herein. The benefits of such fusion polypeptides, as well as methods for making such fusion polypeptides, arc discussed in more detail herein.

6. FGF21 Combination Mutants

As described herein, the wild-type FGF21 sequence possesses several properties that can pose significant challenges when FGF21 is used as a therapeutic molecule. Among these challenges arc the protein's susceptibility to degradation and its propensity for aggregation at high concentration. After an exhaustive effort to identify FGF21 polypeptides that overcome each of these challenges, a directed study was performed to determine whether the amino acid substitutions conferring proteolysis-resistance and those conferring aggregation-reducing properties could be combined in an additive or synergistic fashion in a single polypeptide sequence while maintaining activity levels that arc equal to or greater than the activity of wild-type FGF21. This represented a significant challenge, as it is known in the art that the introduction of multiple mutations in a given polypeptide can sometimes adversely affect the expression, activity, and

0 subsequent manufacture of the protein.

2016204968 15 Jul2016

Surprisingly, as demonstrated in, for example, Examples 19 and 20, it was found that the desirable properties of several FGF21 mutants could indeed be combined in an additive or synergistic fashion to generate an FGF21 mutant having enhanced pharmaceutical properties. FGF23 mutants that are resistant to proteolysis, have a reduced rate of aggregation, and which still retain activity that is the same as, or greater than, wild-type FGF21, are disclosed herein.

One selection criteria for identifying desirable FGF21 combination mutants was that the activity of the FGF21 mutant be similar to, or greater than, the activity of wildtype FGF21. Therefore, another embodiment of the present invention is directed to

FGF21 mutants that arc proteolysis-resistant and have reduced aggregation properties while still retaining an FGF21 activity that is similar to, or greater than, wild-type FGF21. Although less desirable in some cases, FGF21 mutants that are proteolysisresistant and have reduced aggregation properties but exhibit somewhat decreased FGF21 activity form another embodiment of the present invention. In some cases it may be desirable to maintain a degree of proteolysis and/or aggregation, and consequently, FGF21 mutants that allow some degree of proteolysis and/or aggregation also form another embodiment of the present invention.

As with all FGF21 mutants of the present invention, the FGF21 combination mutants of the present invention can be prepared as described herein. Those of ordinary skill in the art, familiar with standard molecular biology techniques, can employ that knowledge, coupled with the instant disclosure, to make and use the FGF21 combination mutants of the present invention. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, tissue culture, and transformation (e.g., electroporation, lipofection). See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, supra, which is incorporated herein by reference for any purpose. Enzymatic reactions and purification techniques can be performed according to manufacturer's specifications, as commonly accomplished in the art, or as described herein. Unless specific definitions arc provided, the nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques can be used for chemical syntheses;

2016204968 15 Jul2016 chemical analyses; pharmaceutical preparation, formulation, and delivery; and treatment of patients.

The FGF21 combination mutants of the present invention can be fused to another entity, which can impart additional properties to the FGF21 combination mutant. In one embodiment of the present invention, an FGF21 combination mutant can be fused to an IgG Fc sequence, e.g., SEQ ID NO: 13. Such fusion can be accomplished using known molecular biological methods and/or the guidance provided herein. The benefits of such fusion polypeptides, as well as methods for making such fusion polypeptides, are discussed in more detail herein,

7._FGF21 Fusion Proteins

As used herein, the term ‘FGF21 fusion polypeptide” or “FGF21 fusion protein” refers to a fusion of one or more amino acid residues (such as a heterologous protein or peptide) at the N-tcrminus or C-tcrminus of any FGF21 polypeptide mutant described herein.

Heterologous peptides and polypeptides include, but arc not limited to, an epitope to allow for the detection and/or isolation of an FGF21 polypeptide mutant; a transmembrane receptor protein or a portion thereof, such as an extracellular domain or a transmembrane and intracellular domain; a ligand or a portion thereof which binds to a transmembrane receptor protein; an enzyme or portion thereof which is catalytically active; a polypeptide or peptide which promotes oligomerization, such as a leucine zipper domain; a polypeptide or peptide which increases stability, such as an immunoglobulin constant region; a functional or non-functional antibody, or a heavy or light chain thereof; and a polypeptide which has an activity, such as a therapeutic activity, different from the

FGF21 polypeptide mutants of the present invention. Also encompassed by the present invention are FGF21 mutants fused to human serum albumin (HSA).

FGF21 fusion proteins can be made by fusing heterologous sequences at cither the N-terminus or at the C-tcrminus of an FGF21 polypeptide mutant. As described herein, a heterologous sequence can be an amino acid sequence or a non-amino acid-containing polymer. Heterologous sequences can be fused either directly to the FGF21 polypeptide mutant or via a linker or adapter molecule, A linker or adapter molecule can be one or

2016204968 15 Jul2016 more amino acid residues (or -mers), e.g., I, 2, 3, 4, 5, 6, 7, 8, or 9 residues (or -mers), preferably from 10 to 50 amino acid residues (or -mers), e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 residues (or -mers), and more preferably from 15 to 35 amino acid residues (or -mers). A linker or adapter molecule can also be designed with a cleavage site for a DNA restriction endonuclease or for a protease to allow for the separation of the fused moieties.

a,_Fc Fusions

In one embodiment of the present invention, an FGF21 polypeptide mutant is fused to one or more domains of an Fc region of human IgG. Antibodies comprise two functionally independent parts, a variable domain known as “Fab,” that binds an antigen, and a constant domain known as “Fc,” that is involved in effector functions such as complement activation and attack by phagocytic cells. An Fc has a long serum half-life, whereas a Fab is short-lived (Capon et al., 1989, Nature 337: 525-31), When joined together with a therapeutic protein, an Fc domain can provide longer half-life or incorporate such functions as Fc receptor binding, protein A binding, complement fixation, and perhaps even placental transfer (Capon eta!., 1989).

In vivo pharmacokinetic analysis indicated that human FGF21 has a short half-life of about 1 hour in mice due to rapid clearance and in vivo degradation. Therefore, to extend the half-life of FGF2I an Fc sequence was fused to the N- or C-terminal end of the FGF21 polypeptide. The fusion of an Fc region to wild type FGF21, in particularly Fc fused to the N-terminus of wild type FGF21, did not extend the half-life as expected, however, which led to an investigation of the proteolytic degradation of FGF2I in vivo and the identification of FGF2I mutants that were resistant to such degradation. Such mutants are described in, for example, Examples 8 and 11, and exhibit longer half-lives than wild-type FGF21. These and other FGF21 fusion proteins form embodiments of the present invention.

Throughout the disclosure, Fc-FGF21 refers to a fusion protein in which the Fc sequence is fused to the N-terminus of FGF21. Similarly, throughout the disclosure,

FGF21-Fc refers to a fusion protein in which the Fc sequence is fused to the C-terminus ofFGF21.

2016204968 15 Jul2016

The resulting FGF21 fusion protein can be purified, for example, by the use of a Protein A affinity column. Peptides and proteins fused to an Fc region have been found to exhibit a substantially greater half-life in vivo than the unfused counterpart. Also, a fusion to an Fc region allows for dimerization/multimerization of the fusion polypeptide.

The Fc region can be a naturally occurring Fc region, or can be altered to improve certain qualities, such as therapeutic qualities, circulation time, or reduced aggregation.

Useful modifications of protein therapeutic agents by fusion with the “Fc” domain of an antibody are discussed in detail in International Publication No. WO 00/024782, which is hereby incorporated by reference in its entirety. This document discusses linkage to a “vehicle” such as polyethylene glycol (PEG), dextran, or an Fc region.

b. Fusion Protein Linkers

When forming the fusion proteins of the present invention, a linker can, but need not, be employed. When present, the linker’s chemical structure may not critical, since it serves primarily as a spacer. The linker can be made up of amino acids linked together by peptide bonds. In some embodiments of the present invention, the linker is made up of from 1 to 20 amino acids linked by peptide bonds, wherein the amino acids arc selected from the 20 naturally occurring amino acids. In various embodiments, the 1 to 20 amino acids are selected from the amino acids glycine, serine, alanine, proline, asparagine, glutamine, and lysine. In some embodiments, a linker is made up of a majority of amino acids that arc stcrically unhindered, such as glycine and alanine. In some embodiments, linkers arc polyglycines (such as (Glyfi (SEQ ID NO:29) and (Giy)s (SEQ ID NO:30)), polyalanines, combinations of glycine and alanine (such as poly(GlyAla)), or combinations of glycine and serine (such as poly(Gly-Ser)). Other suitable

5 linkers include: (Glyjs-Scr-CGiyfi-Ser-fGlyfi-Scr (SEQ ID NO:23), (Gly)j-Ser-(Gly)^Ser-(Glyfi-Ser (SEQ ID NO:31), (Gly)j-Lys-(Glyfi (SEQ ID NO:32), (Gly)rAsn-GlyScr-(G!y)₂ (SEQ ID NO:33), (Gly)j-Cys-(Glyfi (SEQ ID NO:34), and Gly-Pro-Asn-GlyGly (SEQ ID NO:35). While a linker of 15 amino acid residues has been found to work particularly well for FGF21 fusion proteins, the present invention contemplates linkers of any length or composition.

2016204968 15 Jul2016

The linkers described herein arc excmplaiy, and linkers that arc much longer and which include other residues are contemplated by the present invention. Non-peptide linkers arc also contemplated by the present invention. For example, alkyl linkers such as —NH—(CHjjs^-C(O)—, wherein s = 2 to 20, could be used. These alkyl linkers can further be substituted by any non-stcrically hindering group, including, but not limited to, a lower alkyl (e.g., C1-C6), lower acyl, halogen (e.g., Cl, Br), CN, NH₂, or phenyl. An exemplary non-peptide linker is a polyethylene glycol linker, wherein the linker has a molecular weight of 100 to 5000 kD, for example, 100 to 500 kD.

8._Chemically-modified FGF21 Mutants

Chemically modified forms of the FGF21 polypeptide mutants described herein, including the truncated forms of FGF21 described herein, can be prepared by one skilled in the art, given the disclosures described herein. Such chemically modified FGF2I mutants arc altered such that the chemically modified FGF21 mutant is different from the unmodified FGF21 mutant, cither in the type or location of the molecules naturally attached to the FGF21 mutant. Chemically modified FGF21 mutants can include molecules formed by the deletion of one or more naturally-attached chemical groups.

In one embodiment, FGF21 polypeptide mutants of the present invention can be modified by the covalent attachment of one or more polymers. For example, the polymer selected is typically water-soluble so that the protein to which it is attached docs not precipitate in an aqueous environment, such as a physiological environment. Included within the scope of suitable polymers is a mixture of polymers. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable. Non-water soluble polymers conjugated to FGF21 polypeptide mutants of the present invention also form an aspect of the invention.

Exemplary polymers each can be of any molecular weight and can be branched or unbranchcd. The polymers each typically have an average molecular weight of between about 2 kDa to about 100 kDa (the term “about” indicating that in preparations of a water-soluble polymer, some molecules will weigh more and some less than the stated molecular weight). The average molecular weight of each polymer is preferably between

2016204968 15 Jul2016 about 5 kDa and about 50 kDa, more preferably between about 12 kDa and about 40 kDa, and most preferably between about 20 kDa and about 35 kDa.

Suitable water-soluble polymers or mixtures thereof include, but are not limited to, N-Iinked or O-linked carbohydrates, sugars, phosphates, polyethylene glycol (PEG) (including the forms of PEG that have been used to derivatize proteins, including mono(Ci-Cio), alkoxy-, or aryloxy-polycthylenc glycol), monomethoxy-polyethylene glycol, dextran (such as low molecular weight dextran of, for example, about 6 kD), cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopoiymers, polypropylene oxide/cthylene oxide co-polymcrs, polyoxycthylatcd polyols (e.g., glycerol), and polyvinyl alcohol. Also encompassed by the present invention arc bifunctional crosslinking molecules that can be used to prepare covalently attached FGF2I polypeptide mutant multimers. Also encompassed by the present invention arc FGF21 mutants covalently attached to polystaltc acid.

In some embodiments of the present invention, an FGF21 mutant is covalently, or chemically, modified to include one or more water-soluble polymers, including, but not limited to, polyethylene glycol (PEG), polyoxyethylene glycol, or polypropylene glycol. See, e.g., U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; and 4,179,337. In some embodiments of the present invention, an FGF21 mutant comprises one or more polymers, including, but not limited to, monomethoxy-polyethylene glycol, dextran, cellulose, another carbohydrate-based polymer, poly-(N-vinyl pyrrolidone)polycthylcne glycol, propylene glycol homopoiymers, a polypropylene oxide/cthylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, or mixtures of such polymers.

In some embodiments of the present invention, an FGF21 mutant is covalently25 modified with PEG subunits. In some embodiments, one or more water-soluble polymers are bonded at one or more specific positions (for example, at the N-terminus) of the FGF21 mutant. In some embodiments, one or more water-soluble polymers are randomly attached to one or more side chains of an FGF21 mutant. In some embodiments, PEG is used to improve the therapeutic capacity of an FGF21 mutant. Certain such methods are discussed, for example, in U.S. Patent No. 6,133,426, which is hereby incorporated by reference for any purpose.

2016204968 15 Jul2016

In embodiments of the present invention wherein the polymer is PEG, the PEG group can be of any convenient molecular weight, and can be linear or branched. The average molecular weight of the PEG group will preferably range from about 2 kD to about 100 kDa, and more preferably from about 5 kDa to about 50 kDa, e.g., 10, 20, 30,

40, or 50 kDa. The PEG groups will generally be attached to the FGF21 mutant via acylation or reductive alkylation through a reactive group on the PEG moiety (e.g., an aldehyde, amino, thiol, or ester group) to a reactive group on the FGF21 mutant (e.g., an aldehyde, amino, or ester group).

The PEGylation of a polypeptide, including the FGF21 mutants of the present 10 invention, can be specifically carried out using any of the PEGylation reactions known in the art. Such reactions are described, for example, in the following references: Francis et al., 1992, Focus on Growth Factors 3: 4-10; European Patent Nos. 0 154 316 and 0 401 384; and U.S. Patent No. 4,179,337. For example, PEGylation can be carried out via an acylation reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer) as described herein. For the acylation reactions, a selected polymer should have a single reactive ester group. For reductive alkylation, a selected polymer should have a single reactive aldehyde group. A reactive aldehyde is, for example, polyethylene glycol propionaldchyde, which is water stable, or mono Ci-Cio alkoxy or aryloxy derivatives thereof (see, e.g., U.S. Patent No. 5,252,714).

In some embodiments of the present invention, a useful strategy for the attachment of the PEG group to a polypeptide involves combining, through the formation of a conjugate linkage in solution, a peptide and a PEG moiety, each bearing a special functionality that is mutually reactive toward the other. The peptides can be easily prepared with conventional solid phase synthesis. The peptides are “preactivated” with an appropriate functional group at a specific site. The precursors arc purified and fully characterized prior to reacting with the PEG moiety. Ligation of the peptide with PEG usually takes place in aqueous phase and can be easily monitored by reverse phase analytical HPLC. The PEGylatcd peptides can be easily purified by preparative HPLC and characterized by analytical HPLC, amino acid analysis and laser desorption mass spectrometry.

Polysaccharide polymers are another type of water-soluble polymer that can be

2016204968 15 Jul2016 used for protein modification. Therefore, the FGF21 mutants of the present invention fused to a polysaccharide polymer form embodiments of the present invention. Dextrans are polysaccharide polymers comprised of individual subunits of glucose predominantly linked by alpha 1-6 linkages. The dextran itself is available in many molecular weight ranges, and is readily available in molecular weights from about 1 kD to about 70 kD. Dextran is a suitable water-soluble polymer for use as a vehicle by itself or in combination with another vehicle (e.g., Fc). See, e.g., International Publication No. WO 96/11953. The use of dextran conjugated to therapeutic or diagnostic immunoglobulins has been reported. See, e.g., European Patent Publication No. 0 315 456, which is hereby incorporated by reference. The present invention also encompasses the use of dextran of about 1 kD to about 20 kD.

hi general, chemical modification can be performed under any suitable condition used to react a protein with an activated polymer molecule. Methods for preparing chemically modified polypeptides will generally comprise the steps of: (a) reacting the polypeptide with the activated polymer molecule (such as a reactive ester or aldehyde derivative of the polymer molecule) under conditions whereby a FGF21 polypeptide mutant becomes attached to one or more polymer molecules, and (b) obtaining the reaction products. The optimal reaction conditions will be determined based on known parameters and the desired result. For example, the larger the ratio of polymer molecules to protein, the greater the percentage of attached polymer molecule. In one embodiment of the present invention, chemically modified FGF21 mutants can have a single polymer molecule moiety at the amino-terminus (see, e.g., U.S. Patent No. 5,234,784) in another embodiment of the present invention, FGF21 polypeptide mutants can be chemically coupled to biotin. The biotin/FGF21 polypeptide mutants arc then allowed

5 to bind to avidin, resulting in tetravalcnt avidin/biotin/FGF21 polypeptide mutants.

FGF21 polypeptide mutants can also be covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugates precipitated with anti-DNP or antiTNP-IgM to form dccamcric conjugates with a valency of 10,

Generally, conditions that can be alleviated or modulated by the administration of

0 the present chemically modified FGF21 mutants include those described herein for

FGF21 polypeptide mutants. However, the chemically modified FGF21 mutants

2016204968 15 Jul2016 disclosed herein can have additional activities, enhanced or reduced biological activity, or other characteristics, such as increased or decreased half-life, as compared to unmodified FGF2I mutants.

9. Therapeutic Compositions of FGF21 Mutants and Administration Thereof

Therapeutic compositions comprising FGF2I mutants are within the scope of the present invention, and are specifically contemplated in light of the identification of several mutant FGF21 sequences exhibiting enhanced properties. Such FGF21 mutant pharmaceutical compositions can comprise a therapeutically effective amount of an

FGF21 polypeptide mutant in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration.

Acceptable formulation materials preferably are nontoxic to recipients at the dosages and concentrations employed.

The pharmaceutical composition can contain formulation materials for modifying, maintaining, or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption, or penetration of the composition. Suitable formulation materials include, but arc not limited to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite, or sodium hydrogen20 sulfite), buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates, or other organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose, or dextrins), proteins (such as scrum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic polymers (such as polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or

2016204968 15 Jul2016 wetting agents (such as pluronics; PEG; sorbitan esters; polysorbates such as polysorbatc 20 or polysorbatc 80; triton; tromethamine; lecithin; cholesterol or tyloxapal), stability enhancing agents (such as sucrose or sorbitol), tonicity enhancing agents (such as alkali metal halides - preferably sodium or potassium chloride - or mannitol sorbitol), delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants (see, e.g., Remington's Pharmaceutical Sciences (18th Ed., A.R. Gennaro, cd., Mack Publishing Company 1990), and subsequent editions of the same, incorporated herein by reference for any purpose).

The optimal pharmaceutical composition will be determined by a skilled artisan 10 depending upon, for example, the intended route of administration, delivery format, and desired dosage (see, e.g., Remington's Pharmaceutical Sciences, supra). Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the FGF21 polypeptide mutant.

The primary vehicle or carrier in a pharmaceutical composition can be cither 15 aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier for injection can be water, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with scrum albumin arc further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute. In one embodiment of the present invention, FGF21 polypeptide mutant compositions can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents (Remington's Pharmaceutical Sciences, supra) in the form of a lyophilized cake or an aqueous solution. Further, the FGF21 polypeptide mutant product can be formulated as a lyophilizate using appropriate excipients such as sucrose.

The FGF21 polypeptide mutant pharmaceutical compositions can be selected for parenteral delivery. Alternatively, the compositions can be selected For inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.

The formulation components are present in concentrations that are acceptable to

2016204968 15 Jul2016 the site of administration. For example, buffers arc used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

When parenteral administration is contemplated, the therapeutic compositions for 5 use in this invention can be in the form of a pyrogen-free, parenterally acceptable, aqueous solution comprising the desired FGF21 polypeptide mutant in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which an FGF21 polypeptide mutant is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, biocredible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which can then be delivered via a depot injection. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

In one embodiment, a pharmaceutical composition can be formulated for inhalation. For example, an FGF21 polypeptide mutant can be formulated as a dry powder for inhalation. FGF21 polypeptide mutant inhalation solutions can also be

0 formulated with a propellant for aerosol delivery. In yet another embodiment, solutions can be nebulized. Pulmonary administration is further described in International Publication No. WO 94/20069, which describes the pulmonary delivery of chemically modified proteins.

It is also contemplated that certain formulations can be administered orally. In one embodiment of the present invention, FGF21 polypeptide mutants that arc administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the FGF21 polypeptide mutant. Diluents, flavorings, low melting point waxes, vegetable

2016204968 15 Jul2016 oiks, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

Another pharmaceutical composition can involve an effective quantity of FGF21 polypeptide mutants in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

Additional FGF21 polypeptide mutant pharmaceutical compositions will be evident to those skilled in the art, including formulations involving FGF21 polypeptide mutants in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, biocrodible microparticles or porous beads and depot injections, arc also known to those skilled in the art (see, e.g., International Publication No. WO 93/15722, which describes the controlled release of porous polymeric microparticles for the delivery of pharmaceutical compositions, and Wischkc & Schwcndcman, 2008, Int. J. Phann. 364: 298-327, and Freiberg & Zhu, 2004, Int. J. Phann. 282: 1-18, which discuss microsphere/microparticle preparation and use).

Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polylactides (U.S. Patent No. 3,773,919 and European Patent No. 0 058 481), copolymers of L-giutamic acid and gamma ethyl-L-glutamatc (Sidman et al., 1983, Biopolymers 22: 547-56), poly(225 hydroxycthyl-mcthacrylate) (Langer et al., 1981,./. Biomed. Mater. Res. 15: 167-277 and Langer, 1982, Chem. Tech. 12: 98-105), ethylene vinyl acetate (Langer et al., supra) or poly-D(-)-3-hydroxybutyric acid (European Patent No. 0 133 988). Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art. See, e.g., Epstein et al., 1985, Proc. Natl. Acad. Sci. U.S.A.

0 82: 3688-92; and European Patent Nos. 0 036 676, 0 088 046, and 0 143 949.

2016204968 15 Jul2016

The FGF21 polypeptide mutant pharmaceutical composition to be used for in vivo administration typically must be sterile. This can be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method can be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration can be stored in lyophilized form or in a solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Once the pharmaceutical composition has been formulated, it can be stored in 10 sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. Such formulations can be stored cither in a ready-to-usc form or in a form (e.g,, lyophilized) requiring reconstitution prior to administration.

In a specific embodiment, the present invention is directed to kits for producing a single-dose administration unit. The kits can each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this invention arc kits containing single and multi-chambercd prefillcd syringes (e.g., liquid syringes and lyosyringcs).

The effective amount of an FGF21 polypeptide mutant pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the FGF2I polypeptide mutant is being used, the route of administration, and the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician can titer

5 the dosage and modify the route of administration to obtain the optimal therapeutic effect. A typical dosage can range from about 0.1 gg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage can range from 0.1 gg/kg up to about 100 mg/kg; or 1 gg/kg up to about 100 mg/kg; or 5 gg/kg, 10 gg/kg, 15 gg/kg, 20 gg/kg, 25 gg/kg, 30 gg/kg, 35 gg/kg, 40 gg/kg, 45 gg/kg, 50 gg/kg,

55 gg/kg, 60 gg/kg, 65 gg/kg, 70 gg/kg, 75 gg/kg, up to about 100 mg/kg. in yet other embodiments, the dosage can be 50 gg/kg, 100 gg/kg, 150 gg/kg, 200 gg/kg, 250 gg/kg,

2016204968 15 Jul2016

300 gg/kg, 350 gg/kg, 400 gg/kg, 450 gg/kg, 500 gg/kg, 550 gg/kg, 600 gg/kg, 650 gg/kg, 700 gg/kg, 750 gg/kg, 800 gg/kg, 850 ug/kg, 900 gg/kg, 950 gg/kg, 100 gg/kg, 200 gg/kg, 300 gg/kg, 400 gg/kg, 500 gg/kg, 600 gg/kg, 700 gg/kg, 800 gg/kg, 900 gg/kg, 1000 gg/kg, 2000 gg/kg, 3000 gg/kg, 4000 gg/kg, 5000 gg/kg, 6000 gg/kg, 7000 gg/kg, 8000 gg/kg, 9000 gg/kg or 10 mg/kg.

The frequency of dosing will depend upon the pharmacokinetic parameters of the

FGF21 polypeptide mutant in the formulation being used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition can therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages can be ascertained through use of appropriate dose-response data.

The route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally; through injection by intravenous, intraperitoneal, intracerebral (intraparenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, or intralcsiona! routes; by sustained release systems (which may also be injected); or by implantation devices. Where desired, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

Alternatively or additionally, the composition can be administered locally via implantation of a membrane, sponge, or other appropriate materia! onto which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

10. Therapeutic Uses of FGF21 Polypeptide Mutants

FGF21 polypeptide mutants can be used to treat, diagnose, ameliorate, or prevent a number of diseases, disorders, or conditions, including, but not limited to metabolic disorders. In one embodiment, the metabolic disorder to be treated is diabetes, e.g., type 2 diabetes. In another embodiment, the metabolic disorder is obesity. Other

2016204968 15 Jul2016 embodiments include metabolic conditions or disorders such as dyslipidimia; hypertension; hepatostcaotosis, such as non-alcoholic steatohepatitis (NASH); cardiovascular disease, such as atherosclerosis; and aging.

In application, a disorder or condition such as diabetes or obesity can be treated 5 by administering an FGF2I polypeptide mutant as described herein to a patient in need thereof in the amount of a therapeutically effective dose. The administration can be performed as described herein, such as by IV injection, intraperitoneal injection, intramuscular injection, or orally in the form of a tablet or liquid formation. In most situations, a desired dosage can be determined by a clinician, as described herein, and can represent a therapeutically effective dose of the FGF21 mutant polypeptide. It will be apparent to those of skill in the art that a therapeutically effective dose of FGF21 mutant polypeptide will depend, inter alia, upon the administration schedule, the unit dose of antigen administered, whether the nucleic acid molecule or polypeptide is administered in combination with other therapeutic agents, the immune status and the health of the recipient. The term “therapeutically effective dose,” as used herein, means that amount of FGF21 mutant polypeptide that elicits the biological or medicinal response in a tissue system, animal, or human being sought by a researcher, medical doctor, or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

11. Antibodies

Antibodies and antibody fragments that specifically bind to the FGF21 mutant polypeptides of the present invention but do not specifically bind to wild-type FGF21 polypeptides are contemplated and are within the scope of the present invention. The antibodies can be polyclonal, including monospecific polyclonal; monoclonal (MAbs); recombinant; chimeric; humanized, such as complementarity-determining region (CDR)grafted; human; single chain; and/or bispecific; as well as fragments; variants; or chemically modified molecules thereof. Antibody fragments include those portions of the antibody that specifically bind to an epitope on an FGF21 mutant polypeptide.

0 Examples of such fragments include Fab and F(ab’) fragments generated by enzymatic cleavage of full-length antibodies. Other binding fragments include those generated by

2016204968 15 Jul2016 recombinant DNA techniques, such as the expression of recombinant plasmids containing nucleic acid sequences encoding antibody variable regions.

Polyclonal antibodies directed toward an FGF21 mutant polypeptide generally are produced in animals (e.g., rabbits or mice) by means of multiple subcutaneous or intraperitonea 1 injections of the FGF21 mutant polypeptide and an adjuvant. It can be useful to conjugate an FGF21 mutant polypeptide to a carrier protein that is immunogenic in the species to be immunized, such as keyhole limpet hcmocyanin, serum, albumin, bovine thyroglobulin, or soybean trypsin inhibitor. Also, aggregating agents such as alum are used to enhance the immune response. After immunization, the animals arc bled and the scrum is assayed for anti-FGF21 mutant antibody titer.

Monoclonal antibodies directed toward FGF21 mutant polypeptides can be produced using any method that provides for the production of antibody molecules by continuous cell lines in culture. Examples of suitable methods for preparing monoclonal antibodies include the hybridoma methods of Kohler et ai„ 1975, Nature 256: 495-97 and the human B-cell hybridoma method (Kozbor, 1984,,/. Immunol. 133: 3001; Brodeur et al., Monoclonal Antibody Production Techniques and Applications 51-63 (Marcel Dckkcr, Inc., 1987). Also provided by the invention arc hybridoma cell lines that produce monoclonal antibodies reactive with FGF21 mutant polypeptides.

Monoclonal antibodies of the invention can be modified for use as therapeutics.

In one embodiment, the monoclonal antibody is a “chimeric” antibody in which a portion of the heavy (H) and/or light (L) chain is identical with or homologous to a corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is/are identical with or homologous to a corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass. Also included are fragments of such antibodies, so long as they exhibit the desired biological activity. See, e.g., U.S. Patent No. 4,816,567; Morrison et al., 1985, Proc. Natl. Acad. Sci, U.S.A. 81: 6851-55.

In another embodiment, a monoclonal antibody of the invention is a “humanized” antibody. Methods for humanizing non-human antibodies are well known in the art. See,

0 e.g., U.S. Patent Nos. 5,585,089 and 5,693,762. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human.

2016204968 15 Jul2016

Humanization can be performed, for example, using methods described in the art (see, e.g., Jones et ai., 1986, Nature 321: 522-25; Riechmann et al., 1998, Nature 332: 323-27; Vcrhocycn et al., 1988, Science 239: 1534-36), by substituting at least a portion of a rodent complementarity-determining region for the corresponding regions of a human antibody.

Also encompassed by the invention are human antibodies that bind the FGF21 mutant polypeptides of the present invention. Using transgenic animals (e.g., mice) that are capable of producing a repertoire of human antibodies in the absence of endogenous immunoglobulin production such antibodies are produced by immunization with an

FGF21 mutant antigen (i.e,, having at least 6 contiguous amino acids), optionally conjugated to a carrier. See, e.g., Jakobovits et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90: 2551-55; Jakobovits et al., 1993, Nature 362: 255-58; Bruggermann et al., 1993, Year in Immuno. 7: 33. In one method, such transgenic animals arc produced by incapacitating the endogenous loci encoding the heavy and light immunoglobulin chains therein, and inserting loci encoding human heavy and light chain proteins into the genome thereof. Partially modified animals, i.e., animals having less than the full complement of modifications, arc then cross-bred to obtain an animal having all of the desired immune system modifications. When administered an immunogen, these transgenic animals produce antibodies with human (rather than, e.g., murine) amino acid sequences, including variable regions that arc immunospccific for these antigens. See, e.g., International Publication Nos. WO 96/33735 and WO 94/02602. Additional methods arc described in U.S. Patent No. 5,545,807, International Publication Nos. WO 91/10741 and WO 90/04036, and in European Patent No. 0 546 073. Human antibodies can also be produced by the expression of recombinant DNA in host cells or by expression in hybridoma cells as described herein.

In an alternative embodiment, human antibodies can also be produced from phage-display libraries (see, e.g., Hoogcnboom et a!., 1991, ,/. Mol. Biol. 22Ί'. 381; Marks et al., 1991,./, Mol. Biol. 222: 581). These processes mimic immune selection through the display of antibody repertoires on the surface of filamentous bacteriophage, and subsequent selection of phage by their binding to an antigen of choice. One such technique is described in International Publication No. WO 99/10494, which describes

2016204968 15 Jul2016 the isolation of high affinity and functional agonistic antibodies for MPL- and mskreccptors using such an approach.

Chimeric, CDR grafted, and humanized antibodies are typically produced by recombinant methods. Nucleic acids encoding the antibodies are introduced into host cells and expressed using materials and procedures described herein. In one embodiment, the antibodies arc produced in mammalian host cells, such as CHO cells. Monoclonal (e.g., human) antibodies can be produced by the expression of recombinant DNA in host cells or by expression in hybridoma cells as described herein.

The anti-FGF21 mutant antibodies of the invention can be employed in any 10 known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays (see, e.g., Sola, Monoclonal Antibodies: A Manual of Techniques 147-158 (CRC Press, Inc., 1987), incorporated herein by reference in its entirety) for the detection and quantitation of FGF21 mutant polypeptides. The antibodies will bind FGF21 mutant polypeptides with an affinity that is appropriate for the assay method being employed.

For diagnostic applications, in certain embodiments, anti-FGF21 mutant antibodies can be labeled with a detectable moiety. The detectable moiety can be any one that is capable of producing, cither directly or indirectly, a detectable signal. For example, the detectable moiety can be a radioisotope, such as Ή, ^NC, ^?2P, ³⁵S, ^l25I, ^wTc, ^1HIn, or ⁶⁷Ga; a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or lucifcrin; or an enzyme, such as alkaline phosphatase, pgalactosidase, or horseradish peroxidase (Bayer et al., 1990, Meth. Enz. 184: 138-63).

Competitive binding assays rely on the ability of a labeled standard (e.g., an FGF21 mutant polypeptide, or an immunologically reactive portion thereof) to compete with the test sample analyte (e.g.. an FGF2I mutant polypeptide) for binding with a limited amount of anti-FGF21 mutant antibody. The amount of an FGF21 mutant polypeptide in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies typically are insolubilized before or after the competition,

0 so that the standard and analyte that are bound to the antibodies can conveniently be separated from the standard and analyte that remain unbound.

2016204968 15 Jul2016

Sandwich assays typically involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected and/or quantitated. In a sandwich assay, the test sample analyte is typically bound by a first antibody that is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, e.g., U.S. Patent No. 4,376,110. The second antibody can itself be labeled with a detectable moiety (direct sandwich assays) or can be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assays). For example, one type of sandwich assay is an enzyme-linked immunosorbent assay (ELISA), in which case the detectable moiety is an enzyme.

The anti-FGF21 mutant antibodies of the present invention are also useful for in vivo imaging. An antibody labeled with a detectable moiety can be administered to an animal, preferably into the bloodstream, and the presence and location of the labeled antibody in the host assayed. The antibody can be labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other detection means known in the art.

The FGF21 mutant antibodies of the invention can be used as therapeutics. These therapeutic agents arc generally agonists or antagonists, in that they either enhance or reduce, respectively, at least one of the biological activities of an FGF21 mutant polypeptide. In one embodiment, antagonist antibodies of the invention are antibodies or binding fragments thereof which arc capable of specifically binding to an FGF21 mutant polypeptide and which are capable of inhibiting or eliminating the functional activity of an FGF21 mutant polypeptide in vivo or in vitro. In some embodiments, the antagonist antibody will inhibit the functional activity of an FGF21 mutant polypeptide by at least about 50%, and preferably by at least about 80%. In another embodiment, the antiFGF2I mutant antibody is capable of interfering with the interaction between an FGF21 mutant polypeptide and an FGF receptor thereby inhibiting or eliminating FGF21 mutant polypeptide activity in vitro or in vivo. Agonist and antagonist anti-FGF21 mutant antibodies are identified by screening assays that are well known in the art,

The invention also relates to a kit comprising FGF21 mutant antibodies and other reagents useful for detecting FGF21 mutant polypeptide levels in biological samples.

2016204968 15 Jul2016

Such reagents can include a detectable label, blocking scrum, positive and negative control samples, and detection reagents.

EXAMPLES

The Examples that follow are illustrative of specific embodiments of the invention, and various uses thereof. They are set forth for explanatory purposes only, and should not be construed as limiting the scope of the invention in any way.

EXAMPLE I

Preparation of FGF21 Expression Constructs

A nucleic acid sequence encoding the mature FGF21 polypeptide was obtained by polymerase chain reaction (PCR) amplification using primers having nucleotide sequences corresponding to the 5’ and 3’ ends of the mature FGF21 sequence. Table 2 lists the primers that were used to amplify the mature FGF21 sequence.

Table 2

PCR Primers for Preparing FGF21 Construct

Primer	Sequence	SEQ ID NO:
Sense	5'-AGGAGGAATAACATATGCATCCAATTCCAGATTCTTCTCC-3'	5
Antisense	5'-TAGTGAGCTCGAATTCTTAGGAAGCGTAGCTGG-3’	6

The primers used to prepare the FGF21 expression construct incorporated restriction endonuclease sites for directional cloning of the sequence into a suitable expression vector (e.g., pET30 (Novagcn/EMD Biosciences; San Diego, CA) or pAMG33 (Amgen; Thousand Oaks, CA)). The expression vector pAMG33 contains a low-copy number R-100 origin of replication, a modified fac promoter, and a kanamycinrcsistance gene. The expression vector pET30 contains a pBR322-derived origin of replication, an inducible T7 promoter, and a kanamycin-resistance gene. While expression from pAMG33 was found to be higher, pET30 was found to be a more reliable cloning vector. Thus, the majority of the constructs described in the instant application were first generated in pET30 and then screened for efficacy. Selected

2016204968 15 Jul2016 sequences were then transferred to pAMG33 for further amplification.

The FGF21 sequence was amplified in a reaction mixture containing 40.65 pL dH₂O, 5pL PfuUltra II Reaction Buffer (lOx), 1.25 pL dNTP Mix (40 mM - 4 x lOmM), 0.1 pL Template (100 ng/mL), 1 pL Primer I (10 pM), 1 pL Primer? (10 pM), and 1 pL

PfuUltra II fusion HS DNA Polymerase (Stratagene; La Jolla, CA), Amplification reactions were performed by heating for 2 minutes at 95°C; followed by ten cycles at 95°C for 20 seconds, 60°C for 20 seconds (with an additional 1°C subtracted per cycle), and 72°C for 15 seconds/kilobase of desired product; followed by 20 cycles at 94°C for 20 seconds, 55°C for 20 seconds, and 72°C for 15 seconds/kilobase of desired product;

followed by 72°C for 3 minutes. Amplification products were digested with the restriction endonucleases Ndel, Dpnl, and EcoRI; ligated into a suitable vector; and then transformed into competent cells,

EXAMPLE 2

Purification of FGF21 Proteins from Bacteria

In the Examples that follow, various FGF21 proteins, including the wild-type FGF21 polypeptide, truncated FGF21 polypeptides, FGF21 mutants, and FGF21 fusion proteins, were expressed in a bacterial expression system. After expression, which is described below, the FGF21 proteins were purified as described in this Example, unless otherwise indicated.

To purify the wild-type FGF21 polypeptide, truncated FGF21 polypeptides, and FGF21 mutants from bacterial inclusion bodies, double-washed inclusion bodies (DWIBs) were solubilized in a solubilization buffer containing guanidine hydrochloride and DTT in Tris buffer at pH 8.5 and then mixed for one hour at room temperature, and the solubilization mixture was added to a refold buffer containing urea, arginine, cysteine, and cystamine hydrochloride at pH 9.5 and then mixed for 24 hours at 5°C (see, e.g., Clarke, 1998, Chit. Opin. Biotechnol. 9: 157-63; Mannall et at., 2007, Biotechnol. Bioeng. 97: 1523-34; Rudolph et a!., 1997, Folding proteins, Protein Function: A Practical Approach (Creighton, ed„ New York, IRL Press) 57-99; and Ishibashi et a!.,

2005, Protein Expr. Purif. 42: 1-6).

Following solubilization and refolding, the mixture was filtered through a 0.45

2016204968 15 Jul2016 micron filter. The refold pool was then concentrated approximately 10-fold with a 10 kD molecular weight cut-off Pall Omega cassette at a transmembrane pressure (TMP) of 20 psi, and dialfiltercd with 3 column volumes of 20 mM Tris, pH 8.0 at a TMP of 20 psi.

The clarified sample was then subjected to anion exchange (AEX) 5 chromatography using a Q Sepharose HP resin. A linear salt gradient of 0 to 250 mM NaCl in 20 mM Tris was run at pH 8.0 at 5°C. Peak fractions were analyzed by SDSPAGE and pooled.

The AEX eluate pool was then subjected to hydrophobic interaction chromatography (HIC) using a Phenyl Sepharose HP resin. Protein was eluted using a decreasing linear gradient of 0.7 M to 0 M ammonium sulfate at pH 8.0 and ambient temperature. Peak fractions were analyzed by SDS-PAGE (Laemmli, 1970, Nature 227: 680-85) and pooled.

The HIC pool was concentrated with a 10 kD molecular weight cut-off Pall Omega 0.2 m² cassette to 7 mg/mL at a TMP of 20 psi. The concentrate was dialfiltercd with 5 column volumes of 10 mM KPCfi. 5% sorbitol, pH 8.0 at a TMP of 20 psi, and the recovered concentrate was diluted to 5 mg/mL. Finally, the solution was filtered through a Pall mini-Klecnpac 0.2 μΜ Posidync membrane.

To purify FGF21 fusion proteins and FGF21 fusion mutant proteins from bacterial inclusion bodies, double-washed inclusion bodies (DWIBs) were solubilized in a solubilization buffer containing guanidine hydrochloride and DTT in Tris buffer at pH 8.5 and then mixed for one hour at room temperature, and the solubilization mixture was added to a refold buffer containing urea, arginine, cysteine, and cystamine hydrochloride at pH 9.5 and then mixed for 24 hours at 5°C (see, e.g., Clarke, 1998, Curr. Opin. BiotechnoL 9: 157-63; Mannall et al., 2007, BiotechnoL Bioeng. 97: 1523-34; Rudolph et a!., 1997, “Folding proteins,” Protein Function: A Practical Approach (Creighton, ed.,

New York, 1RL Press) 57-99; and Ishibashi et al., 2005, Protein Expr. Purif. 42: 1-6).

Following solubilization and refolding, the mixture was dialyzed against 5 volumes of 20 mM Tris, pH 8.0 using 10 kD dialysis tubing. The pH of the dialyzed refold was adjusted to 5,0 with 50% acetic acid, and then clarified by centrifugation for

30 minutes at 4K.

The clarified sample was then subjected to anion exchange (AEX)

2016204968 15 Jul2016 chromatography using a Q Scpharosc HP resin. A linear salt gradient of 0 to 250 rnM NaCl in 20 mM Tris was run at pH 8.0 at 5°C. Peak fractions were analyzed by SDSPAGE {Laemmli, 1970, Nature 227: 680-85) and pooled.

The AEX eluate pool was then subjected to hydrophobic interaction 5 chromatography (H1C) using a Phenyl Sepharose HP resin. Protein was eluted using a decreasing linear gradient of 0.6 M to 0 M ammonium sulfate at pH 8.0 at ambient temperature. Peak fractions were analyzed by SDS-PAGE and pooled.

Following the HIC step, the pool was then dialyzed 60 volumes of 10 mM Tris, 2.2% sucrose, 3.3% sorbitol, pH 8.5. The dialyzed pool was concentrated to 5 mg/mL using a jumbosep. Finally, the solution was filtered through a Pall mini-Kleenpac 0.2 liM

Posidyne membrane.

EXAMPLE 3

Preparation and Expression of Truncated FGF21 Proteins 15 Constructs encoding the truncated FGF21 proteins listed in Table 3 were prepared by PCR amplification of the wild-type FGF21 expression vector as described below (the construction of the wild-type FGF21 expression vector is described in Example 1).

Table 3

FGF21 Truncations

Amino Acid Residues	Number of Residues Truncated*
C-terminus Truncations
1 - 180	1
1 - 179	2
I - 178	3
1 - 177	4
1 - 176	5
1 - 175	6
1 - 174	7
1 - 173	8
1 - 172	9
1 - 171	10
1 - 169	12
1 - 168	13

2016204968 15 Jul2016

1 - 167	14
I - 166	15
1 - 165	16
1 - 164	17
1 - 160	21
1 - 156	25
1 - 152	29
1 - 149	32
1 - 113	68
N-terminus Truncations
2-181	1
3-181	2
4-181	3
5 - 181	4
6-181	5
7- 181	6
8-181	7
9- 181	8
C- and N-terminus Truncations
5- 174	11
7- 172	17
9- 169	20
9-149	40
15-169	26
15- 149	46
15-113	82

* relative to mature FGF21 polypeptide

Truncated FGF21 protein constructs were prepared using primers having sequences that arc homologous to regions upstream and downstream of a codon (or codons) to be deleted (resulting in the truncation). The primers used in such amplification reactions also provided approximately 15 nucleotides of overlapping sequence to allow' for recircularization of the amplified product, namely the entire vector now having the desired mutant.

An exemplary truncated FGF21 construct, encoding an FGF21 protein lacking the 10 histidine residue at position 1 of the mature FGF21 sequence (i.e., the 2-181 truncation mutant), was prepared using the primers shown in Table 4.

2016204968 15 Jul2016

Table 4

PCR Primers for Preparing Exemplars- Truncation FGF21 Mutant

Primer	Sequence	SEQ ID NO:
Sense	5'-GGAGATATACATATGCCAATTCCAGATTCTTCTCCATTATT-3'	7
Antisense	5’-CATATGTATATCTCCTTCTTAAAGTTAAACAAAA-3'	8

The primers shown in Table 4 allow for the deletion of the histidine residue as 5 shown below, wherein the upper sequence (SEQ ID NO: 10) is a portion of a mature FGF21 polypeptide comprising a N-terminal methionine, the second sequence is the sense primer (SEQ ID NO: 7), the third and fourth sequences (SEQ ID NOs: 11 and 12) are portions of an FGF21 expression construct, and the fifth sequence is the antisense primer (SEQ ID NO: 9):

MetHisProIleProAspSerSerProLeu 5'-GGAGATATACATATG---CCAATTCCAGATTCTTCTCCATTATT

TTTTGTTTAACTTTAAGAAGGAGATATACATATGCATCCAATTCCAGATTCTTCTCCATTATT

AAAACAAATTGAAATTCTTCCTCTATATGTATACGTAGGTTAAGGTCTAAGAAGAGGTAATAA

AAAACAAATTGAAATTCTTCCTCTATATGTATAC-5'

Truncated FGF21 protein constructs were prepared using essentially the PCR conditions described in Example 1. Amplification products were digested with the restriction endonuclease Dpnl, and then transformed into competent cells. The resulting clones were sequenced to confirm the absence of polymerase-generated errors.

Truncated FGF21 proteins were expressed by transforming competent BL21 (DE3) or BL21 Star (Invitrogen; Carlsbad, CA) cells with the construct encoding a particular truncated FGF21 protein. Transformants were grown overnight with limited aeration in TB media supplemented with 40 Ltg/mL kanamycin, were aerated the next morning, and after a short recovery period, were induced in 0.4 mM IPTG. FGF21 mutants were harvested by centrifugation 18-20 hours after induction.

2016204968 15 Jul2016

EXAMPLE 4

In vitro Activity of Truncated FGF2I Proteins Experiments were performed to identify truncated FGF21 proteins that retain wild-type FGF21 activity in an ELK-luciferase in vitro assay. Table 5 summarizes the 5 results obtained for FGF21 proteins having truncations at the N-terminus, the C-terminus, or at both the N-terminus and C-tcrminus. ELK-luciferase assays were performed using a recombinant human 293T kidney cell system, in which the 293T cells overexpress betaklotho and luciferase reporter constructs. These constructs also contain sequences encoding GAL4-ELK1 and 5xUAS-Luc, a luciferase reporter driven by a promoter containing five tandem copies of the Gal4 binding site. Beta-klotho is a co-receptor that is required by FGF21 for activation of its FGF receptors and induction of intracellular signal transduction, which in turn leads to Erk and ELK phosphorylation. Luciferase activity is regulated by the level of phosphorylatcd Erk/ELKl, and is used to indirectly monitor and quantify FGF21 activity.

ELK-luciferase assays were performed by culturing the 293T cells in the presence of different concentrations of wild-type FGF21 or FGF21 mutant polypeptide for 6 hours, and then assaying the cell lysates for luciferase activity. Figures 1A-1B show the results of an ELK-luciferase activity assay performed on the FGF21 truncation mutants 7-181 and 8-181 (Figure 1A) and the FGF2I truncation mutants 1-172, 1-171, 1-169, and 1-164

0 (Figure 1B). The luminescence obtained in ELK-lucifcrasc assays for each of the FGF21 truncation mutants 3-181,4-181, 5-181, 7-181, 8-181, 1-180, 1-178, 1-177, 1-176, 1-175, 1-174, 1-173, 1-172, 9-181, and 1-149 is shown in Figure 2.

FGF21 mutant polypeptides were compared with a wild-type FGF21 standard and mutants showing an efficacy of at least 50% of the efficacy of wild-type FGF21 were considered as having not lost FGF21 activity and were assigned a “+” in Table 5.

Table 5

Truncated FGF21 Proteins: in vitro Assay

C-terminus Truncations
Amino Acid Residues	Efficacy	Activity (+/-)
1 - 180	93.2%	+
I - 178	95.0%	+

2016204968 15 Jul2016

1 - 177	112.0%	+
1 - 376	104.8%	+
1 - 374	104.6%	+
1 - 173	96.1%	+
1 - 172	97.5%	+
1 - 171	113.0%	+
1 - 169	84.9%
1 - 167	20%	—
1 - 166	20%	—
1 -165	10%	-
N-terminus Truncations
Amino Acid Residues	Efficacy	Activity (+/-)
2-381	112.5%	+
3-381	130.3%	+
4-181	117.0%	+
5-181	119.6%	4-
7-181	74.2%	+
8-181	24.9%	—
9-181	12.5%	-

Collectively, the results presented in Table 5 indicate that C-terminal deletions of 14 or more amino acid residues (i.e., a C-tcrminally truncated FGF21 protein consisting of amino acid residues 1-167 and shorter proteins) eliminate the activity of FGF21. In addition, Table 5 indicates that N-terminal deletions of 7 or more amino acid residues (i.e., an N-terminally truncated FGF21 protein consisting of amino acid residues 8-181 and shorter proteins) eliminate the activity of FGF21. Not surprisingly, truncated FGF21 proteins possessing both an N-terminal truncation of 8 to 14 residues and a C-tcrminal truncation of 12 or 32 residues were found to lack activity in ELK-lucifcrasc assays.

Consistent with the data presented in Table 5, truncated FGF21 polypeptides having N-terminal truncations of fewer than 7 amino acid residues constitute embodiments of the present invention. Similarly, truncated FGF21 polypeptides having C-tcrminal truncations of fewer than 13 amino acid residues constitute embodiments of the present invention.

EXAMPLES

In vivo Activity of Truncated FGF21 Proteins FGF21 possesses a number of biological activities, including the ability io lower

2016204968 15 Jul2016 blood glucose, insulin, triglyceride, or cholesterol levels; reduce body weight; or improve glucose tolerance, energy expenditure, or insulin sensitivity. Truncated FGF21 polypeptides were further analyzed for in vivo FGF21 activity, by introducing the truncated FGF21 polypeptides into insulin resistant ob/ob mice, and measuring the ability of a particular truncated FGF21 polypeptide to lower blood glucose. The truncated FGF21 polypeptide to be tested was injected intraperitoncally into an 8 week old ob/ob mouse (Jackson Laboratory), and blood samples were obtained at various time points following a single injection, e.g., 0, 6, 24, 72, 120, and 168 hours after injection. Blood glucose levels were measured with a OneTouch Glucomcter (LifeScan, inc. Milpitas,

CA), and the results expressed as a percent change of blood glucose relative to the baseline level of blood glucose (i.e., at time 0).

The results of one experiment are provided in Figure 3, which shows the amount of blood glucose detected in mice injected with the FGF21 truncation mutants 8-181 and 9-181. This experiment demonstrated that truncated FGF21 fusion proteins comprising amino acid residues 8-181 exhibit blood glucose lowering activity in vivo however the activity is slightly less than the activity of wild-type FGF21 at 3 and 6 hours after injection, but that truncated FGF21 fusion proteins comprising amino acid residues 9-181 do not exhibit such activity. Thus, the in vivo analysis of truncated FGF21 polypeptides indicated that the deletion of up to 7 amino acids from the N-terminus of mature FGF21 does not abolish the molecule's biological activity (in contrast with the in vitro analysis, which suggested that the deletion of 7 amino acids from the N-tcrminus of mature FGF21 would abolish activity).

The differing results obtained with particular N-terminally truncated FGF21 polypeptides (e.g., FGF21 8-181) in in vitro and in vivo assays can be explained by the interaction of FGF21 with beta-klotho and FGF receptor in effecting signal transduction. In particular, FGF21 activates a dual receptor complex comprising the co-receptor betaklotho and FGF receptor (FGFR), which initiates a signaling cascade involving tyrosine kinase. The N-tcrminus of FGF21 has been shown involved in binding and activation of FGFR while the C-terminus of FGF21 is required for beta-klotho interaction (Yie et al.,

2009 FEBS Lett. 583:19-24). The ELK-lucifcrase in vitro assay is performed in 293 kidney cells in which the co-receptor beta-klotho is overexpressed and FGFR is

2016204968 15 Jul2016 expressed at normal levels. The amount of FGFR is low in relative to that of bcta-klotho and the ratio of beta-klotho to FGFR in 293 cells is therefore non-phystological, which may affect receptor complex formation and ultimately ligand binding and activation of FGFR. The 293 in vitro system appears to be more vulnerable to N-terminally truncated

FGF2I polypeptides and therefore may have produced loss of activity results for a few of the N-terminally truncated mutants tested, such as FGF21 8-181. Thus, in determining whether a particular N-terminally truncated FGF21 mutant retained wild-type FGF21 activity, the activity of that FGF21 mutant in the in vivo assay was considered to be dispositive. Accordingly, truncated FGF21 polypeptides having N-terminal truncations of fewer than 8 amino acid residues are encompassed by the invention.

EXAMPLE 6

Preparation and Expression of Truncated FGF21 Fusion Proteins

Because the half-life of a protein can be increased by fusing the protein to an Fc 15 sequence, fusion proteins comprising truncated FGF21 polypeptides were prepared and analyzed. The truncated FGF21 fusion proteins listed in Table 6 were prepared from amplified FGF21 sequences by SOEing (gene splicing by overlap extension) PCR. FGF21 fusion proteins were prepared such that the Fc portion of the human immunoglobulin IgGl gene (SEQ ID NO: 13) was fused to either the N-terminus or the

0 C-tcrminus of the FGF21 protein.

Table 6

Truncated FGF21 Fusion Proteins

Amino Acid Residues	Fc Position	Linker
C-terminus Truncations
1 - 178	-NH₂	15
1 - 175	-nh₂	14
1 - 175	-COOH	15
1 - 171	-nh₂	15
I - 171	-COOH	15
1 - 170	-COOH	15
N-terminus	Yuncations
5-181	-nh₂	15
5-181	-COOH	15

2016204968 15 Jul2016

7- 181	-NH₂ 1 15
7- is]	-COOH j 15
C- and N-terminus Truncations
5-175	-nh₂	15
5-175	-COOH	15
5-171	-nh₂	15
5-171	-COOH	15
6-170	-COOH	15
7-178	-COOH	35
7-175	-nh₂	15
7-175	-COOH	15
7-174	-COOH	35
7-172	-COOH	35
7-171	-NH₂	15
7-171	-COOH	35
7-171	-COOH	15

In particular, FGF21 fusion protein constructs (including those encoding truncated FGF21 fusion proteins) were prepared in a series of three amplification reactions using essentially the reaction conditions described in Example 1. In the first reaction, a pair of primers was designed to produce a sequence containing an Ndcl cloning site, Fc region, and linker sequence. In the second reaction, a pair of primers was designed to produce a sequence containing an overlapping portion of the linker, a portion of the FGF21 coding sequence, and an EcoRl cloning site. Finally, in the third reaction, a pair of primers was designed for the purpose of linking the products of the first two reactions. An exemplary set of primers for the construction of Fc-FGF21 1-181 is listed in Table 7.

Table 7

PCR Primers for Preparing Exemplary FGF21 Fusion Protein Construct

Primer	Sequence	SEQ ID NO:
Reaction 1
Sense	5’-AGGAGGAATAACATATGGACAAAACTCACACATG-3'	14
Antisense	5’-GGATCCACCACCACCGCTACCAC-3'	15
Reaction 2
Sense	5'-GGTGGTGGTGGATCCCATCCAATTCCAGATTCTTCTCCA-3’	16
Antisense	5'-TAGTGAGCTCGAATTCTTAGGAAGCGTAGCTGG-3'	17
Reaction 3

2016204968 15 Jul2016

Sense	5'-AGGAGGAATAACATATGGACAAAACTCACACATG-3’	14
Antisense	5'“TAGTGAGCTCGAATTCTTAGGAAGCGTAGCTGG-3’	17

The product of the final reaction was digested with the restriction endonucleases Ndel and EcoRI, ligated into the pET30 vector, and then transformed into competent cells. The resulting clones were sequenced to confirm the absence of polymerase5 generated errors.

EXAMPLE 7 in vivo Activity of Truncated FGF21 Fusion Proteins

Fusion proteins comprising a truncated FGF21 sequence fused to an Fc sequence 10 were generated and assayed for in vivo activity. Truncated FGF21 fusion proteins were prepared by fusing an lgGl Fc molecule to either the N-tcrminal or C-terminal end of a truncated FGF21 protein to form a single contiguous sequence. To distinguish between N-tcrminal and C-tcrminal fusions, FGF21 fusion proteins in which the Fc molecule was fused to the N-tcrminal end of the FGF21 protein arc designated as Fc-FGF21, and fusion proteins in which the Fc molecule was fused to the C-tcrminal end of the FGF21 protein are designated as FGF21-Fc,

FGF21 possesses a number of biological activities, including the ability to lower blood glucose, insulin, triglyceride, or cholesterol levels; reduce body weight; or improve glucose tolerance, energy expenditure, or insulin sensitivity. To assess in vivo FGF21 activity, FGF21 polypeptides, FGF21 mutant polypeptides, and FGF21 fusion polypeptides were introduced into insulin resistant ob/ob mice, and the ability of a particular FGF21 protein to lower blood glucose levels was measured. The FGF2I polypeptide, FGF21 mutant polypeptide, or FGF21 fusion polypeptide to be tested was injected intraperitoneally into 8 week old ob/ob mice (Jackson Laboratory), and blood samples were obtained at various time points following a single injection, e.g., 0, 6, 24, 72, 120, and 168 hours after injection. Blood glucose levels were measured with a OneTouch Glucometer (LifeScan, Inc. Milpitas, CA), and the results expressed as a percent change of blood glucose relative to the baseline level of blood glucose (i.e., at time 0).

The results of one experiment are provided in Figure 4, which shows the percent

2016204968 15 Jul2016 change in blood glucose levels observed in mice injected with a PBS control, a wild-type Fc-FGF21 control comprising amino acid residues 1-181, or truncated Fc-FGF21 fusion proteins comprising amino acid residues 5-181 or 7-181. This experiment demonstrated that truncated Fc-FGF21 fusion proteins comprising amino acid residues 5-181 or 7-181 exhibit blood glucose lowering activity that is similar to the activity of wild-type FcFGF21 at 6 hours after injection. Thus, the in vivo analysis of truncated FGF21 polypeptides indicated that the deletion of up to 6 amino acids from the N-tcrminus of mature FGF21 does not affect the molecule's biological activity, in vivo analysis also indicated, however, that the ability of truncated FGF2I polypeptides to lower blood glucose was reduced and that blood glucose levels returned to baseline at 24 hours after injection (similar results were obtained with wild-type FGF21). The short in vivo activity was found to be a result of the proteolytic degradation of FGF23, as described in Example 8.

The results of another experiment arc provided in Figure 5, which shows the percent change in blood glucose levels observed in mice injected with a PBS control, a wild-type FGF23-Fc control comprising amino acid residues 1-181, a truncated FGF21Fc fusion protein comprising residues 1-175, or a truncated Fc-FGF21 protein comprising amino acid residues 1-171. This experiment demonstrates that the wild-type FGF21-Fc comprising amino acid residues i-181 has a sustained glucose-lowering activity resulting in a reduction of blood glucose levels of approximately 30% over the time period of 24 hours to 120 hours following injection. The truncated Fc-FGF21 protein comprising amino acid residues 1-171 exhibits delayed blood glucose lowering activity evident only at 72 hours after injection. However, the activity observed is the same as the activity of wild-type FGF2I-Fc. The truncated FGF21-Fc fusion protein comprising residues 1-175 is not active in vivo in lowering blood glucose.

Collectively, the truncation experiments described herein demonstrate that truncated FGF21 fusion proteins having an N-tcrminal truncation exhibit blood glucose lowering activity that is similar to that of the wild-type FGF21 fusion protein, and further, that truncated FGF21 fusion proteins in which the Fc molecule has been fused to the N30 terminal end of the truncated FGF21 protein exhibit more activity than fusion proteins in which the Fc molecule has been fused to the C-terminal end of the truncated FGF2I

2016204968 15 Jul2016 protein.

EXAMPLE 8

Observed in vivo Degradation of FGF21

FGF21 degradation was first observed with FGF21 Fc fusion protein constructs as described in Example 7. In vivo pharmacokinetic analysis indicated that human FGF21 has a short half-life of about 1 hour in mice due to rapid clearance and in vivo degradation. Therefore, to extend the half-life of FGF21 an Fc sequence was fused to the N- or C-terminal end of the FGF21 polypeptide. However, the fusion of an Fc region did not completely resolve the half-life issue since fusion proteins in which an Fc sequence was fused to the N- or C-tcrminal end of the FGF21 polypeptide (and in particular FcFGF21 fusions, i.e., in which the Fc sequence is fused to the N-terminus of mature FGF21), did not exhibit the expected in vivo efficacy, and instead were found to maintain blood glucose lowering activity for no more than 24 hours in ob/ob mice. As described in Figure 4, Fc-FGF21 fusion proteins reduced blood glucose levels by about 30-40% at 6 hours after injection, while the blood glucose levels returned to baseline levels at 24 hours.

The proteolytic degradation of wild-type FGF21 was subsequently investigated, and the rapid loss of in vivo activity with Fc-FGF21 fusion proteins was found to be the result of in vivo degradation of FGF21. Proteolytic degradation leads to decreased biological activity of the molecule in vivo and thus a shorter effective half-life, and such degradation adversely impacts the therapeutic use of that molecule. Accordingly, the observed degradation of FGF21 Fc fusion proteins led to the investigation of the proteolytic degradation of FGF21 in vivo and to identify FGF21 mutants that were resistant to such degradation.

To determine the sites of degradation, LC-MS analysis and Edman sequencing was performed on wild-type human FGF21 and FGF21 Fc fusion proteins obtained at various time points after injection into male C57B6 mice. The Edman sequencing helped confirm whether the N-terminal or C-terminal end of the protein was undergoing degradation. When an Fc sequence was fused to the N-terminus of human FGF21, degradation was found to occur at the peptide bond between amino acid residues 151 and

2016204968 15 Jul2016

152 and between amino acid residues 171 and 172 of the human FGF21 portion of the fusion molecule (the residue numbering above is based on the mature FGF21 sequence and does not include the Fc portion of the fusion protein). The degradation at 171-172 was found to occur first, and was followed by degradation at 151-152. Degradation at

171-172 appears to be the rate-limiting step and plays a role in the half-life of the molecule. When an Fc sequence was fused to the C-terminus of FGF21, degradation was found to occur at the peptide bond between amino acid residues 4 and 5 and between amino acid residues 20 and 21. As a result of these experiments, it was determined that the Fc sequence appears to protect the portion of the FGF21 sequence that is adjacent to the Fc sequence from degradation. An analysis of the in vivo degradation of wild-type FGF21 and Fc-FGF21 fusion proteins was further conducted in cynomolgus monkeys. These studies confirmed that the cleavage site of FGF21 at amino acid residues 171-172 is the major site of degradation in monkeys and that this site of degradation is conserved between murine and primate.

EXAMPLE 9

Identification of FGF21 Proteolvsis-Resistant Mutants

Suitable FGF21 mutants were identified by experimentally determining the positions of the wild-type FGF21 sequence that arc sites of major proteolytic activity, and

0 specific amino acid substitutions were introduced at these sites. Amino acid substitutions were based on FGF21 sequence conservation with other species (as described in Example 8) and biochemical conservation with other amino acid residues. A list of amino acid substitutions that were or can be introduced into the wild-type FGF21 protein is provided in Table 8, although Table 8 is only exemplary and other substitutions can be made. The

5 numbers of the positions given in Table 8 correspond to the residue position in the mature FGF21 protein, which consists of 181 amino acid residues.

Table 8

FGF21 Residues Mutated

Amino Acid Position	Native Residue	Mutations
19	Arg	Gin, lie, Lys
20	Tyr	His, Leu, Phe

2016204968 15 Jul2016

21	Leu	lie, Phc, Tyr, Val
22	Tyr	lie, Phe, Val
150	Pro	Ala, Arg
151	Gly	Ala, Val
152	He	His, Leu, Phc, Val
170	Gly	Ala, Asn, Asp, Cys, Gin, Glu, Pro, Scr
171	Pro	Ala, Arg, Asn, Asp, Cys, Glu, Gin, Gly, His, Lys, Ser, Thr, Trp, Tyr
172	Ser	Leu, Thr
173	Gin	Arg, Glu

EXAMPLE 10

In vivo Analysis of Fc-FGF21 and FGF21-Fc Degradation The stability of FGF2I Fc fusion proteins in vivo was determined by injecting mice with a fusion protein, drawing blood from the mice at various time points, and analyzing the serum by liquid chromatography-mass spectrometry (LC-MS). Γη particular, mice were intraperitoneally injected with 10 mg/kg of Fc(5)FGF21 (expressed in E. coli and purified as described in Example 2) or FGF21(3)Fc (expressed in mammalian cells and purified according to standard procedures). Blood was drawn from the mice at 6, 24, and 48 hours after injection (Table 9) and collected into EDTA tubes pretreated with protease inhibitor cocktails (Roche Diagnostics). Plasma was separated by centrifuging the samples at 12,000 g for 10 minutes. FGF21 proteins were affinity purified from blood using an anti-human-Fc agarose resin.

Table 9

FGF21 Samples

Sample	Protein Administered	Blood Withdrawn
D6	Fc-FGF21	6 hours
D24	FC-FGF21	24 hours
D48	FC-FGF21	48 hours
E6	FGF21-Fc	6 hours
E24	FGF21-FC	24 hours
E48	FGF21-FC	48 hours

Prior to analyzing the affinity purified samples by LC-MS, Fc-FGF21 and FGF21-Fc protein standards were analyzed as a reference. Protein standards were either

2016204968 15 Jul2016 reduced with tris[2-carboxycthyl] phosphine (TCEP) or not reduced. Reduced and nonreduccd standards were analyzed by LC-MS using an ACE cyano 0.3 mm x 30 cm column with the column effluent spraying into an LCQ Classic ion-trap mass spectrometer. Since the deconvoluted spectra of the reduced samples were cleaner, the affinity purified samples were reduced prior to LC-MS analysis.

The observed masses for the reduced Fc(5)FGF2I standard and samples D6, D24, and D48 are shown in Figures 6A-6D. The observed masses for the reduced FGF2I(3)Fc standard and samples E6, E24, and E48 are shown in Figures 7A-7D. Some of the standard and sample eluates were subjected to Edman sequencing in order to confirm the

N-tcrminus of the proteins and the fragments as determined by LC-MS. Results of the LC-MS analysis of the standards and samples are provided in Table 10.

Table 10

Results of LC-MS Analysis and Predicted Fragments

FGF21 Sample	Major Observed Masses	Fragment	Intact N-terminus?
Fc(5)FGF21 standard	45,339 Da	1-414	Yes
D6	45,338 Da 44,317 Da	1-414 1-404	Yes
D24	44,321 Da	1-404	Yes
D48	44,327 Da 42,356 Da	1-404 ?	Yes
FGF21 (3)Fc standard	46,408 Da (glycosylated, G0F) 44,964 Da (non-glycosylated)	1-410 1-410	Yes
E6	45,963 Da (glycosylated, G0F) 44,516 Da (non-glycoylated)	5-410 5-410	No
E24	45,963 Da (glycosylated, G0F) 44,526 Da (non-glycosylated) 44,130 Da (glycosylated, G0F)	5-410 5-410 21-410	No
E48	45,984 Da 44,130 Da 44,022 Da	5-410? 21-410 7	No

As indicated in Table 10, all of the affinity purified samples showed some degree of degradation after only 6 hours of circulation. After 24 hours of circulation, the major product of Fc-FGF21 was a fragment consisting of amino acid residues 1-404, which was seen in both the D and E samples. In the E samples, however, the major product of

2016204968 15 Jul2016

FGF21-Fc was a fragment consisting of amino acid residues 5-410. For both of the fusion proteins tested, the FGF21 portion of the fusion protein was more susceptible to degradation than the Fc portion of the protein.

EXAMPLE 11

Preparation and Expression of ProteolvsSs-Resistant FGF21 Mutants and Fusion

Proteins

Constructs encoding the FGF21 mutants listed in Table 11 were prepared by PCR amplification of the wild-type FGF21 expression vector as described below (the construction of the wild-type FGF21 expression vector is described in Example 1). The goal of these experiments was to generate FGF21 mutants that arc resistant to proteolysis and exhibit longer half-lives.

Table 11

Proteolysis-Resistant FGF21 Mutants

Mutation(s)	Fc	Linker
R19I
R19I	-COOH	15
R19K
R19K	-COOH	15
R19Q
R19Q	-COOH	15
R19K, Y20H
R19K, Y20H	-COOH	15
R19K, L211
R19K, L21I	-COOH	15
R19K, Y20H, L211
R19K, Y20H, L21I	-COOH	15
Y20F
Y20F	-COOH	15
Y20H
Y20H	-COOH	15
Y20L
Y20L	-COOH	15
Y20H, L211
Y20H.L211	-COOH	15
L21I
L21I	-COOH	15

2016204968 15 Jul2016

L21F
L21F	-COOH	15
L21V
L21V	-COOH	15
L21Y
L21Y	-COOH	15
Y22F
Y22F	-COOH	15
Y221
Y22I	-COOH	15
Y22V
Y22V	-COOH	15
P150A
P150A	-nh₂	15
PI50R	-nh₂	15
P150A, G151A
P150A, G151A	-nh₂	15
PI50AJ152V
PI50A, 1152V	-nh₂	15
PI50A, GI51A, I152V
P150A, GI51A, 1152V	-nh₂	15
G151A
G151A	-nh₂	15
G151V
G151V	-nh₂	15
G151A, I152V
G151A, I152V	-nh₂	15
I152F
I152F	-nh₂	15
I152H
I152H	-nh₂	15
1152L
I152L	-nh₂	15
1152 V
G170A
G170A	-nh₂	15
G170C
G170C	-nh₂	15
G170D
G170D	-nh₂	15
G170E
G170E	-nh₂	15
G170N
G170N	-nh₂	15
G170P

2016204968 15 Jul2016

G170P	-nh₂	15
G170Q
G170Q	-nh₂	15
G170S
G170S	-nh₂	15
G170E, P171A
G170E, P171A	-nh₂	15
G170E, S172L
G170E, S172L	-nh₂	15
G170E, P171A, S172L
G170E, P171A, S172L	-nh₂	15
P171A
P171A	-nh₂	15
P171C	-nh₂	15
P371D	-nh₂	15
P171E	-nh₂	15
P171G	-nh₂	15
P171H	-nh₂	15
P171K	-nh₂	15
P171N	-nh₂	15
P171Q	-nh₂	15
P171S	-nh₂	15
P171T	-nh₂	15
P171W	-nh₂	15
P171Y	-nh₂	15
P171A, S172L
P171A, S372L	-nh₂	15
S172L	-nh₂	15
S172T
S172T	-nh₂	15
Q173E
Q173E	-nh₂	15
Q173R
Q173R	-nh₂	15

FGF21 mutant constructs were prepared using primers having sequences that are homologous to regions upstream and downstream of a codon (or codons) to be mutated. The primers used in such amplification reactions also provided approximately 15 nucleotides of overlapping sequence to allow for recircularization of the amplified product, namely the entire vector now having the desired mutant.

2016204968 15 Jul2016

An exemplary FGF21 mutant construct, encoding an FGF21 mutant having a glutamic acid residue at position 170 instead of the native glycine residue (i.e., the G170E mutant) was prepared using the primers shown in Table 12.

Table 12

PCR Primers for Preparing Exemplary FGF21 Mutant

Primer	Sequence	SEQ ID NO:
Sense	5'-ATGGTGGAACCTTCCCAGGGCCGAAGC-3¹	18
Antisense	5'-GGAAGGTTCCACCATGCTCAGAGGGTCCGA-3'	19

The primers shown in Table 12 allow for the substitution of the glycine residue with a glutamic acid residue as shown below, wherein the upper sequence is the sense primer (SEQ ID NO: 18), the second and third sequences (SEQ ID NOs: 20 and 22) are portions of an FGF21 expression construct, and the fourth sequence is the antisense primer (SEQ ID NO: 21):

5'-ATGGTGGAACCTTCCCAGGGCCGAAGC

CTCCTCGGACCCTCTGAGCATGGTGGGACCTTCCCAGGGCCGAAGCCCCA GAGGAGCCTGGGAGACTCGTACCACCCTGGAAGGGTCCCGGCTTCGGGGT

AGCCTGGGAGACTCGTACCACCTTGGAAGG-5’

FGF21 mutant constructs were prepared using essentially the PCR conditions described in Example 1. Amplification products were digested with the restriction endonuclease Dpnl, and then transformed into competent cells. The resulting clones were sequenced to confirm the absence of polymerase-generated errors. Fc-FGF21 and FGF2I-Fc fusion proteins were generated as described herein, e.g., in Example 6.

FGF21 mutants were expressed by transforming competent BL21 (DE3) or BL21

Star (Invitrogen; Carlsbad, CA) cells with the construct encoding a particular mutant. Transformants were grown overnight with limited aeration in TB media supplemented with 40 ug/ml. kanamycin, were aerated the next morning, and after a short recovery period, were induced in 0.4 mM 1PTG. FGF21 mutant polypeptides were harvested by centrifugation 18-20 hours after induction.

2016204968 15 Jul2016

FGF21 mutants were also analyzed for predicted immunogenicity. Immune responses against proteins arc enhanced by antigen processing and presentation in the major histocompatability complex (MHC) class II binding site. This interaction is required for T cell help in maturation of antibodies that recognize the protein. Since the binding sites of MHC class II molecules have been characterized, it is possible to predict whether proteins have specific sequences that can bind to a series of common human alleles. Computer algorithms have been created based on literature references and MHC class II crystal structures to determine whether linear amino acid peptide sequences have the potential to break immune tolerance. The TEPITOPE computer program was used to determine if point mutations in particular FGF21 mutants would increase antigen specific T cells in a majority of humans. Based on an analysis of the linear protein sequence of each FGF21 mutant, none of the mutants was predicted to enhance immunogenicity.

EXAMPLE 12

Impact of Linker Sequence on FGF21 Degradation

To determine whether the presence of a longer amino acid linker between the Fc sequence and the FGF21 sequence affects FGF21 degradation, mice were injected with FGF21 fusion proteins in which the Fc region was separated from the FGF2I sequence by a 15 amino acid linker having the sequence GGGGGSGGGSGGGGS (SEQ ID NO:

23), blood was withdrawn from the mice at various time points, and the scrum was analyzed by LC-MS. In particular, mice were injected with Fc(15)FGF21 or FGF21(15)Fc (obtained from E. coti) at 23 mg/kg, blood was drawn at 6, 24, and 48 hours, and drawn blood was affinity purified using an anti-human-Fc agarose resin.

Prior to analyzing the purified samples by LC-MS, Fc(15)FGF21 and

FGF21(15)Fc protein standards were analyzed as a reference. Protein standards were either reduced with TCEP or not reduced. Both reduced and non-reduced standards were analyzed by LC-MS using an ACE cyano 0.3 mm x 30 cm column with the column effluent spraying into an LCQ Classic ion-trap mass spectrometer. Since the deconvolved spectra of the reduced samples were cleaner, the affinity purified samples

0 were reduced prior to LC-MS analysis.

2016204968 15 Jul2016

The observed masses for the reduced Fc(15)FGF21 standard and corresponding affinity purified samples withdrawn at various time points are shown in Figures 8A-8D, The observed masses for the reduced FGF21(15)Fc standard and corresponding affinity purified samples withdrawn at various time points are shown in Figures 9A-9D. Some of the standard and sample eluates were subjected to Edman sequencing in order to confirm the N-terminus of the proteins and assist in predicting the identity of the fragments observed by LC-MS. Results of the LC-MS analysis of the standards and samples and an indication of predicted fragments are provided in Table 13.

Table 13

Results of LC-MS Analysis and Predicted Fragments

FGF21 Sample	Major Observed Masses	Percent of Total	Fragment	Intact N-terminus?
Fc(15)FGF21 standard	46,002 Da	100%	1-424	Yes
Fc(15)FGF21 6 hours	46,000 Da 44,978 Da	65% 35%	1-424 1-414	Yes
Fc(15)FGF21 24 hours	44,978 Da 43,022 Da	85% 15%	1-414 1-394	Yes
Fc(I5)FGF21 48 hours	44,976 Da 43,019 Da	60% 40%	1-414 1-394	Yes
FGF21(15)Fc standard	45,999 Da	100%	1-424	Yes
FGF21(I5)Fc 6 hours	45,870 Da	100%	1-423	Yes
FGF21(15)Fc 24 hours	45,869 Da 45,301 Da 43,460 Da	40% 35% 25%	1-423 6-423 22-423	Some
FGF21(15)Fc 48 hours	45,870 Da 45,297 Da 43,461 Da	15% 20% 65%	1-423 6-423 22-423	Some

As indicated in Table 13, all of the affinity purified samples showed some degree of degradation after only 6 hours of circulation. After 24 hours of circulation, the major products of Fc(15)FGF21 were Fragments consisting of amino acid residues 1-414 (85% of sample) and 1-394 (15% of sample), and the major products of FGF21(15)Fc were fragments consisting of amino acid residues 1-423 (40% of sample), 6-423 (35% of

2016204968 15 Jul2016 sample), and 22-423 (25% of sample). Identified cleavage points for the Fc(15)FGF21 and FGF21(15)Fc proteins are shown in Figures 10A and 10B, respectively.

EXAMPLE 13 /» vivo Activity of Proteolvsis-resistant Fc(15)FGF21 Mutants at 1-7 Days after Injection

As described herein, proteolytic cleavage of FGF21 Fc fusion proteins depends upon the orientation of the Fc sequence, with the Fc end of the fusion protein being more stable than the FGF21 end of the fusion protein (i.e., the N-terminal portion of Fc-FGF21 fusion proteins and the C-terminal portion of FGF21-Fc fusion proteins were found to be more stable). For example, cleavage was identified at positions 5 and 21 of FGF21-Fc and positions 151 and 171 of Fc-FGF21.

As a result of these observations, an investigation was performed to identify proteolysis-resistant FGF21 mutants. LC-MS analysis of Fc-FGF21 demonstrates that in vivo proteolytic degradation first occurs between amino acid residues 171-172, followed by degradation between amino acid residues 151-152. By blocking proteolytic degradation at position 171, the cleavage at position 151 can be prevented, effectively extending the half-life of the molecule. However, proteolysis-resistant mutants in which cleavage is prevented at position 151 can still possess residues at position 171 that arc susceptible to protease attack, thereby resulting in a molecule missing the last 10 amino acids, which arc known to be involved in the binding of the co-receptor bcta-klotho, which is a determinant of ligand receptor affinity and in vitro and in vivo potency. Therefore, the mutagenesis of amino acid residues surrounding position 171 in mature FGF21 appear to be more critical for improving the in vivo stability, potency, and efficacy of the molecule.

The in vivo activity of particular proteolysis-resistant Fc(15)FGF21 mutants was assayed by intraperitoneally injecting ob/ob mice with an FGF21 mutant, drawing blood samples from injected mice at 0, 0.25, 1, 3, 5, and 7 days after injection, and then measuring blood glucose levels in the samples. The results of one experiment are

0 provided in Figure 11, which shows the blood glucose levels measured in mice injected with a PBS control, an Fc(15)FGF2I control, or the Fc(15)FGF21 mutants Fc(15)FGF21

2016204968 15 Jul2016

G170E, Fc(15)FGF21 P171A, Fc(15)FGF21 S172L, Fc(15)FGF21

G170E/P171A/S172L, or Fc(15)FGF21 G151A. Figure 12 shows the percent change in blood glucose levels as determined in this experiment. This experiment demonstrates that the Fc(15)FGF21 G170E, Fc(35)FGF21 Pl 71 A, Fc(15)FGF21 S172L, and

Fc(15)FGF21 G170E/P171A/S172L mutants exhibit sustained blood glucose lowering activity for up to 5 days, which is superior to the activity of wild-type Fc-FGF21 The Fc(I5)FGF21 G151A mutant only partially improved the duration of blood glucose lowering activity as compared with wild-type Fc-FGF21 fusion protein. Surprisingly, although the Fc(35)-FGF21 S172L mutant is not a proteolysis-resistant mutant, and therefore has similar degradation profile as the wild-type Fc(15)-FGF21 polypeptide, this mutant was found to exhibit improved in vivo efficacy as compared with the wild-type Fc(15)-FGF21 polypeptide.

The results of another experiment are provided in Figure 13, which shows the blood glucose levels measured in mice injected with a PBS control, an Fc(15)FGF21 control, or the Fc( 15)FGF21 mutants Fc(15)FGF21 P150A/G15IA/I152V, Fc(15)FGF21 G170E, Fc(15)FGF21 G170E/P171A, or Fc(15)FGF2I G170E/S172L. Figure 14 shows the percent change in blood glucose levels as determined in this experiment. As in the experiment described above, the wild-type Fc-FGF21 fusion protein and the Fc(15)FGF21 P150A/G15IA/I152V mutant do not exhibit sustained blood glucose lowering activity, possibly because the degradation at 171 site could still occur, and blood glucose levels in animals injected with these proteins returned to baseline at 24 hours after injection. However, the Fc(15)FGF21 G170E, Fc(15)FGF21 G170E/P171A, or Fc(I5)FGF21 G170E/S172L exhibit maximal blood glucose lowering activity up to 5 days after injection, which is superior to the wild-type Fc-FGF23 fusion protein and the

Fc(15)FGF21 P150A/G151A/1152V mutant.

The results of another experiment are provided in Figure 15, which shows the blood glucose levels measured in mice injected with a PBS control or the Fc(15)FGF21 mutants Fc(15)FGF21 G170E, Fc(15)FGF21 G170A, Fc(15)FGF21 G170C,

Fc(15)FGF21 G170D, Fc(15)FGF21 G170N, or Fc(15)FGF21 G170S. Figure 16 shows the percent change in blood glucose levels as determined in this experiment. All of the FGF21 mutants tested in this experiment exhibited sustained blood glucose lowering

2016204968 15 Jul 2016 activity for up to 5 days after injection.

The results of another experiment are provided in Figure 17, which shows the blood glucose levels measured in mice injected with PBS or the Fc(15)FGF21 mutants Fc(35)FGF2l G170E, Fc(15)FGF21 P171E, Fc(15)FGF2l P171H, Fc(15)FGF21 P171Q,

Fc(15)FGF21 P171T, or Fc(15)FGF2I P171Y. Figure 18 shows the percent change in blood glucose levels as determined in this experiment. All of the FGF21 mutants tested in this experiment exhibited improved blood glucose lowering activity when compared with wild-type Fc-FGF21.

EXAMPLE 14

In vivo Degradation of Proteolysis-resistant Fc(15)FGF21 Mutants at 6 to 120 Hours after Injection

The in vivo stability of selected FGF21 mutants was analyzed by injecting mice with an FGF2I mutant, drawing blood from the mice at various time points, and analyzing the scrum by LC-MS. In particular, mice were injected with cither the Fc(15)FGF21 G170E, Fc(15)FGF21 P171A, or Fc(I5)FGF21 S172L mutants (obtained from E. coli as described in Example 2), each of which were diluted in approximately 180 pL of 10 mM HC1 prior to injection, and blood was drawn at 6, 24, 48, 72, and 120 hours. FGF21 proteins were affinity purified from the drawn blood using an anti-human20 Fc agarose resin column. Samples were eluted from the column using 10 mM HC1. All of the FGF21 constructs comprise an Fc region and 15 amino acid linker at the aminotcrminal end of the FGF21 protein. Mice were also injected with a wild-type FGF21 control.

Prior to analyzing the affinity purified samples by LC-MS, unprocessed wild-type

FGF21 and unprocessed FGF21 mutants were analyzed as a reference. All standards and time point samples were reduced with TCEP, and then analyzed by LC-MS using an ACE cyano 0.3 mm x 30 cm column with the column effluent spraying into an LCQ Classic ion-trap mass spectrometer. Affinity purified samples were diluted with ammonium acetate, reduced with TCEP, and then analyzed by LC-MS as described above.

2016204968 15 Jul2016

The observed masses for wild-type Fc(15)FGF21 at 0, 6, 24, and 48 hours after injection are shown in Figures 19A-I9D, respectively. The observed masses for Fc(15)FGF21 G170E at 0, 6, 24, and 48 hours after injection are shown in Figures 20A20D, respectively. The observed masses for Fc(15)FGF21 P171A at 0, 6, 24, and 48 hours after injection are shown in Figures 21A-23D, respectively. The observed masses for Fc(15)FGF21 S172L at 0, 6, 24, and 48 hours after injection arc shown in Figures 22A-22D, respectively.

All of the samples drawn at 72 and 120 hours were found to contain a high molecular weight (>200 kDa by non-reducing SDS-PAGE) component of fibrinogen that is much more abundant than the remaining Fc(15)FGF21 fusion protein. Results of the LC-MS analysis of the other standards and samples are provided in Table 14.

Table 14

Results of LC-MS Analysis and Predicted Fragments

FGF21 Sample	Major Observed Masses	Percent oi Total	Fragment	Edman
Fc(15)FGF21 WT standard	45,994 Da	300%	1-424	—
Fc(15)FGF21 WT 6 hours	46,001 Da 44,987 Da	80% 20%	1-424 1-414	No
Fc(15)FGF21 WT 24 hours	44,979 Da	-100%	1-414	No
Fc(15)FGF21 WT 48 hours	44,980 Da	-100%	1-414	—
Fc(15)FGF21 G170E standard	46,068 Da	100%	1-424
Fc(15)FGF2i G170E 6 hours	46,078 Da	100%	1-424	No
Fc(15)FGF21 G170E 24 hours	46,074 Da 45,761 Da	80% 20%	1-424 1-421	No
Fc(15)FGF21 G170E 48 hours	46,072 Da 45,760 Da	-60% -40%	1-424 1-421	No
Fc(15)FGF21 P171A standard	45,970 Da	100%	1-424	—
Fc(15)FGF2I P171A 6 hours	45,980 Da	100%	1-424	No
Fc(15)FGF21 P171A 24 hours	45,973 Da 45,657 Da	-70% -30%	1-424 1-421	No
Fc(15)FGF21 P171A	45,992 Da	-50%	1-424	No

2016204968 15 Jul 2016

48 hours	45,673 Da	-50%	1 -421
Fc(l 5)FGF21 S172L standard	46,022 Da	100%	1-424
Fc(15)FGF21 S172L 6 hours	46,027 Da	100%	I-424	No
Fc(15)FGF21 S172L 24 hours	44,984 Da	100%	1-414	No
Fc(15)FGF21 S172L 48 hours	44,985 Da	100%	1-414	No

As indicated in Table 14, the degradation of wild-type Fc(15)FGF21 and the S172L mutant look similar, in that after 24 hours of circulation, the major product of the fusion protein was a fragment consisting of amino acid residues 1-414. The degradation products of the Fc( 15)FGF21 G170E and Fc( 15)FGF21 P171A mutants also look similar in that the samples drawn after 24 hours of circulation contain 70-80% intact protein (amino acids 1-424) and 20-30% of a fragment consisting of amino acid residues 1-421. Even after 48 hours, the Fc(15)FGF21 G170E and Fc(15)FGF21 P171A mutants still retain intact protein while showing an increase in the amount of the fragment consisting of amino acid residues 1-421. As observed in prior analyses of Fc-FGF21 constructs, degradation of the FGF21 portion of the fusion protein was detected and the Fc portion was found to remain stable. The cleavage sites identified for wild-type, Fc(15)FGF21 G170E, Fc(15)FGF21 P17IA, and Fc(15)FGF21 S172L are shown in Figures 23A-23D, respectively.

EXAMPLE 15

Identification of Aggregation-reducing FGF21 Mutants

One property of wild-type FGF21 is its propensity to aggregate. Aggregationreducing FGF23 mutants were identified on the basis of two hypotheses. The first hypothesis is that, with respect to FGF21, aggregation (or dimerization) is triggered by hydrophobic interactions and van der Waals interactions between FGF2I molecules caused by hydrophobic residues that are exposed to hydrophilic water-based solvent environment. The second hypothesis is that these exposed hydrophobic residues can be substituted to create aggregation-reducing point-mutation variants without compromising

5 FGF21 activity.

2016204968 15 Jul2016

A systematic rational protein engineering approach was used to identify exposed hydrophobic residues in FGF21. As there were no known X-ray or NMR structures of FGF21 that could be used to identify exposed hydrophobic residues, a high resolution (1.3 A) X-ray crystal structure of FGF19 (1PWA) obtained from the Protein Databank (PDB) was used to create a 3D homology model of FGF21 using MOE (Molecular Operating Environment; Chemical Computing Group; Montreal, Quebec, Canada) modeling software. FGF19 was chosen as a template, since among the proteins deposited in the PDB, FGF19 is the most closely related protein to FGF21 in terms of the amino acid sequence homology.

Solvent accessibility was calculated by the following method using MOE. A first measure of surface area (SAI) is defined as the area of the residue's accessible surface in A². While a particular amino acid residue appears in a protein's primary sequence multiple times, each occurrence of the residue can have a different surface area due to differences in, inter alia, the residue's proximity to the protein surface, the orientation of the residue's side-chain, and the spatial position of adjacent amino acid residues. Therefore, a second measure of surface area (SA2) is made wherein the residue of interest is extracted from the protein structure along with that residue's neighboring, or adjacent, residues. These spatially adjacent residues arc mutated in silico to glycines to remove their side-chains, and then the SA2 for the residue of interest is calculated, giving a measure of the total possible surface area for that residue in its particular conformation. A ratio of SAI to SA2 (SA1/SA2) can then give a measure of the percentage of the possible surface area for that residue that is actually exposed.

Several hydrophobic residues that are highly exposed to the solvent were selected for further analysis, and in silico point mutations were made to these residues to replace the selected residue with the other naturally occurring amino acid residues. The changes in protein thermal stability resulting from different substitutions were calculated using the FGF21 model and the interactive web-based program CUPSAT (Cologne University Protein Stability Analysis Tools) according to instructions provided at the CUPSAT website. See Parthiban et al., 2006, Nucleic Acids Res. 34: W239-42; Parthlban et al.,

2007, BMC Struct. Biol. 7:54. Significantly destabilizing or hydrophobic mutations were excluded in the design of aggregation-reducing point-mutation variants. Stabilizing (or.

2016204968 15 Jul2016 in rare cases, slightly destabilizing) substitutions that introduce improved hydrophilic and/or ionic characteristics were considered as candidates for aggregation-reducing FGF2I mutants.

A summary of the data generated through this rational protein engineering 5 approach is provided in Table 15, which also lists exemplary FGF21 mutants expected to have reduced protein aggregation and improved stability.

Table 15

Calculated Effect of FGF21 Mutants on Stability

Residue #	WT Residue	Mutation	Stabilization (Kcal/mol)
26	A	K E R	1.25 1.54 2.016
45	A	T Q K E R	0.66 0.71 1.8 2.34 1.59
52	L	T	-0.33
58	L	G S C E	0.16 -0.15 1.0 0.08
60	P	A K. E R	1.3 1.51 0.66 1.31
78	P	A C R H	0,14 2.48 0.08 0.13
86	L	T C	0.18 4.1
88	F	A S K E	2.52 3.08 2.88 1.48
98	L	T Q K c	0.49 0.17 -0.19 3.08

2016204968 15 Jul2016

		E R	0.84 3.4
99	L	C E D R	7.34 2.0 1.01 1.61
111	A	T K	0.47 -0.12
129	A	Q K. N E D R H	3.93 1.02 3.76 3.01 3.76 1.68 2.9
134	A	K Y E R H	5.37 4.32 5.13 6.18 2.86

EXAMPLE 16

Preparation and Expression of Aggregation-reducing FGF21 Mutants and Fusion

Proteins

Constructs encoding the FGF21 mutants listed in Table 16 were prepared by PCR amplification of the wild-type FGF21 expression vector as described in Example 11 (the construction of the wild-type FGF21 expression vector is described in Example 1). Fusion proteins were generated as described herein, e.g., in Example 6.

Table 16

Aggregation-reducing FGF21 Mutants

Mutation(s)	Fc	Linker
A26E
A26K
A26R
A45E
A45K
A45K	-nh₂	15
A45R	-nh₂	15
A45Q	-nh₂	15

2016204968 15 Jul2016

A45T	-nh₂	15
A45K, L98R	-nh₂	15
L52T
L58C
L58E
L58G
L58S
P60A
P60E
P60K
P60R
P78A
P78C
P78H
P78R
L86C
L86T
F88A
F88E
F88K
F88R
F88S
L98C
L98E	-nh₂	15
L98K	-nh₂	15
L98Q	-nh₂	15
L98R
L98R	-nh₂	15
L99C
L99D
L99E
L99R
A111K	-nh₂	15
Al 1 IT
A129D
A129E	-nh₂	15
A129H	-nh₂	15
A129K
A129N	-nh₂	15
A129R	-nh₂	15
A129Q
A134E
A134H	-nh₂	15
A134K
A134Y

2016204968 15 Jul2016

The aggregation of various FGF21 proteins, including wild-type FGF21, truncated FGF21 polypeptides, FGF21 mutants, and FGF21 fusion proteins was assayed by Size Exclusion Chromatography (SEC). Samples to be analyzed were incubated at

4°C, room temperature, or 37°C for various time points, and then subjected to SEC analysis. Experiments were performed on a Beckman HPLC system equipped with a SEC column. For wild-type FGF21, a TOSOHAAS TSK-Gel G2000 SEC column was used with 2x PBS containing 2% isopropyl alcohol as the mobile phase. For FGF21 Fc fusion proteins and FGF21 mutant polypeptides, a TOSOHAAS TSK-Gel G3000 SEC column was used with 2x PBS as the mobile phase.

EXAMPLE 17

In vitro Activity of Aggregation-reducing FGF21 Mutants Experiments were performed to identify aggregation-reducing mutants that retain wild-type FGF21 activity in an ELK-lucifcrasc in vitro assay. ELK-Iuciferase assays were performed as described in Example 4. Figures 24A-24C show the results of an ELK-lucifcrasc activity assay performed on the FGF21 mutants FGF21 L99R, FGF21 L99D, and FGF21 All IT (Figure 24A); the FGF21 mutants FGF21 A129D, FGF21 A129Q, and FGF21 A134K (Figure 24B); and the FGF21 mutants FGF21 A134Y,

FGF21 A134E, and FGF21 A129K (Figure 24C). The results of these experiments demonstrate that some of the aggregation-reducing mutations did not adversely impact FGF21 activity as assayed in ELK-luciferase assays.

EXAMPLE 18

5 Preparation and Expression of Fc(15)FGF21 Combination Mutants

Showing Longer Half-life anti Lower Levels of Aggregation

A number of FGF21 combination mutants, containing mutations shown to reduce aggregation as well as to increase half-life by disrupting proteolytic degradation, were prepared and conjugated to IgGl Fc molecules. These FGF21 mutants were prepared essentially as described in Example 11.

2016204968 15 Jul2016

EXAMPLE 19

In vitro Studies of Fc(15)FGF21 Mutants Showing Longer Half-life and Lower Levels of Aggregation

Experiments were performed to identify FGF21 combination mutants that retain 5 wild-type FGF21 activity in an ELK-luctferase in vitro assay. ELK-luciferase assays were performed as described in Example 4.

Figures 25A-25D show the results of an ELK-luciferase activity assay performed on the Fc-FGF21 mutants Fc-FGF21 P171G, Fc-FGF21 P171S, and Fc-FGF21 P171T (Figure 25A); the Fc-FGF21 mutants Fc-FGF21 PI71Y, Fc-FGF21 Pl71W, and Fc10 FGF21 P171C (Figure 25B); Fc(I5)FGF21, Fc(15)FGF21 A45K/G170E, and FGF21 A45K (Figure 25C); and Fc(15)FGF21, Fc(15)FGF2I P171E, and Fc(15)FGF21 A45K/G170E (Figure 25D), The results of these experiments demonstrate that mutations aimed at improving stability, or both stability and solubility, did not compromise the in vitro activity as compared with wild-type Fc-FGF2I. Interestingly, the FGF21 A45K mutant showed improved potency relative to wild-type Fc-FGF21.

Figure 26A shows the change in percent aggregation for an FGF21 control (WT) and FGF21 A45K. following incubation of 65 mg/mL protein at 4°C for I, 2, and 4 days. The data indicated that the A45K mutation leads to a decrease in aggregation of the protein, compared to the wild-type protein.

Figure 26B shows the change in percent aggregation for an FGF21 control (WT) and FGF21 P78C, P78R, L86T, L86R, L98C, L98R, All IT, A129D, AI29Q, A129K, A134K, A134Y, and A134E following incubation of 65 mg/mL protein at 4oC for 1, 6, and 10 days. The data indicated that the L86R, L98C, L98R, AI 1 IT, A129Q, and A129K lead to a decrease in aggregation of the protein, compared to the wild-type protein.

Figure 27 shows the results of an ELK-luciferase activity assay performed on a human FGF21 control and the FGF21 mutants FGF21 A45K, FGF21 L52T, and FGF21 L58E. This experiment demonstrates that the FGF21 A45K mutant retains the full efficacy of wild-type FGF21 and exhibits a potency that is even greater than wild-type FGF21. However, the FGF21 L52T, and FGF21 L58E mutants show reduced potency and efficacy as compared with wild-type FGF21.

Figures 28A-28B show the change in aggregation levels for the Fc(15)FGF21

2016204968 15 Jul2016 mutants Fc(I5)FGF2I 6-181/G170E, Fc(15)FGF21 A45K/G170E, Fc(15)FGF21 P171E, Fc(15)FGF21 P171A, Fc(15)FGF21 G170E, and an FGF21 control following incubation at 4°C for 1,4, and 8 days. This experiment demonstrates that over the 8 day period, the Fc(15)FGF21 A45K/G170E mutant showed less aggregation than did the Fc(15)FGF21

G170E or Fc(15)FGF21 P171E mutants, but all three mutants showed less aggregation than did the Fc(I5)FGF21 control. Table 17 shows the percent aggregation obtained for an Fc-FGF21 control and the Fc-FGF21 A45K/G170E mutant following incubation at 4°C or room temperature for 0, 2, 3, 4, or 7 days.

Table 17

Percent Aggregation for Fc-FGF21 and Fc-FGF21 Mutant

Sample	Day 0	Day 2	Day 3	Day 4	Day 7
Fc(15)-FGF21 WT	4°C	1.12	1.71	1.89	2.14	2.32
32 mg/mL	RT	1.12	6.09	7.94	9.57	12.59
Fc(15)-FGF21 A45K/G170E	4°C	0.45	0.77	0.88	1.03	1.24
33 mg/mL	RT	0.45	3.86	5.22	6.62	8.60

EXAMPLE 20

Preparation and Expression of Fc-FGF2f Fusion Combination Mutants

As described above, the stability and solubility of FGF21 can be modulated through the introduction of specific truncations and amino acid substitutions. In addition, FGF21 stability can be further enhanced by fusing such modified FGF21 proteins with the Fc portion of the human immunoglobulin IgGl gene. Moreover, by introducing combinations of the above modifications, FGF21 m olecules having both enhanced stability and solubility can be generated. Nucleic acid sequences encoding the FGF2I combination mutants listed in Table 18 were prepared using the techniques described above.

2016204968 15 Jul2016

Table 18

FGF21 Combination Mutants

Amino Acid Residues	Proteolysis Mutation	Aggregation Mutation	Fc	Linker
1-181	G170E	A45K	-nh₂	15
1-181	G170E	L98R	-nh₂	15
1-181	G170E	A45K, L98R	-nh₂	15
1-181	P171G	A45K	-nh₂	15
1-181	P171S	A45K	-nh₂	15
1-181	P171G	L98R	-nh₂	15
1-181	P17IS	L98R	-nh₂	15
1-181	P171G	A45K, L98R	-nh₂	15
1-178	G170E		-nh₂	15
6-181	G170E		-nh₂	15
6-181	G170E	A45K	-nh₂	15
6-181	G170E	L98R	-nh₂	15
6-181	PI71G		-nh₂	15
6-181	PI71G	L98R	-nh₂	15
7-181	G170E		-nh₂	15

Figure 29 shows the blood glucose levels measured in mice injected with the 5 Fc(15)FGF21 combination mutants Fc(15)FGF21 A45K/G170E, Fc(I5)FGF21

A45K/P171G, or Fc( 15)FGF21 L98R/P171G.

In another experiment the FGF21 mutant Fc(15)FGF21 L98R/P171G was studied side-by-side with wild-type mature FGF21 and Fc-FGF21. in o ne experiment, a recombinant 293T cell line was cultured in the presence of different concentrations of

FGF21, Fc-FGF21, or Fc(15)-FGF21L98R/P171G for 6 hours. Cell lysates were then assayed for luciferase activity. As shown in Figure 30, Fc(15)-FGF21 L98R/P171G had similar activity to Fc-FGF21, indicating that the introduction of the two poi nt mutations didn’t alter the molecule’s in vitro activity.

In yet another experiment, the stability of the Fc(15)-FGF21 L98R/P171G at 65 mg/mL was evaluated for ni ne days at two different temperatures, namely room temperature and 4°C, side-by-side with FGF2S and Fc-FGF21, After the incubation period cell lysates were then analyzed with SEC-HPLC to determine an aggregation versus time profile at various temperatures. The data shown in Figure 31A and 3IB indicate that the rate of aggregation formation was significantly reduced in the

Fc(15)-FGF21

2016204968 15 Jul2016

L98R/P171G at room temperature (solid triangles, dotted line in Figure 31 A) and at 4°C (solid triangles, dotted line in Figure 3IB).

EXAMPLE 21

Proteolysis-resistant FGF21 Mutants Comprising C-terminal Mutations

The in vivo stability of combination mutants was also studied. Specifically, the in vivo stability of Fc(15)-FGF2I L98R/P171G was compared with the stability of FcFGF2I in murine and cynomolgus models. The results were found to be similar in both species. In the cynomolgus study, Fc(15)-FGF21 L98R/P171G and Fc(15)-FGF21 were injected IV at 23.5 mg/kg and aliquots of serum and plasma were collected at time points out to 840 hours post dose. Time points out to 168 hours were analyzed. Time point samples were affinity-purified using anti-Fc reagents, then analyzed using MALDI mass spectrometry. The results correlated well between the two analyses.

Analyzing data generated using immunoaffinity-MALDI, clipping atthe P171 site was seen to be eliminated in the Fc(15)-FGF21 L98R/P171G molecule as a result of the mutation of Pl 71 to Pl71G. However, a minor and slow degradation resulting in a loss of up to 3 C-terminal residues was observed for Fc(15)-FGF21 L98R/P171G (Figure 32). The minor cleavages at the three C-terminal residues were also observed with other FGF21 mutants after the more susceptible cleavage site between amino acid residues 171 and 172 was blocked as shown in Figures 20 and 21. The 3 C-terminal residue cleavage may represent the cessation of cleavage from the C-terminal end of the molecule by a carboxypeptidase in a sequential, residue-by-residue fashion or a specific protease attack at amino acid residues 178 and 179 with non-specific clipping at amino acid residues 179-180 and 180-181. The loss of2-3 amino acids atthe C-terminus could cause reduced beta-klotho binding and ultimately decreased potency and in vivo activity of the molecule See, e.g., Yie et al., 2009, FEBS Lett. 583:19-24. To address the apparent carboxypeptidase degradation of the C-terminus, the impact of adding an amino acid residue “cap” to various FGF21 mutant polypeptides were studied. A variety of constructs, including those presented in Table 19, were made and assayed using the techniques described herein. Table 19 summarizes the results of the in vitro ELK luciferase assay.

2016204968 15 Jul2016

Suitable amino acid caps can be between 1 and 15 amino acids in length, for example 1, 2, 3, 4, 5, 10 or 15 amino acids in length. Any number and type of amino acid(s) can be employed as a cap, for example, a single proline residue, and single glycine residue, two glycine residues, five glycine residues, as well as other combinations. Additional examples of caps arc provided in the instant Example and in Table 19.

Additionally, to address the apparent protease attack at amino acid residues 178 and 179, mutation of amino acid residues at positions 179, 180 and 181 was studied. Again, a variety of constructs, including those presented in Table 19, were made and assayed using the techniques described herein. The impact of combinations of cap and mutations at these sites was also explored. Tabic 19 summarizes exemplary constructs that were made and studied in the in vitro ELK-luciferase assay, which was performed as described herein. Consistent with the terminology used herein, hFc means a human Fc sequence (i.e., SEQ ID NO: 13), LI5 refers to a linker having 15 residues (i.e., SEQ ID

NO:23)

Table 19

Efficacy and EC50 Values for FGF21 Polypeptides

Comprising C-terminal Modifications

Constructs	Efficacy	EC50(nM)
huFGF2l	0.4	100.0%
hFc.L15.hFGF21(L98R, P171G)	2.5	76.1%
hFc.L 15.hFGF21 (L98R, P i 71G, Y179F)	2,6	78,3%
hFc.L 15.hFGF21 (L98R, P171G, 1-180)
hFc.L 15,hFGF21 (L98R, P171G, 1 -179)	7.8	77.4%
hFc.L 15.hFGF21(L98R, P171G, A180E)	1.9	79.6%
hFc.L 15.hFGF21 (L98R, P171G, S18 3 K)	130	87.9%

GSGSGSGSGS.hFGF21 .L15.hFc

MKEDD.hFGF21.L15.hFc	834	83.1%
hFc.L 15.hFGF2!(L98R, P171G, Si8IP, PI82)	272	69.9%
hFc.L 15.hFGF21(L98R, P171G, A180G)	3.25	76.9%
hFc.L 15.hFGF2 l(L98R, P171G, S181G)	3.43	77.3%

hFc.L 15.hFGF21(L98R, P171G, LI82) hFGF21(L98R, P171G, G182)

2016204968 15 Jul2016 hFc.L15.hFGF21(L98R, P17IG, Y179P) hFc.L15.hFGF21(L98R, P171G, Y179G) hFc.Ll 5.hFGF21(L98R, P171G, Y179S) hFc.Ll 5.hFGF21(L98R, P171G, Y179A) hFc.L 15.hFGF2i (L98R, P171G, S181T) hFc.L15.hFGF21(L98R, PI71G, S181 A) hFc.L15.hFGF21(L98R, PI71G, SI81L) hFc.L15.hFGF21(L98R, P171G, S181P) hFc.L 15.hFGF21(L98R. P17IG, A180P) hFc.Ll 5.hFGF21(L98R, P171G, A180S) hFGF21(L98R, P171G, GGGGG182-6) hFc.L15.hFGF2I(L98R, P171G, Pl82) hFc.L 15,hFGF21 (L98R, P171G, G182) hFc.L15.hFGF21(l-178, L98R, P171G) hFc.L15.hFGF21(L98R, Pl71G, GG182-3) hFc.L15.hFGF21(L98R, P17IG, GGGGG182-6)

428	44.4%
61	82.6%
25,3	74.8%
43.2	79.6%
3.07	77.6%
2.66	73.5%
3.46	72.6%
33.8	79.5%
617	77,1%
2.18	84.7%

6.1	85.9%
6.5	71.1%
167	63.9%

1941 84.2%

4307 99.7%

Figure 33 shows the percent change in biood glucose levels observed in diabetic db/db mice (C57B6 background) injected with a PBS control, wild type native FGF21, Fc(15)-FGF21 (L98R, P171G) and two capped molecules to which either a proline or glycine residue was added at the C-terminal end, i.e. Fc(15)-FGF21 (L98R, P171G, 182P) and Fc(15)-FGF21 (L98R, P171G, 182G). In the instant Example, when a residue was added to the C-terminus of a wild-type or mutant FGF21 polypeptide, the residue is referred to by its position in the resultant protein. Thus, “182G” indicates that a glycine residue was added to the C-terminus of the mature 181 residue wild-type or mutant protein. Figure 33 shows that native FGF21 lowered blood glucose levels for 6 hours while all three Fc-FGF21 mutants studied showed sustained blood glucose-lowering activity for at least 120 hours. Fc(15)-FGF21 (L98R, P171G, 182P), molecule comprising the addition of a proline residue at the C-terminus of the FGF21 component of the fusion molecule, appeared most potent and resulted in lowest blood glucose levels compared with Fc(15)-FGF21 (L98R, P171G) and Fc(15)-FGF21 (L98R, P171G, 182G).

In a subsequent experiment, the in vivo activity of Fc-FGF21 (L98R, P171G,

182G) and Fc(15)-FGF21 (L98R, P171G, 182P) was studied and compared to the in vivo activity of a capped molecule comprising a two glycine addition at the C-term inus,

2016204968 15 Jul2016 namely Fc(15)-FGF21 (L98R, P171G, 182G 183G). Figure 34 shows the results of that experiment. Figure 34 shows the percent change in blood glucose levels observed in ob/ob mice injected with PBS control, Fc(15)-FGF21 (L98R, P171G), Fc(15)-FGF21 (L98R, P171G, 182G 183G), Fc(15)-FGF21 (L98R, P171G, 182G) and Fc(15)-FGF21 (L98R, P171G, 182P).

As shown in Figure 34, all of the molecules studied showed sustained glucoselowering activity compared with the PBS c ontrol. T his experiment confirmed the previous results (Figure 33) that Fc(15)-FGF21 (L98R, P171G, 182P) with a proline addition at the C-terminus showed slightly enhanced glucose-lowering efficacy compared with the molecule without a proline cap, e.g. Fc(15)-FGF21 (L98R, Pl71G). However, the addition of two glycine residues at the C-terminus, e.g. Fc(15)-FGF21 (L98R, P171G, 182G 183G), appeared to reduce the molecule’s in vivo potency and shortened the duration of in vivo glucose-lowering effect.

Figure 35 shows the percent change in blood glucose levels observed in diabetic db/db mice (C57B6 background) injected with PBS c ontrol or the FGF21 mutant polypeptides Fc(15)-FGF21 (L98R, P171G), Fc(15)-FGF2I (L98R, P171G, Y17 9S), Fc(15)-FGF21 (L98R, P171G, YI79A), Fc(15)-FGF2I (L98R, P171G, AI SOS), and Fc(15)-FGF21 (L98R, P171G, A180G). All mutants showed similar glucose-lowering activity with similar duration of action.

Figure 36 shows the percent change in blood glucose levels observed in diabetic db/db mice (C57B6 background) injected with vehicle control, Fc(15)-FGF21 (L98R, PI71G), Fc(15)-FGF21 (L98R, P171G, Y179F), and Fc(15)-FGF21 (L98R, PI71G, A180E). Compared with Fc(l 5)-FGF21 (L98R, P171G), Fc(15)-FGF21 {L98R, P171G, Y179F) was less efficacious in lowering blood glucose. However, Fc(l 5)-FGF21 (L98R,

P171G, A180E), in which alanine at amino acid position of 180 was mutated to glutamic acid, was more efficacious than Fc(15)-FGF21 (L98R, P171G) and caused additional 20% reduction of blood glucose levels compared with Fc(15)-FGF21 (L98R, P171G). These data suggest that A180E mutation may have reduced the C-terminal degradation in vivo and thereby improved in vivo potency and efficacy of the molecule.

2016204968 15 Jul2016

EXAMPLE 22 Rhesus Monkey Study

An Fc-Linker-FGF21 construct was generated using methodology described herein. The construct comprised an IgGl Fc sequence (SEQ ID NO: 13) fused at the C5 terminus to a (Gly)5-Ser-(Gly)3-Ser-(GIy)4-Ser linker sequence (SEQ ID NO: 23) which was then fused at the C-terminus to the N terminus of a mature FGF21 sequence (SEQ ID NO:4), into which two mutations, L98R and P171G, had been introduced. This construct was then expressed and purified as described herein, and was isolated as a dimeric form of the protein, each monomer of which was linked via intermolecular disulfide bonds between the Fc region of each monomer. This molecule is referred to in the instant Example as “ Fc-FGF21 (RG)” and has the amino acid sequence of the protein and is encoded by SEQ ID NO:37. In this Example, FGF21 refers to the mature form of FGF21, namely SEQ ID NO:4.

22.1 Study Design

The Fc-FGF21(RG) construct was ad ministered chronically and subcutaneously (“SC”) into non-diabetic male Rhesus monkeys with a BMI > 35. Two other groups of monkeys (n= 10 per group) were treated with either mature FGF21 (i.e., SEQ IDNO:4) or a vehicle control.

Animals were acclimated for 42 days prior to a dministration of any test compound and were then divided into groups of 10 and administered multiple SC injections of test compounds or control article in a blinded fashion, as depict ed graphically in Figure 37. In brief, each animal was injected once a day with compound or vehicle. FGF21 was administered daily, whereas Fc-FGF21(RG) was administered weekly, Fc-FGF21(RG) and FGF21 doses were escalated every 2 weeks, as shown in Figure 37, Body weight and food intake were monitored throughout the study. The CRO was blinded to the treatment.

Two oral glucose tolerance tests (OGTTs) were performed prior to the start of the treatment. OGTT1 was used to sort the animals into three equivalent groups having a similar distribution of animals based on area under the curve (AUC) and body weight. The results of the second OGTT (OGTT2) was used to confirm the sorting of the first

2016204968 15 Jul2016

OGTT (OGTT1), Monkeys with OGTT profiles that were inconsistent from one test (OGTT1} to the next (OGTT2) were excluded. The results of OGTTs 1 and 2 are shown in Figures 38A and 38B, with AUC measurements shown in Figure 38C. Baseline body weight is shown in Figure 38D and Table 20.

OGTTs 3, 4, and 5 were performed every 2 weeks at the end of each dose treatment of low, mid and high doses. Blood samples were collected from fasted animals weekly and were used to measure glucose, insulin, triglyceride levels, as well as the levels of test compound. Blood samples were also collected weekly during the 3-week washout period.

Baseline OGTT1 and OGTT2 showed an expected glucose profile as seen in normal animals, with a maximum plasma glucose obtained at 30 minutes, and demonstrated stable AUCs for the 3 different groups.

Fasting baselines values for plasma chemistry are shown in Table 20. Plasma chemistry measurements were performed on blood samples collected prior to the start of the treatment.

Table 20

Baseline Values for Body Weight, Fasting Plasma Glucose, Insulin, and Triglyceride Levels of the Three Groups of Rhesus Monkeys

	Vehicle	FGF21	Fc-FG2I(RG)
N	10	10	10
Body weight (kg)	8.5 ±0.5	8.7 ±0.4	8.5 ±0.4
Plasma glucose (mg/dL)	91.9 ±4.8	94.8 ± 5.3	82.2 ±3.7
Insulin (pg/mL)	942.6 ± 121.4	976.1 ±107.7	1023.4 ±205.1
Triglycerides (mg/dL)	44.4 ±4.8	58.6 ±5.2	71.7 ±9.8

0

Three different dose levels were selected, the low dose was 0.1 and 0.3 mg/kg, the mid dose was 0.3 and 1 mg/kg and the high dose was 1 and 5 mg/kg for FGF21 and FcFGF21(RG), respectively. Dose levels were chosen based on the observed dose-response in mice, with a dosing regimen based on the anticipated frequency of injection in humans.

Equimolar doses of FGF21 were used for the low and mid doses, and the Fc-FGF21 (RG)

2016204968 15 Jul2016 high dose was raised to 5 mg/kg (i.e., instead of 3 rng/kg, which would have been equimolar to the 1 mg/kg FGF21 dose).

22.2 Effect of Test Compounds on Body Weight 5 In this experiment, in order to measure effect of the test compounds on body weight measured weekly, the percent body weight change from baseline was calculated weekly In the three different groups of Rhesus monkeys. Body weight was also measured during the three week of wash out period. Baseline body weight values for each group are included in Table 20,

Body weight was followed throughout the study, both pre- and postadministration of test compounds. Body weight percent change from baseline of the vehicle animals increased with time, whereas body weight of animals treated with FcFGF21(RG) and FGF21 decreased in a dose-dependent fashion over the course of the 6 week treatment period, as shown in Figure 39. As observed previously in rodents (Xu et aL, Diabetes 58(1):250-9 (2009)), treatment with FGF21 statistically significantly decreased body weight. Fc-FGF21(RG) had a greater exposure than did FGF21 (Figure 48 and Figure 47, respectively), offering a possible explanation for the observation that Fc-FGF21(RG) showed a more pronounced body weight decrease than FGF21.

22.3. Effect of Test Compounds on Insulin Levels

Insulin levels were measured in blood samples that had been collected after an overnight fast or after an afternoon meal.

Fasting plasma insulin levels were measured in Rhesus monkeys every week in animals treated with either vehicle, FGF21 or Fc-FGF21(RG) and during the 3-week washout period. Fasted blood samples were drawn approximately five days after the last Fc-FGF21(RG) injection and approximately 21 hours after the last FGF21 injection.

Fed plasma insulin levels were measured in Rhesus monkeys during the fifth and sixth week of treatment with either vehicle or FGF21 during the high dose treatment. Fed blood samples were drawn approximately three days after Fc-FGF21(RG) injection and approximately 2 hours after last FGF21 injection. Figure 40 shows the effect of vehicle, FGF21 and Fc-FGF21(RG) on fasted insulin levels over the full nine week study, while

2016204968 15 Jul2016

Figure 41 depicts fed insulin levels determined from samples taken during weeks 5 and 6.

Summarily, at the two highest doses, both FGF21 and Fc-FGF2I(RG) statistically significantly decreased fasted and fed plasma insulin levels. The observation that insulin levels of animals treated with FGF21 and Fc-FGF21(RG) were decreased without observing increased glucose levels is indicative of increased insulin sensitivity.

22.4 Effect of Test Compounds on OGTT (Glucose and Insulin)

Three OGTTs (OGTTs 3, 4 and 5) were performed after treatment was initiated. OGTT5 glucose and insulin level profiles were measured in animals treated for 6 weeks with vehicle, FGF21 or Fc-FGF21(RG), corresponding to the last two weeks of the high dose escalation regimen. OGTTS was conducted approximately 7 days after the last FcFGF21(RG) injection, and approximately 21 hours after the last FGF21 injection. The OGTTS glucose and insulin profiles are shown in Figure 42 and Figure 43, respectively. Animals treated with Fc-FGF21(RG) showed an improved glucose clearance compared to vehicle-treated animals only at the highest dose and at the last time point measured, as shown in Figure 42. At the end of the last dose, Fc-FGF21(RG) showed the strongest improvement in glucose clearance. FGF21 showed no improvement in glucose clearance. Fc-FGF21(RG) had a greater exposure than did FGF21 (Figure 48 and Figure 47, respectively), offering a possible explanation for the observation that Fc-FGF21(RG) showed a more pronounced effect in glucose clearance than FGF21. Insulin levels during OGTTS were statistically significantly lowered at the last time point measured in animals treated with Fc-FGF21(RG) compared to animals treated with vehicle.

Glucose AUC percent change from baseline was calculated for the three OGTT (OGTTs 3, 4 and 5) performed at the end of each of the low, mid and high doses in the three groups different groups of Rhesus monkeys as shown in Figure 44. OGTT5 was conducted approximately seven days after the last Fc-FGF21(RG) injection and 21 hours after last FGF21 injection and showed that Fc-FGF21(RG) statistically significantly reduced AUC5. Baseline OGTT values for each group arc shown on Figure 38C,

Fasted plasma glucose levels were measured on days when no OGTTs were performed. There were no meaningful statistical differences observed in fasted plasma glucose levels measured among the three groups of animals.

2016204968 15 Jul2016

22.5 Effect of Test Compounds on Triglyceride Levels

Percent change of fasting plasma triglyceride levels was calculated in Rhesus monkeys every week in animals treated with either vehicle, FGF21 or Fc-FGF21(RG) and during the 3-week washout period. Fasted blood samples were drawn approximately five days after last Fc-FGF21(RG) injection and approximately 23 hours after last FGF21 injection. Triglyceride levels were measured every week after the treatment was initiated and percent changes from baseline are shown in Figure 45, fasting baseline values are shown in Table 20.

As depicted in Figure 45, animals treated with cither Fc-FGF21(RG) or FGF21 showed a dose-dependent decrease in triglyceride levels, with Fc-FGF21(RG) having the greatest lowering effect compared to FGF21.

Figure 46 shows the plasma triglyceride levels in samples acquire from Rhesus monkeys in a fed state, during the fifth and sixth week of treatment with vehicle or Fc15 FGF21(RG) or FGF21. Fed blood samples were drawn approximately 3 days after FcFGF21(RG) injection and approximately 2 hours after last FGF21 injection. Fed plasma triglyceride levels of animals treated with FGF21 and Fc-FGF21(RG) were statistically significantly reduced, compared to the triglyceride levels of animals treated with vehicle (Figure 46).

22.6 Concentration of Test Compounds The exposure of the tested compounds administered at approximately equivalent molar dose levels was assessed throughout the study period. The concentration of FcFGF21(RG) was measured at pre-dose, and approximately 5 days after the last injection.

FGF21 levels were measured at pre-dose, and at 5, 12, 19, and 26 days. Blood samples were drawn at approximately 21 hours after the last injection.

The individual concentration of the tested compounds in each monkeys arc shown in Figures 47 and 48. As shown in Figure 47, the majority of the animals in the FGF21treated group had concentrations below the quantitation limit. Figure 48 shows that animals in the Fc-FGF21 (RG)-treated group had detectable levels of Fc-FGF2I(RG) during each dosing phase (two weekly doses at the same dose strength). The average

2016204968 15 Jul2016 concentration from each dosing phase increased approximately dosc-proporttonally from 0.3 to 5 mg/kg for Fc-FGF21(RG). There is minimal accumulation as demonstrated by the steady concentrations after the first and second weekly dose within each dose escalation phase for both compounds. During the treatment-free phase (washout period)

Fc-FGF21(RG) levels were detectable up to approximately day 47 (12 days post last dose) and were below lower limit of quantification (LLOQ) afterwards.

Exposure of the test compounds was also monitored during each OGTT. FGF21 was not detectable during OGTTs 3 and 4, following low- and mid-dose FGF21 treatment. However, measurable levels were observed during OGTT5, following high10 dose treatment. A dose proportional increase in Fc-FGF21(RG) levels was observed across the third to fifth OGTT with escalating dose levels, as shown in Figure 49.

Compound levels data confirm that the animals were exposed to the expected amount of each compound, namely FGF21 and Fc-FGF21(RG), in a dose escalation manner. A large variability was observed in the amount of FGF21 measured, which was an expected result considering the sampling was performed approximately 21 hours post the last dose and the half life of FGF21 is approximately 1 hour.

22.7 Conclusions

FGF21 decreased fasted and fed plasma triglyceride and insulin levels and 20 decreased body weight at the highest doses. Fc-FGF21(RG) improved OGTT and decreased insulin levels at the highest dose, and dose dependcntly decreased fasted and fed plasma triglyceride levels as well as body weight. Both FGF21 and Fc-FGF2I(RG) decreased a number of metabolic parameters in the non diabetic Rhesus monkeys. Insulin and triglyceride level decreases were identical between FGF21 and Fc-FGF21(RG) when circulating compound levels were in a similar range, in the fed condition. Due to its improved properties, Fc-FGF2I(RG) was superior to FGF21 in most of the parameters measured and could be administered oncc-a-week to observe efficacy on metabolic parameters.

While the present invention has been described in terms of various embodiments, it is understood that variations and modifications will occur to those skilled in the art.

2016204968 15 Jul2016

Therefore, it is intended that the appended claims cover all such equivalent variations that come within the scope of the invention as claimed. In addition, the section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

All references cited in this application are expressly incorporated by reference herein.

2016204968 24 Jan 2018

Claims

1. An isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 4, further comprising substitution of the amino acid at position 180 with a glycine, proline, serine or glutamic acid residue.

2. The polypeptide according to claim 1, further comprising substitution of the amino acid at position 98 with an arginine, cysteine, glutamic acid, glutamine, lysine or threonine residue.

3. The polypeptide according to claim 2, wherein the substituted amino acid at position 98 is an arginine residue.

4. The polypeptide according to any one of claims 1 to 3, further comprising the substitution of the amino acid at position 171 with an alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, lysine, serine, threonine, tryptophan or tyrosine residue.

5. The polypeptide according to claim 4, wherein the substituted amino acid at position 180 is a glutamic acid residue and the substituted amino acid at position 171 is a glycine residue.

6. The polypeptide according to any one of claims 1 to 5, wherein the polypeptide comprises:

(a) an amino-terminal truncation of no more than 8 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal;

(b) a carboxyl-terminal truncation of no more than 12 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; or (c) an amino-terminal truncation of no more than 8 amino acid residues and a carboxyl-terminal truncation of no more than 12 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal.

7. The polypeptide according to any one of claims 1 to 6, wherein the polypeptide is covalently linked to one or more polymers.

8. The polypeptide according to claim 7, wherein the polymer is PEG.

9. A fusion polypeptide comprising the isolated polypeptide according to any one of claims 1 to 8, fused to a heterologous amino acid sequence.

2016204968 24 Jan 2018

-9610. The polypeptide according to claim 9, wherein the heterologous amino acid sequence is an Fc domain or fragment thereof.

11. The polypeptide according to claim 10, wherein the Fc domain comprises the amino acid sequence of SEQ ID NO: 11.

12. The polypeptide according to claim 11, wherein the polypeptide is fused to the Fc domain via a linker.

13. The polypeptide according to claim 12, wherein the linker comprises GGGGSGGGGSGGGGS (SEQ ID NO:31).

14. The polypeptide according to any one of claims 9 to 13, wherein the polypeptide comprises SEQ ID NO:47.

15. A multimer comprising two or more polypeptides according to any one of claims 9 to 14.

16. A pharmaceutical composition comprising the polypeptide according to any one of claims 1 to 14 and a pharmaceutically acceptable formulation agent.

17. The pharmaceutical composition according to claim 16, wherein the pharmaceutically acceptable formulation agent is a hydrogel.

18. An isolated nucleic acid encoding a polypeptide according to any one of claims 1 to 14.

19. The nucleic acid according to claim 18, wherein the nucleic acid comprises SEQ ID NO: 46.

20. A vector comprising the nucleic acid according to claim 18 or claim 19.

21. A host cell comprising the nucleic acid according to claim 18 or claim 19, or the vector according to claim 20.

22. A method for:

(a) treating type 2 diabetes in a subject;

(b) reducing triglyceride levels in a subject;

(c) improving glucose tolerance in a subject;

(d) lowering body weight in a subject; or (e) lowering insulin levels in a subject,

2016204968 24 Jan 2018

-97the method comprising administering to the subject the polypeptide according to any one of claims 1 to 14 or the pharmaceutical composition according to claim 16 or claim 17.

23. Use of the polypeptide according to any one of claims 1 to 14 for the manufacture of a medicament for:

(a) treating type 2 diabetes in a subject;

(b) reducing triglyceride levels in a subject;

(c) improving glucose tolerance in a subject;

1/89

2016204968 15 Jul2016

CM τ— τ— LL CO CO Ο γ LL 1- co Μ φ

<

Ο

LL

Λ||Α||3Β sajp^

2/89

2016204968 15 Jul2016

CN CN LL h0 V LL vV- CO 'ΐΓ r~- cd co

CO o

LL © ** φ« «

O) o

CM <£M ©

CM

X|iAi|oe 3Afi@|e^

3/89 o

<N

2016204968 15 Ju

CM

O

LL ^Az * V <5^! \z_s z_v

A, ^€z.

.<J*e <A z,

o o O o O £3 o o C5 o O C3 o O C3 O o o C5 o O o O o o O o O o fw «5 in *:.} co C4 <“-

‘Cs?

<r\ %

4s %

»9U95$9UlUHn

4/89

2016204968 15 Jul2016 o

o

I ω

co cl

2* 2* Q. Q. Q. E E E φ > 00 00 τ- τ- (0 ι 00 ι σ> c ——* τ— CM CM CM LL LL LL 0 0 0 u> o LL LL LL o o o 3 3 3 o o o V V V D. D. D. 0 i I < + %

co

O

LL ω

— E </> iz (ηρ/βω) esoonig pooig

5/89

2016204968 15 Jul 2016 ω

QQ

CL

CM CM CM

LL LL LL o o o

CO CO CO m T- _o © © © .

O O o V V V 0-0-0.

Ο

LL esoon|6 pooiq ui eBueqo %

Time (hr)

6/89

2016204968 15 Jul2016

MM

IO ©

© v

Q_ o

© ©

v

Q_ m

O

LL esoon|β pooiq uieBueqo %

7/89

2016204968 15 Jul2016

SE5 o

PS as <

CD

O

LL

-PS is as

MS Y

S| War

XnininininininininininininininininininininininininiMtt^^^ t o «... I o & > «.V

CN

LL

L£^

O .„ 7+7

O

8/89

2016204968 15 Jul2016

CO

O

LL

9/89

2016204968 15 Jul 2016

10/89

2016204968 15 Jul2016

Q

CD

O

LL

Di ¢3

11/89

2016204968 15 Jul2016 <

Ο

LL £3 & §

S3 SS us % +ο

S3

S3 <3 ό

ο e*5

S3

12/89

2016204968 15 Jul2016 s' a

d>

^s}*

CO

O

LL

I· O t o l· o s se>

S' *r

13/89

2016204968 15 Jul 2016

Ο

LL ο

14/89

2016204968 15 Jul2016 ά

α ο

LU α

Ν «>

«Μ

CM ω

=3

Ο

Ο οο LL r

Γ $χ>

S3

Β

15/89

2016204968 15 Jul 2016 <

Ο

LL

Jr .J ξ $ <£? dS

C\l

LL

16/89

2016204968 15 Jul2016

CO ό

LL

CN LL

0 LL m o'

LL CD ω

=3 o

□V

17/89

2016204968 15 Jul2016

Ο oo

Ο

LL

C\l

LL

Ο

LL m

ci ω

=3

Ο ^r

C\l

5 £3 ^8**

18/89

2016204968 15 Jul2016

Q

Ο ’«------χ ....

w#» $$

WP*

C\l

LL

Ο

LL m

ω =3

Ο

Ο 00 LL ^Τ

19/89

2016204968 15 Jul2016

20/89

2016204968 15 Jul2016 co σ>

O

LL

m —' ω C\l =3 LL o

o

LL CO ^Y?^>?YY'}YY^Y^Y$^>iYiYYY'$Y1‘’'YYiYY?YY^:?YY'?YY';^>iYY|YYiYY5YY5YY'>YYiYY?^s^':^s^Y^:;^s|YY^YYr?YJYY5YY|YY$YYY$YY^'?i^!$Y'i'^s' g £5¾ ss***·

21/89

2016204968 15 Jul2016

Ο σ>

Ο

LL •SC- P “STL

Ο

LL m

C\l

LL =3 o

c\i

-ξλΚ>

S3 ⁵o mass •••^^XXXXXXXXXXXXXXXXXXXXX'· ^^^ίίί^ΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧΧ'Χ'Χ'Χ'Χ·^, jf.ssOSW

22/89

2016204968 15 Jul2016

Q σ>

Ο

LL

23/89

2016204968 15 Jul2016

Mt¹ <

Ο

LL

-3» «Γ* ό

«0 £&

’’W·’· ^ννΓ^·

CM

LL

Ο

LL^

CT

V

_ΐΓ~ΐΤ£_ '«*** \SSis diditMMMMMC Λ Λ <*» «** 0» to o· CL 4gM« CO W* CL 12 §2 CL j££ %c <8© CL CM

24/89

2016204968 15 Jul2016 co

CM

Ml?

CO o

LL

ST* <** so so <M WS ^¾¾¾^

2 2 mt

CO

CM «**««» ,χ***»* <*> i$s

SO O CO CM tltl iWtf ••••νΓ· ^W4£M^*

Stotts )ο£μ·ο>

yj

0,-,ν o

§ s <«t

O ?v B w

>$$$$&

(¾ t¥ &s«

Sss &

gi

Jk

NJ f k % kJ ^s^^s «j w IX &

m d kO J» ^ssJ

W b <^$SSx «w>

$¢¢¢¢^ im Λ W;

SSSSS'I <ss$ssx

H

UI > co w O Ck.$ S®» kJ Nsa w CO

.....§ s\WW

Hl ex kkl o

m gj

CO

Mg·** <y &0 ylsHy

IO

CM

LL ^jM*K mF

25/89

2016204968 15 Jul2016

CM r-~

CO <

r-~

CL

LU < _1 LU < O CM O T“ r-~ r-~ LO _T— o CL CO o o CM CM CM CM CM CM LL LL LL LL LL LL O O O O O O LL LL LL LL LL LL LO LO LO LO LO LO _1 _1 _1 _1 _1 _1 ό ό ό ό ό ό LL LL LL LL LL LL

* =tt <

Ο

LL

I □ I 0 Π s (ip/Bui) asoon|B pooig

26/89

2016204968 15 Jul2016

CM l·ω <

LU < _l LU < O CM o t— l·- l·- l·- l·- LO t- τ— T^- T^- 0 CL ω 0 0 T— T— T— τ— T— T— CM CM CM CM CM CM LL LL LL LL LL LL 0 0 0 0 0 0 LL LL LL LL LL LL .C .C .C .C .C .C LT) LT) LT) LT) LT) LT) y— y— y— y— y— y— _l _l _l _l _l _l ύ ύ ύ ύ ύ ύ LL LL LL LL LL LL

m το o

o o

V V 0- Q_ o

o o

V

Q_

H U H +

CM

LL esoon|6 pooiq ui peBueqo %

27/89

2016204968 15 Jul2016

CXI

LL o

co

O

LL (IP/Blu) esoorqB pooig

28/89

2016204968 15 Jul2016 >

esoon |6 pooiq ui eSueqo % σ>

oo rco

CM ©

2016204968 15 Jul2016

30/89

2016204968 15 Jul2016

czr o r- < o l''- o o l''- Q o l''- z o l''- co o r- o O O O O O m CM I 1 CM I 1 CM I 1 CM I 1 CM I 1 CM I 1 DQ π ^{1 1} o ^{1 1} o ^{1 1} o ^{1 1} o ^{1 1} o ^{1 1} o m τ- LL LL LL LL LL LL LL ο 2 in in in in in in o ω _l _l _l _l _l _l V V o v jXj c DQ CL ό LL ό LL ό LL ό LL ό LL ό LL 0_ 0_ 0_ <D p Φ UH * * * * * * ro <D s_ 1—

asoon|6 pooiq ui aBueqo %

31/89

2016204968 15 Jul2016

UJ ο

to

LL

llT I σ P > to to to to to £ £ £ £ £ ω LL 0 1 1 LL 0 I | LL 0 I | LL 0 I | LL 0 I | CO Q_ _c Lf) _c Lf) _c Lf) _c Lf) _c Lf) IO o o O o 2 _l _l _l _l _l o o o ω ύ LL ύ LL ύ LL ύ LL ύ LL V Q_ V Q_ V Q_ c <D c 1 S 9 I * < c ro £

|to

Ο <

1 1 1 1 o o o o o o o o co CM

(|P/BlU) θδΟΟΠ|β pooia

32/89

2016204968 15 Jul2016

LU LU I 0 1- > O to- to- to- to- to- to- 0 CL CL CL CL 0. LL LL LL LL LL LL 0 0 0 0 0 0 LL LL LL LL LL LL 1= 1= 1= 1= 1= 1= L0 L0 L0 L0 L0 L0 τ— τ— τ— x- x- x- _l _l _l _l _l _l ό ό ό ό ό ό LL LL LL LL LL LL

Η Η I Η

Treatments vs. PBS asoon|6 pooiq ui pa6ueqa %

33/89

15 Jul 2016

34/89

2016204968 15 Jul 2016

35/89

2016204968 15 Jul2016

Ο σ>

Ο

LL

36/89

2016204968 15 Jul 2016

37/89

2016204968 15 Jul 2016

38/89

2016204968 15 Jul2016

39/89

2016204968 15 Jul2016

Ο ο

CN

Ο

LL

40/89

2016204968 15 Jul 2016

41/89

2016204968 15 Jul2016 <

CM o

LL

42/89

2016204968 15 Jul2016

CO

CM o

LL

43/89

2016204968 15 Jul 2016

44/89

2016204968 15 Jul2016

Q

CM o

LL i- S3 55 ( Un $2 I ® r

' Γ < g k ____ r* ^fei>iwm.w

I I .. nWo-t · ·*^^ 'ΑΜβκκκκκ·.·.. £ ^«Ssites»···· ( ·Λ·λ·»τ^' X' — . '•'yjati

C\l Jg

LL O >»»»«5555^

O< _v.._;JgffSSk | “L —5 2±§ t

LO θ iSi^ssssssww·· £ o 00 *

LL 'sj^X«SSSS55SS cw

45/89

2016204968 15 Jul2016

46/89

2016204968 15 Jul2016 co

CM

CM o

LL

47/89

2016204968 15 Jul2016

o w* CN CN i* 0 LL

ο

CN ρω

CN

LL

LL m

ci ω

=3 o

CN

48/89

2016204968 15 Jul2016

49/89

2016204968 15 Jul2016

Xxx*· § -5·§ w

HI

I

WWN 'V

Mb ft <

CM

O

LL

S·' ' 8 <»»» w

§ sXXXXX*

Η»

Sxxxxx

W¹ >

O

Sfc •K· <« >\\\\\\' xssftsv $

x\\\\« xxxxxl $

xxxx\4*

IX sssssxx·

Xf co <$C: s § \\X<· xfc'SSS;· -X NS·. \χ$>

S

XXX<··: •X NS; \-,X 0

Χ-,Χ

N$T 5$^ c5$i

SSSxxx iS'ifS;

0 >0

1*1 0 0 0 o a S ^λ*8 O⁵0 0 V 0 xx<SxXX i$Ss;

Wk.

Oi

0»;

sssssS \\\\χχ· w·' V «*» 0 0 O. 0 M 0 vs? 0 0 so IX

0 «** 4¾ * .....S Ub

XVW§ NSSV& _0> x<^ & ^xS

W sir lit SSSSsi S>Cs a bi 0 <S 0

0 0 0

4¾¾ 4¾

0, SV» &M$ <?' 'V ΐ 4.4Sf N/

C-s

ΧχΧχΝ w

•sx x'» \\x<^ to «χΧΧΧ^

III n** xvixx $

xWwSS o

X-XxN <

IX

-Ss w

0' &&.X

..4-4'

IX

— — —'· ..,.-. . ^Μ·Α·Α>·$ jiriYftLn- .W.Ob iiAk .. O is 0 CJ* TgM* V 'w' US &— X» wrtfr· Mr

CM Mr

50/89

2016204968 15 Jul2016

51/89

2016204968 15 Jul2016

Ο co

CN o

LL

52/89

2016204968 15 Jul2016 a

cj

-•KS&ft sxX.

cl co

L>

MB MB «jp· jj^X ,****“«

W W?

’Wal· .^AAAx.

igp O O

JHWfcfc MMAf MMAA

Λ*«* ME*

8 S 8

AAAAf AMAfr ^Mf •--Λ JMMA Λ·.·.·· ss>

CM $Ssss

W □

KSjSSS

CL

0» o

w <0 p

Xx.’’ w

tf*

Q

CM

LL

CM ω

CM

LL

LL^

CT θ' l>

sc

KSSgjS:

i xwwx <w* §

w··

CO p

£$$ sssssss

IO ill Ik.

-L « y) i §-\ L&

W y> w <· $\ 'N

W m „s o\ W’ kJ m .-$--.

O U·

0 m w <0 R w* &s&&

co ui

0 IX &&* p

o <

y>

R §<<$$·?

IL »J io ^y ky

V# & »3 w

ft.

CO

CL

CO

53/89

2016204968 15 Jul2016 or q

CD CD __ CD CD ™ -¹ -¹ < LL^-^-tC9 CN CN CN H LL LL LL

3 O O O _C LL LL LL t I H

-CO

I <

Ν’

CN

Ο

LL

CN m o m o m

CN CN t- tma

54/89

2016204968 15 Jul2016

Q o CM a O CM M CO CM < < < LL τ— τ— τ— 0 CM CM CM I 1 LL LL LL 0 0 0

my

55/89

2016204968 15 Jul2016 > LU \J- 0

CO CO CM ^ < < < LL ^Q CM CM CM n LL LL LL

O O O ♦ HI

O

M

CM

O

LL mu

56/89

2016204968 15 Jul2016

T CM CM CM C\l LL LL LL ft 0 0 0

LL LL LL ξξ» ύ ύ ύ

HH ma

57/89

2016204968 15 Jul2016 > > Ο

CL CL CL

Σ CN CN CN LL LL LL fc 0 o o ~ LL LL LL 3 0 0 0 ♦ HI

CO m

CN

O

LL ma

58/89

2016204968 15 Jul2016

LU

O

LO

M <

CM CM LL LL

0 0

LO

M <

CM LO LO c\j LL Γ\ Γ\ LL 0 0^0

HH ma

59/89

LU

O

2016204968 15 Jul2016 r- in CL <

Q m

CM

O

LL cm in m m

O 'o' 'o' 'o'

LL LL LL LL

Η H ma

60/89

2016204968 15 Jul2016 θ|εβθ3ββε %

61/89

2016204968 15 Jul2016

FIG. 26B

2016204968 15 Jul2016

63/89

2016204968 15 Jul 2016

LU LU O O T— o O - LU < LU τ— kf O 00 IO η^- M T— T— co < CL CL o T— T— T— T— T— CM CM CM CM CM LL LL LL LL LL O O O O O LL LL LL LL LL LT? LT? LT? LT? LT? τ— τ- τ- τ- τ- o' ο' ο' ο' ο' LL LL LL LL LL

LL LL LL LL LL LL

4 111 (

ΛΛΙΛΙΗ |BIO± %

64/89

2016204968 15 Jul2016 m

CN

O

LL co

Q co

Q oo >co

Q □

65/89

2016204968 15 Jul 2016

Φ >

OT >

OT

C

CO

Φ

MM

Γ

Time (D)

CO (ip/Biu) esoon|6 pooig

2016204968 15 Jul2016

66/89 uCL or

CD

C\l C\l LL LL C\l 0 0 LL LL LL 0 ύ ύ

67/89

2016204968 15 Jul2016 σ>

oo rCD

IO co

CM

68/89

2016204968 15Jul2016

Time (days)

69/89

2016204968 15 Jul2016

Fig. 32

FC-FGF21 L98R/P171G co c

<b

-*3

TO ω

it

000

200

200 0

\ 0 min -- ] 5 min . J·^ 1 2 h jL· 6 h : 12 h K- : 24 h j 48 h loos of f -3 /©©/does ΐ - 96 h J 168 h H-1--Γ-1- Αλ~. . . .— . . Ί-1-1-1-1-1-1-1-1-1-1-1 *'^r 1-1-1-1-1-1-r

45000 47500 m/z

70/89

2016204968 15 Jul2016

Q. CO CM co CM E a? O co CM CM CM OO OO ___ CD CD CD 1- 1- 1- _l Q. E CL of CL of CL of <> oo oo oo CM O) _1 O) _| O) _1 CO LL I co CD o o ό Q_ LL LL LL LL <e CO Ω Lij LL

CM CM CO

III esoon|6 pooiq ui e6ueqo%

71/89

2016204968 15 Jul2016 ο

co co

0 0 6?

C\J c\j C\J

CO CO CO

0 0 0 0 r— r—

CL of co σ>

CL CL □f of CO co σ> σ>

CL

Of co σ>

C\J C\J C\J C\J

LL LL LL LL

0 0 0 0

LL LL LL LL

O O O O + HH

Μ^-

CO

O

LL %, esoonio pooig

72/89

2016204968 15 Jul2016

ο ο ο ο cm cm cm cm Ω_ - Ε co < co Ο Ο σ> σ> ο ο Ι~- Ι~- οο οο cm >- >- < < Ο Ο Ο Ο Ο Ι~- Ι~- Ι~- Ι~- Ι~- ο_ ο_ ο_ ο_ ο_ θ' θ' θ' θ' θ' οο οο οο οο οο σ> σ> σ> σ> σ> _J _J _J _J _J ο ο ο ο ο LL LL LL LL LL

φ + + + φ *

73/89

2016204968 15 Jul2016

CL E oo c\i CL E co c\i Q_ LJ? llT CO o CO to oo c\i > < CD CD CD to to to CL CL CL or QC QC oo oo oo co co co _l _l _l CM CM CM LL LL LL CD CD CD LL LL LL 0 0 0 LL LL LL m 0 ci

CD

CO o

LL co co co

CM

CO σ>

CM r** co

CM ω

ω co

I ο

co

74/89

2016204968 15 Jul2016 ό

LL ω

c CM

A- I— I— ω i_ i_ ro Ο O co O O

75/89

2016204968 15 Jul2016 φ

o _□

Ο

Ό

Ο

CO

FIG. 38A

Β

Ο- C

I I I I I I I

0 30 60 90 120 150 180

Time (minutes)

76/89

2016204968 15 Jul2016

FIG. 38B

I-1-1-1-1-1-Γ

0 30 60 90 120 150 180

Time (minutes)

77/89

2016204968 15 Jul2016 < co ο ο

oo co

Ο

LL □

s ω ιο ο cm □ην

78/89

2016204968 15 Jul2016 < CO Ο

010

Q oo co

O

LL σ> co o- co in ί CO 04 ? o (B>1) μ)βιθΛΛ Apog

79/89

2016204968 15 Jul2016 φ

(Λ

Ο

Τ3

Φ (Λ

Ο

Τ3

Φ (Λ

Ο

Τ3

Ο) (Λ (0 (ΝωΝΓΐηωι^οοσ) □□□□ (%) θβιΐΒμο ιμβιθΜ Apog

80/89

2016204968 15 Jul2016

Φ (Λ

Ο

Τ3 £

Ο

Φ w +j 3 t/> o T3 o T3 O W T3 O CO Ϊ £

τ- 04 CO Ν' □ □ □ □ lo <ο υ- οο

Ο

Ν’

Ο

LL

CM

LL

I υ

CM

LL

Φ υ

V

Φ >

(%) duipseq luojj sBubijo ui|nsu|

81/89

2016204968 15 Jul2016

FIG. 41

Week

3000q

High dose

Vehicle

FGF21

FC-FGF21 (RG)

82/89

2016204968 15 Jul2016

CM

Μ^-

O

LL o

£

CM

LL

LL ώ

+

Γ“ σ> E co

CD

E

I (ηρ/βω) esoon|6 euiseid

83/89 kO ο

(Μ

IT) οο kO ο

(Μ kO ο

(Μ

FIG. 43

5000

ΣΤ 4000 Ε g 3000 = 2000 ω

- 1000 ο - “I-1 I-1-1-1-Γ0 30 60 90 120 150 180 Time (minutes)

-·- Vehicle Η3· FGF21

Fc-FGF21(RG)

84/89

2016204968 15 Jul2016 suipseq luojj 96ubl|o%

Vehicle FGF21 Fc-FGF21(RG)

85/89

2016204968 15 Jul2016

Φ (Λ o T3 £ o _l Φ w o T3 T3 Φ w O T3 O) Ϊ +j 3 O w (0 % Λ A a τ~ C\| CO m ω n 00 CD

kN VJ XT UJ

I □□□□

OIAOIAOIAOIAOIAOIAOIAO M-rjT-OOOlDlflOCN T- CM St If) I— (%) eBueqo θρμθοΛ|6μι

86/89

2016204968 15 Jul2016

87/89

2016204968 15 Jul2016

Ο

LL co σ

ω

Ε (|/\|U) U0RBJ1U90U0Q LSdOd

88/89

2016204968 15 Jul2016 oo

Ν’

Ο

LL σ

ο ω

ΙΌ

Ο

ΙΌ

VT

Ο

VT

ΙΌ

CO

Ο

CO

ΙΌ <Ν

Ο <Ν

Ο

Π3 ω

(|/\|U) U0RBJ1U90U00 (9d) LSdOJ-Od

89/89

2016204968 15 Jul2016 ο

£

CM

LL

I o

CM

LL

Treatment

2016204968 15 Jul2016

A- 1429- V£> PCT_ST25 SEQUENCE LI STI NG <110> Bel ouski , Edward J.

El I i son, Mir i el I e M Harrburger, Agnes E.

Hecht , Randy I .

Li , Yue- Sheng M chael s, E/hr k L.

Sun, Jeonghoon Xu, Ji ng <120> FGF21 Mut ant s and Uses Thereof <130> A- 1429 NP PCT <1 60> 37 <170> Patentln version 3.3 <210> 1 <211> 630 <212> DNA <213> Homo sapi ens <400> 1

at ggact egg acgagaccgg gt t cgagcac t caggact gt gggt 11 ct gt get gget ggt 60 ct t ct get gg gagcct gcca ggcacacccc at ccct gact ccagt cct ct cct gcaat t c 120 gggggccaag t ccggcagcg gt acct ct ac acagat gat g cccagcagac agaagcccac 180 ct ggagat ca gggaggatgg gacggtgggg ggeget get g accagagccc egaaagt ct c 240 ct gcagct ga aagcct t gaa geegggagt t at t caaat ct t gggagt caa gacat ccagg 300 11 cct gt gcc agcggccaga t ggggccct g t at ggat ege t ccact 11 ga ccct gaggee 360 t gcagct t cc gggaget get t ct t gaggac ggat acaat g 111 accagt c cgaagcccac 420 ggcct cccgc t gcacct gcc agggaacaag t ccccacacc gggaccct gc accccgagga 480 ccagct eget t cct gccact accaggcct g ccccccgcac ccccggagcc acccggaat c 540 ct ggcccccc agccccccga t gt ggget cc t cggaccct c t gagcat ggt gggacct t cc 600 cagggccgaa gccccagct a eget t cct ga 630 <210> 2 <211> 209 <212> PRT <213> Home i sapi ens <400> 2 IVfet Asp Ser 1 Asp Q u Thr Q y Phe 5 Q u Hi s Ser 10 Q y Leu Tr p i Val Ser 15 Val Leu Al a i Gl y Leu Leu Leu Q y 20 Al a Cys Q n 25 Al a Hi s Pr c 30 i lie Pr o Asp Ser Ser 35 Pr o Leu Leu Q n Phe 40 Gy Gy G n Val Ar g G r 45 i Arg Tyr Leu Tyr Thr Asp Asp Al a Q n Q n Thr G u Al a Page 1 Hi s Leu Q l i lie Ar g

2016204968 15 Jul2016

A- 1429- V£> PCT_ST25

50 55 60 G u Asp G y Thr Val G y G y Al a Al a Asp G n Ser Pr 0 G u Ser Leu 65 70 75 80 Leu G n Leu Lys Al a Leu Lys Pr o G y Val I I e G n I I e Leu G y Val 85 90 95 Lys Thr Ser Arg Phe Leu Cys G n Arg Pr o Asp G y Al a Leu Tyr G y 100 105 110 Ser Leu Hi s Phe Asp Pr o G u Al a Cys Ser Phe Arg G u Leu Leu Leu 115 120 12 !5 G u Asp G y Tyr Asn Val Tyr G n Ser G u Al a Hi s G y Leu Pr o Leu 130 135 140 Hi s Leu Pr o G y Asn Lys Ser Pr o Hi s Arg Asp Pr o Al a Pr o Arg G y 145 150 155 160 Pr o Al a Arg Phe Leu Pr o Leu Pr o G y Leu Pr o Pr o Al a Pr o Pr o G u 165 170 175 Pr o Pr o G y I I e Leu Al a Pr o G n Pr o Pr o Asp Val G y Ser Ser Asp 180 185 190 Pr o Leu Ser N/bt Val G y Pr o Ser G n G y Arg Ser Pr 0 Ser Tyr Al a 195 200 2C 15

Ser <210> 3 <211> 546 <212> DNA <213> Homo sapi ens <400> 3

caccccat cc ct gact ccag t cct ct cct g caat t cgggg gccaagt ccg gcagcggt ac 60 ct ct acacag at gat gccca gcagacagaa gcccacct gg agat caggga ggat gggacg 120 gtggggggcg ct get gacca gagccccgaa agt ct cct gc aget gaaagc ct t gaagccg 180 ggagt t at t c aaat ct t ggg agt caagaca t ccaggt t cc t gt gccagcg gccagat ggg 240 gccct gt at g gat eget cca ct 11 gaccct gaggcct gca get t ccggga get get t ct t 300 gaggacggat acaat gt 11 a ccagt ccgaa gcccacggcc t cccgct gca cct gccaggg 360 aacaagt ccc cacaccggga ccct gcaccc cgaggaccag ct eget t cct gccact acca 420 ggcct gcccc ccgcaccccc ggagccaccc ggaat cct gg ccccccagcc ccccgat gt g 480 ggct cct egg accct ct gag cat ggt ggga cct t cccagg gccgaagccc cagct aeget 540

t cct ga

546

Page 2

2016204968 15 Jul2016

A- 1429- W> PCT_ST25

<210> 4 <211> 181 <212> PRT <213> Homo sapi ens <400> 4 Hi s Pr o lie 1 Pr o Asp 5 Ser Ser Pr o Leu Leu 10 G n Phe Gy Gy G n 15 Val Ar g Q n Ar g Tyr 20 Leu Tyr Thr Asp Asp 25 Al a G n G n Thr G u 30 Al a Hi s Leu 0 u I I e 35 Arg G u Asp Gy Thr 40 Val Gy Gy Al a Al a 45 Asp G n Ser Pro G u Ser 50 Leu Leu G n Leu 55 Lys Al a Leu Lys Pr o 60 Gy Val I I e G n I I e Leu Q y 65 Val Lys Thr 70 Ser Arg Phe Leu Cys 75 G n Arg Pr o Asp Gy 80 Al a Leu Tyr Gy Ser 85 Leu Hi s Phe Asp Pr o 90 G u Al a Cys Ser Phe 95 Arg Q u Leu Leu Leu 100 G u Asp Gy Tyr Asn 105 Val Tyr G n Ser G u 110 Al a Hi s Q y Leu Pr o 115 Leu Hi s Leu Pr o Gy 120 Asn Lys Ser Pr o Hi s 125 Arg Asp Pr o Al a Pr o Ar g 130 Gy Pr o Al a Arg 135 Phe Leu Pr o Leu Pr o 140 Gy Leu Pr o Pr o Al a Pr o Pr o 145 G u Pr o Pr o 150 Gy I I e Leu Al a Pr o 155 G n Pr o Pr o Asp Val 160 Q y Ser Ser Asp Pr o 165 Leu Ser K/fet Val Gy 170 Pr o Ser G n Gy Arg 175 Ser Pro Ser Tyr Al a 180 Ser <210> 5 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> PCR pr i mer <400> 5 aggaggaat a acatatgcat ccaat t ccag at t ct t ct cc Page 3

2016204968 15 Jul2016

A- 1429- V£> PCT_ST25

<21 0> 6 <211> 33 <212> DNA <213> Ar t i f i ci al Sequence <220> <223> PCR pr i rrer <400> 6 t agt gagct c gaat t ct t ag gaagcgt age tgg <210> 7 <211> 41 <212> DNA <213> Ar t i f i ci al Sequence <220> <223> PCR pr i rrer <400> 7 ggagat at ac at at gccaat t ccagat t ct t ct ccat t at t <210> 8 <211> 34 <212> DNA <213> Ar t i f i ci al Sequence <220> <223> PCR pr i rrer <400> 8 cat at gt at a t ct cct t ct t aaagt t aaac aaaa <210> 9 <211> 34 <212> DNA <213> Ar t i f i ci al <220> <223> PCR pr i rrer <400> 9 aaaacaaat t gaaat t ct t c ct ct at at gt at ac <210> 10 <211> 10 <212> PRT <213> Ar t i f i ci al Sequence <220> <223> portion of a mature human FGF21 pol ypept <400> 10 rvfet Hi s Pro lie Pro Asp Ser Ser Pro Leu 1 5 10 <21 0> 11 <211> 63 <212> DNA <213> Ar t i f i ci al Sequence

Page 4

2016204968 15 Jul2016

A- 1429- V£> PCT_ST25 <220>

<223> sense strand from a portion of an FGF21 expression construct <400> 11

1111 gt 11 aa ct 11 aagaag gagat at aca t at goat cca at t ccagat t ct t ct coat t 60 at t 63 <210> 12 <211> 63 <212> DNA <213> Ar t i f i ci al <220>

<223> antisense strand from a portion of an FGF21 expression construct <400> 12 aaaacaaat t gaaat t ct t c ct ct at at gt at acgt aggt t aaggt ct aa gaagaggt aa 60 t aa 63 <210> 13 <211> 227 <212> PRT

<213> Homo sapi ens <400> 13 Asp Lys Thr Hi s Thr Cys Pr o Pr o Cys Pr o Al a Pr o G u Leu Leu Gy 1 5 10 15 G y Pr o Ser Val Phe Leu Phe Pr o Pr o Lys Pr o Lys Asp Thr Leu IVbt 20 25 30 I I e Ser Arg Thr Pr o G u Val Thr Cys Val Val Val Asp Val Ser Hi s 35 40 45 G u Asp Pr o G u Val Lys Phe Asn Tr p Tyr Val Asp Gy Val G u Val 50 55 60 Hi s Asn Al a Lys Thr Lys Pr o Arg G u G u G n Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu Hi s G n Asp Tr p Leu Asn G y 85 90 95 Lys G u Tyr Lys Cys Lys Val Ser Asn Lys Al a Leu Pr o Al a Pr o I I e 100 105 110 G u Lys Thr I I e Ser Lys Al a Lys G y G n Pr o Arg G u Pr o G n Val 115 120 125 Tyr Thr Leu Pr o Pr o Ser Arg Asp G u Leu Thr Lys Asn G n Val Ser 130 135 140 Leu Thr Cys Leu Val Lys G y Phe Tyr Pr o Ser Asp I I e Al a Val G u 145 150 155 160

Page 5

2016204968 15 Jul2016

A- 1429- W> PCT_ST25

Trp Q u Ser Asn Gy 165 G n Pr o Q u Asn Asn 170 Tyr Lys Thr Thr Pr o 175 Pr o Val Leu Asp Ser Asp G y Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Tr p G n G n G y Asn Val Phe Ser Cys Ser Val iyfet 195 200 205 Hi s G u Al a Leu Hi s Asn Hi s Tyr Thr G n Lys Ser Leu Ser Leu Ser

210 215 220

Pro Q y Lys 225 <210> 14 <211> 34 <212> DNA <213> Artificial Sequence <220>

<223> PCR pr i mer <400> 14 aggaggaat a acatatggac aaaact caca cat g 34 <210> 15 <211> 23 <212> DNA <213> Artificial Sequence <220>

<223> PCR pr i mer <400> 15 ggatccacca ccaccgctac cac 23 <210> 16 <211> 39 <212> DNA <213> Artificial Sequence <220>

<223> PCR pr i mer <400> 16 ggt ggt ggt g gat cccat cc aat t ccagat t ct t ct cca 39 <210> 17 <211> 33 <212> DNA <213> Artificial Sequence <220>

<223> PCR pr i mer <400> 17 t agt gagct c gaat t ct t ag gaagcgt age t gg

Page 6

2016204968 15 Jul2016

A- 1429- W> PCT_ST25 <210> 18 <211> 27 <212> DNA <213> Artificial Sequence <220>

<223> PCR pr i mer <400> 18 at ggt ggaac ct t cccaggg ccgaagc 27 <210> 19 <211> 30 <212> DNA <213> Artificial Sequence <220>

<223> PCR pr i mer <400> 19 ggaaggt t cc accat get ca gagggt ccga 30 <210> 20 <211> 50 <212> DNA <213> Artificial Sequence <220>

<223> sense strand from a portion of an FGF21 expression construct <400> 20 ct cct cggac cct ct gagca t ggt gggacc 11 cccagggc cgaagcccca 50 <210> 21 <211> 30 <212> DNA <213> Ar t i f i ci al <220>

<223> PCR pr i mer <400> 21 agcct gggag act cgt acca cct t ggaagg 30

<21 0> 22 <211> 50 <212> DNA <213> ar t i f i ci al <220> <223> antisense strand from a portion of an FGF21 expression construct <400> 22 gaggagcctg ggagactcgt accaccctgg aagggtcccg get t cggggt 50

<210> 23 <211> 15 <212> PRT <213> Ar t i f i ci al Sequence

<220>

Page 7

2016204968 15 Jul2016

A- 1429- V£> PCT_ST25 <223> I i nker sequence <400> 23

Q y Q y Q y Q y Q y Ser G y G y G y Ser GyGyGyGySer 15 10 15 <210> 24 <211> 424 <212> PRT <213> Ar t i f i ci al <220>

<223> Recorrbi nant fusion protein sequence

<400> 24 IVfet 1 Asp Lys Thr Hi s 5 Thr Cys Pr o Pr o Cys 10 Pr o Al a Pr o G u Leu 15 Leu Gy Gy Pr o Ser 20 Val Phe Leu Phe Pr o 25 Pr o Lys Pr o Lys Asp 30 Thr Leu b/bt I I e Ser 35 Arg Thr Pr o G u Val 40 Thr Cys Val Val Val 45 Asp Val Ser Hi s G u 50 Asp Pr o G u Val Lys 55 Phe Asn Tr p Tyr Val 60 Asp Gy Val G u Val 65 Hi s Asn Al a Lys Thr 70 Lys Pr o Arg G u G u 75 G n Tyr Asn Ser Thr 80 Tyr Arg Val Val Ser 85 Val Leu Thr Val Leu 90 Hi s G n Asp Tr p Leu 95 Asn Gy Lys G u Tyr 100 Lys Cys Lys Val Ser 105 Asn Lys Al a Leu Pr o 110 Al a Pr o I I e G u Lys 115 Thr I I e Ser Lys Al a 120 Lys Gy G n Pr o Arg 125 G u Pr o G n Val Tyr 130 Thr Leu Pr o Pr o Ser 135 Arg Asp G u Leu Thr 140 Lys Asn G n Val Ser 145 Leu Thr Cys Leu Val 150 Lys Gy Phe Tyr Pr o 155 Ser Asp I I e Al a Val 160 G u Tr p G u Ser Asn 165 Gy G n Pr o G u Asn 170 Asn Tyr Lys Thr Thr 175 Pr o Pr o Val Leu Asp 180 Ser Asp Gy Ser Phe 185 Phe Leu Tyr Ser Lys 190 Leu Thr Val Asp Lys 195 Ser Arg Tr p G n G n 200 Gy Asn Val Phe Ser 205 Cys Ser Val

Page 8

2016204968 15 Jul2016

A- 1429- W> PCT_ST25

l\/bt Hi s 210 G u Al a Leu Hi s Asn Hi s 215 Tyr Thr Q n Lys Ser 220 Leu Ser Leu Ser Pr o Gy Lys Gy Gy Gy Gy Ser Gy Gy Gy Gy Ser Gy Gy 225 230 235 240 Gy Gy Ser Hi s Pr o I I e Pr o Asp Ser Ser Pr o Leu Leu G n Phe Gy 245 250 255 Gy G n Val Arg G n Arg Tyr Leu Tyr Thr Asp Asp Al a G n G n Thr 260 265 270 G u Al a Hi s Leu G u I I e Arg G u Asp Gy Thr Val Gy Gy Al a Al a 275 280 285 Asp G n Ser Pr o G u Ser Leu Leu G n Leu Lys Al a Leu Lys Pr o Gy 290 295 300 Val I I e G n I I e Leu Gy Val Lys Thr Ser Arg Phe Leu Cys G n Arg 305 310 315 320 Pr o Asp Gy Al a Leu Tyr Gy Ser Leu Hi s Phe Asp Pr o G u Al a Cys 325 330 335 Ser Phe Arg G u Leu Leu Leu G u Asp Gy Tyr Asn Val Tyr G n Ser 340 345 350 G u Al a Hi s Gy Leu Pr o Leu Hi s Leu Pr o Gy Asn Lys Ser Pr o Hi s 355 360 365 Arg Asp Pr o Al a Pr o Arg Gy Pr o Al a Arg Phe Leu Pr o Leu Pr o Gy 370 375 380 Leu Pr o Pr o Al a Pr o Pr o G u Pr o Pr o Gy I I e Leu Al a Pr o G n Pr o 385 390 395 400 Pr o Asp Val Gy Ser Ser Asp Pr o Leu Ser IVfet Val Gy Pr o Ser G n 405 410 415 Gy Arg Ser Pr o Ser Tyr Al a Ser

420

<21 0> 25 <211> 424 <212> PRT <213> Ar t i f i ci al <220> <223> Recorrbi nant fusion protei <400> 25

Page 9

2016204968 15 Jul2016

A- 1429- W> PCT ST25

IVbt 1 Hi s Pr o I I e Pr o 5 Asp Ser Ser Pr o Leu 10 Leu G n Phe Gy Gy 15 G n Val Arg G n Arg 20 Tyr Leu Tyr Thr Asp 25 Asp Al a G n G n Thr 30 G u Al a Hi s Leu G u 35 I I e Arg G u Asp Gy 40 Thr Val Gy Gy Al a 45 Al a Asp G n Ser Pr o 50 G u Ser Leu Leu G n 55 Leu Lys Al a Leu Lys 60 Pr o Gy Val I I e G n 65 I I e Leu Gy Val Lys 70 Thr Ser Arg Phe Leu 75 Cys G n Arg Pr o Asp 80 Gy Al a Leu Tyr Gy 85 Ser Leu Hi s Phe Asp 90 Pr o G u Al a Cys Ser 95 Phe Arg G u Leu Leu 100 Leu G u Asp Gy Tyr 105 Asn Val Tyr G n Ser 110 G u Al a Hi s Gy Leu 115 Pr o Leu Hi s Leu Pr o 120 Gy Asn Lys Ser Pr o 125 Hi s Arg Asp Pr o Al a 130 Pr o Arg Gy Pr o Al a 135 Arg Phe Leu Pr o Leu 140 Pr o Gy Leu Pr o Pr o 145 Al a Pr o Pr o G u Pr o 150 Pr o Gy I I e Leu Al a 155 Pr o G n Pr o Pr o Asp 160 Val Gy Ser Ser Asp 165 Pr o Leu Ser IVfet Val 170 Gy Pr o Ser G n Gy 175 Arg Ser Pr o Ser Tyr 180 Al a Ser Gy Gy Gy 185 Gy Gy Ser Gy Gy 190 Gy Ser Gy Gy Gy 195 Gy Ser Asp Lys Thr 200 Hi s Thr Cys Pr o Pr o 205 Cys Pr o Al a Pr o G u 210 Leu Leu Gy Gy Pr o 215 Ser Val Phe Leu Phe 220 Pr o Pr o Lys Pr o Lys 225 Asp Thr Leu IVbt I I e 230 Ser Arg Thr Pr o G u 235 Val Thr Cys Val Val 240 Val Asp Val Ser Hi s 245 G u Asp Pr o G u Val 250 Lys Phe Asn Tr p Tyr 255 Val Asp Gy Val G u 260 Val Hi s Asn Al a Lys 265 Thr Lys Pr o Arg G u 270 G u G n

Page 10

2016204968 15 Jul2016

A- 1429- W> PCT ST25

Tyr Asn Ser 275 Thr Tyr Arg Val Val 280 Ser Val Leu Thr Val 285 Leu Hi s G n Asp Tr p 290 Leu Asn Gy Lys G u 295 Tyr Lys Cys Lys Val 300 Ser Asn Lys Al a Leu 305 Pr o Al a Pr o I I e G u 310 Lys Thr I I e Ser Lys 315 Al a Lys Gy G n Pr o 320 Arg G u Pr o G n Val 325 Tyr Thr Leu Pr o Pr o 330 Ser Arg Asp G u Leu 335 Thr Lys Asn G n Val 340 Ser Leu Thr Cys Leu 345 Val Lys Gy Phe Tyr 350 Pr o Ser Asp I I e Al a 355 Val G u Tr p G u Ser 360 Asn Gy G n Pr o G u 365 Asn Asn Tyr Lys Thr 370 Thr Pr o Pr o Val Leu 375 Asp Ser Asp Gy Ser 380 Phe Phe Leu Tyr Ser 385 Lys Leu Thr Val Asp 390 Lys Ser Arg Tr p G n 395 G n Gy Asn Val Phe 400 Ser Cys Ser Val IVbt 405 Hi s G u Al a Leu Hi s 410 Asn Hi s Tyr Thr G n 415 Lys Ser Leu Ser Leu 420 Ser Pr o Gy Lys <210> 26 <211> 424

<212> PRT <213> Ar t i f i ci al <220>

<223> Recorrbi nant f usi on pr ot ei n <400> 26 IVbt Asp Lys Thr Hi s Thr Cys Pro Pro Cys Pro Al a Pro Q u Leu Leu 1 5 10 15 G y G y Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 rvbt 11 e Ser Arg Thr Pr o G u Val Thr Cys Val Val Val Asp Val Ser 35 40 45 Hi s G u Asp Pr o Q u Val Lys Phe Asn Trp Tyr Val Asp Q y Val Q u 50 55 60 Val Hi s Asn Al a Lys Thr Lys Pro Arg Qu Qu Qn Tyr Asn Ser Thr 65 70 75 80 Page 11

2016204968 15 Jul2016

A- 1429- W> PCT_ST25

Tyr Arg Val Val Ser 85 Val Leu Thr Val Leu 90 Hi s G n Asp Tr p Leu 95 Asn Gy Lys G u Tyr 100 Lys Cys Lys Val Ser 105 Asn Lys Al a Leu Pr o 110 Al a Pr o I I e G u Lys 115 Thr I I e Ser Lys Al a 120 Lys Gy G n Pr o Arg 125 G u Pr o G n Val Tyr 130 Thr Leu Pr o Pr o Ser 135 Arg Asp G u Leu Thr 140 Lys Asn G n Val Ser 145 Leu Thr Cys Leu Val 150 Lys Gy Phe Tyr Pr o 155 Ser Asp I I e Al a Val 160 G u Tr p G u Ser Asn 165 Gy G n Pr o G u Asn 170 Asn Tyr Lys Thr Thr 175 Pr o Pr o Val Leu Asp 180 Ser Asp Gy Ser Phe 185 Phe Leu Tyr Ser Lys 190 Leu Thr Val Asp Lys 195 Ser Arg Tr p G n G n 200 Gy Asn Val Phe Ser 205 Cys Ser Val IVbt Hi s 210 G u Al a Leu Hi s Asn 215 Hi s Tyr Thr G n Lys 220 Ser Leu Ser Leu Ser 225 Pr o Gy Lys Gy Gy 230 Gy Gy Ser Gy Gy 235 Gy Gy Ser Gy Gy 240 Gy Gy Ser Hi s Pr o 245 I I e Pr o Asp Ser Ser 250 Pr o Leu Leu G n Phe 255 Gy Gy G n Val Arg 260 G n Arg Tyr Leu Tyr 265 Thr Asp Asp Al a G n 270 G n Thr G u Al a Hi s 275 Leu G u I I e Arg G u 280 Asp Gy Thr Val Gy 285 Gy Al a Al a Asp G n 290 Ser Pr o G u Ser Leu 295 Leu G n Leu Lys Al a 300 Leu Lys Pr o Gy Val 305 I I e G n I I e Leu Gy 310 Val Lys Thr Ser Arg 315 Phe Leu Cys G n Arg 320 Pr o Asp Gy Al a Leu 325 Tyr Gy Ser Leu Hi s 330 Phe Asp Pr o G u Al a 335 Cys Ser Phe Arg G u Leu Leu Leu G u Asp Gy Tyr Asn Val Tyr G n Ser

340 345 350

Page 12

2016204968 15 Jul2016

A- 1429- V£> PCT_ST25

G u Al a Hi s 355 Gy Leu Pr o Leu Hi s 360 Leu Pr o Gy Asn Lys 365 Ser Pr o Hi s Arg Asp 370 Pr o Al a Pr o Arg Gy 375 Pr o Al a Arg Phe Leu 380 Pr o Leu Pr o Gy Leu 385 Pr o Pr o Al a Pr o Pr o 390 G u Pr o Pr o Gy I I e 395 Leu Al a Pr o G n Pr o 400 Pr o Asp Val Gy Ser 405 Ser Asp Pr o Leu Ser 410 IVbt Val G u Pr o Ser 415 G n Gy Arg Ser Pr o 420 Ser Tyr Al a Ser <21o> ; <211> ‘ 27 424

<212> PRT <213> Ar t i f i ci al <220>

<223> Recorrbi nant 1 I usi on pr ot ei n <400> : 27 ITfet Asp Lys Thr Hi s Thr Cys Pr o Pr o Cys Pr o Al a Pr o G u Leu Leu 1 5 10 15 Gy Gy Pr o Ser Val Phe Leu Phe Pr o Pr o Lys Pr o Lys Asp Thr Leu 20 25 30 IVbt I I e Ser Arg Thr Pr o G u Val Thr Cys Val Val Val Asp Val Ser 35 40 45 Hi s G u Asp Pr o G u Val Lys Phe Asn Tr p Tyr Val Asp Gy Val G u 50 55 60 Val Hi s Asn Al a Lys Thr Lys Pr o Arg G u G u G n Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu Hi s G n Asp Tr p Leu Asn 85 90 95 Gy Lys G u Tyr Lys Cys Lys Val Ser Asn Lys Al a Leu Pr o Al a Pr o 100 105 110 I I e G u Lys Thr I I e Ser Lys Al a Lys Gy G n Pr o Arg G u Pr o G n 115 120 125 Val Tyr Thr Leu Pr o Pr o Ser Arg Asp G u Leu Thr Lys Asn G n Val 130 135 140

Page 13

2016204968 15 Jul2016

A- 1429- W> PCT ST25

Ser 145 Leu Thr Cys Leu Val 150 Lys Gy Phe Tyr Pro Ser 155 Asp I I e Al a Val 160 G u Tr p G u Ser Asn Gy G n Pr o G u Asn Asn Tyr Lys Thr Thr Pr o 165 170 175 Pr o Val Leu Asp Ser Asp Gy Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Tr p G n G n Gy Asn Val Phe Ser Cys Ser Val 195 200 205 IVbt Hi s G u Al a Leu Hi s Asn Hi s Tyr Thr G n Lys Ser Leu Ser Leu 210 215 220 Ser Pr o Gy Lys Gy Gy Gy Gy Ser Gy Gy Gy Gy Ser Gy Gy 225 230 235 240 Gy Gy Ser Hi s Pr o I I e Pr o Asp Ser Ser Pr o Leu Leu G n Phe Gy 245 250 255 Gy G n Val Arg G n Arg Tyr Leu Tyr Thr Asp Asp Al a G n G n Thr 260 265 270 G u Al a Hi s Leu G u I I e Arg G u Asp Gy Thr Val Gy Gy Al a Al a 275 280 285 Asp G n Ser Pr o G u Ser Leu Leu G n Leu Lys Al a Leu Lys Pr o Gy 290 295 300 Val I I e G n I I e Leu Gy Val Lys Thr Ser Arg Phe Leu Cys G n Arg 305 310 315 320 Pr o Asp Gy Al a Leu Tyr Gy Ser Leu Hi s Phe Asp Pr o G u Al a Cys 325 330 335 Ser Phe Arg G u Leu Leu Leu G u Asp Gy Tyr Asn Val Tyr G n Ser 340 345 350 G u Al a Hi s Gy Leu Pr o Leu Hi s Leu Pr o Gy Asn Lys Ser Pr o Hi s 355 360 365 Arg Asp Pr o Al a Pr o Arg Gy Pr o Al a Arg Phe Leu Pr o Leu Pr o Gy 370 375 380 Leu Pr o Pr o Al a Pr o Pr o G u Pr o Pr o Gy I I e Leu Al a Pr o G n Pr o 385 390 395 400 Pr o Asp Val Gy Ser Ser Asp Pr o Leu Ser IVbt Val Gy Al a Ser G n

405 410 415

Page 14

2016204968 15 Jul2016

A- 1429- W> PCT_ST25

Gy Arg Ser Pro Ser Tyr Ala Ser 420 <210> 28 <211> 424 <212> PRT <213> Ar t i f i ci al <220>

<223> Recorrbi nant fusion protein

<400> 28 iyfet 1 Asp Lys Thr Hi s 5 Thr Cys Pr o Pr o Cys 10 Pr o Al a Pr o G u Leu 15 Leu Gy Gy Pr o Ser 20 Val Phe Leu Phe Pr o 25 Pr o Lys Pr o Lys Asp 30 Thr Leu iybt I I e Ser 35 Arg Thr Pr o G u Val 40 Thr Cys Val Val Val 45 Asp Val Ser Hi s G u 50 Asp Pr o G u Val Lys 55 Phe Asn Tr p Tyr Val 60 Asp Gy Val G u Val 65 Hi s Asn Al a Lys Thr 70 Lys Pr o Arg G u G u 75 G n Tyr Asn Ser Thr 80 Tyr Arg Val Val Ser 85 Val Leu Thr Val Leu 90 Hi s G n Asp Tr p Leu 95 Asn Gy Lys G u Tyr 100 Lys Cys Lys Val Ser 105 Asn Lys Al a Leu Pr o 110 Al a Pr o I I e G u Lys 115 Thr I I e Ser Lys Al a 120 Lys Gy G n Pr o Arg 125 G u Pr o G n Val Tyr 130 Thr Leu Pr o Pr o Ser 135 Arg Asp G u Leu Thr 140 Lys Asn G n Val Ser 145 Leu Thr Cys Leu Val 150 Lys Gy Phe Tyr Pr o 155 Ser Asp I I e Al a Val 160 G u Tr p G u Ser Asn 165 Gy G n Pr o G u Asn 170 Asn Tyr Lys Thr Thr 175 Pr o Pr o Val Leu Asp 180 Ser Asp Gy Ser Phe 185 Phe Leu Tyr Ser Lys 190 Leu Thr Val Asp Lys 195 Ser Arg Tr p G n G n 200 Gy Asn Val Phe Ser 205 Cys Ser Val IVbt Hi s 210 G u Al a Leu Hi s Asn 215 Hi s Tyr Thr G n Lys 220 Ser Leu Ser Leu

Page 15

2016204968 15 Jul2016

A- 1429- W> PCT_ST25

Ser Pr o Gy Lys Gy Gy Gy Gy Ser Gy Gy Gy Gy Ser Gy Gy 225 230 235 240 Gy Gy Ser Hi s Pr o I I e Pr o Asp Ser Ser Pr o Leu Leu G n Phe Gy 245 250 255 Gy G n Val Arg G n Arg Tyr Leu Tyr Thr Asp Asp Al a G n G n Thr 260 265 270 G u Al a Hi s Leu G u I I e Arg G u Asp Gy Thr Val Gy Gy Al a Al a 275 280 285 Asp G n Ser Pr o G u Ser Leu Leu G n Leu Lys Al a Leu Lys Pr o Gy 290 295 300 Val I I e G n I I e Leu Gy Val Lys Thr Ser Arg Phe Leu Cys G n Arg 305 310 315 320 Pr o Asp Gy Al a Leu Tyr Gy Ser Leu Hi s Phe Asp Pr o G u Al a Cys 325 330 335 Ser Phe Arg G u Leu Leu Leu G u Asp Gy Tyr Asn Val Tyr G n Ser 340 345 350 G u Al a Hi s Gy Leu Pr o Leu Hi s Leu Pr o Gy Asn Lys Ser Pr o Hi s 355 360 365 Arg Asp Pr o Al a Pr o Arg Gy Pr o Al a Arg Phe Leu Pr o Leu Pr o Gy 370 375 380 Leu Pr o Pr o Al a Pr o Pr o G u Pr o Pr o Gy I I e Leu Al a Pr o G n Pr o 385 390 395 400 Pr o Asp Val Gy Ser Ser Asp Pr o Leu Ser IVbt Val Gy Pr o Leu G n 405 410 415 Gy Arg Ser Pr o Ser Tyr Al a Ser 420 <210> 29 <211 > 4

<212> PRT <213> Ar t i f i ci al <220>

<223> I i nker <400> 29 G y G y 1 G y G y

Page 16

2016204968 15 Jul2016 <210> 30 <211> 5 <212> PRT <213> Ar t i f i ci al <220>

<223> I i nker <400> 30

Gy Gy Gy Gy Gy 1 5

A- 1429- V£> PCT_ST25 <210> 31 <211> 15 <212> PRT <213> Ar t i f i ci al <220>

<223> I i nker <400> 31

GyGyGyGySer GyGyGyGySer GyGyGyGySer 15 10 15 <210> 32 <211> 8 <212> PRT <213> Ar t i f i ci al <220>

<223> I i nker <400> 32

Gy Gy Gy Lys Gy Gy Gy Gy 1 5 <210> 33 <211> 8 <212> PRT <213> Ar t i f i ci al <220>

<223> I i nker <400> 33

Gy Gy Gy Asn Gy Ser Q y Q y 1 5 <210> 34 <211> 8 <212> PRT <213> Ar t i f i ci al <220>

<223> I i nker <400> 34

Gy Gy Gy Cys Gy Gy Gy Gy 1 5

Page 17

2016204968 15 Jul2016 <210> 35 <211> 5 <212> PRT <213> Ar t i f i ci al <220>

<223> I i nker <400> 35

Q y Pro Asn Gly Q y 1 5 <210> 36 <211> 424 <212> PRT <213> Ar t i f i ci al

A- 1429- V£> PCT_ST25 <220>

<223> recorrbinant fusion protein

<400> 36 IVfet Asp Lys Thr Hi s Thr Cys Pr o Pr o Cys Pr o Al a Pr o G u Leu Leu 1 5 10 15 Gy Gy Pr o Ser Val Phe Leu Phe Pr o Pr o Lys Pr o Lys Asp Thr Leu 20 25 30 b/bt I I e Ser Arg Thr Pr o G u Val Thr Cys Val Val Val Asp Val Ser 35 40 45 Hi s G u Asp Pr o G u Val Lys Phe Asn Tr p Tyr Val Asp Gy Val G u 50 55 60 Val Hi s Asn Al a Lys Thr Lys Pr o Arg G u G u G n Tyr Asn Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu Hi s G n Asp Tr p Leu Asn 85 90 95 Gy Lys G u Tyr Lys Cys Lys Val Ser Asn Lys Al a Leu Pr o Al a Pr o 100 105 110 I I e G u Lys Thr I I e Ser Lys Al a Lys Gy G n Pr o Arg G u Pr o G n 115 120 125 Val Tyr Thr Leu Pr o Pr o Ser Arg Asp G u Leu Thr Lys Asn G n Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gy Phe Tyr Pr o Ser Asp I I e Al a Val 145 150 155 160 G u Tr p G u Ser Asn Gy G n Pr o G u Asn Asn Tyr Lys Thr Thr Pr o 165 170 175

Page 18

2016204968 15 Jul2016

A- 1429- W> PCT_ST25

Pr o Val Leu Asp 180 Ser Asp Q y Ser Phe Phe 185 Leu Tyr Ser Lys 190 Leu Thr Val Asp Lys Ser Arg Tr p G n G n Gy Asn Val Phe Ser Cys Ser Val 195 200 205 IVbt Hi s G u Al a Leu Hi s Asn Hi s Tyr Thr G n Lys Ser Leu Ser Leu 210 215 220 Ser Pr o Gy Lys Gy Gy Gy Gy Ser Gy Gy Gy Gy Ser Gy Gy 225 230 235 240 Gy Gy Ser Hi s Pr o I I e Pr o Asp Ser Ser Pr o Leu Leu G n Phe Gy 245 250 255 Gy G n Val Arg G n Arg Tyr Leu Tyr Thr Asp Asp Al a G n G n Thr 260 265 270 G u Al a Hi s Leu G u I I e Arg G u Asp Gy Thr Val Gy Gy Al a Al a 275 280 285 Asp G n Ser Pr o G u Ser Leu Leu G n Leu Lys Al a Leu Lys Pr o Gy 290 295 300 Val I I e G n I I e Leu Gy Val Lys Thr Ser Arg Phe Leu Cys G n Arg 305 310 315 320 Pr o Asp Gy Al a Leu Tyr Gy Ser Leu Hi s Phe Asp Pr o G u Al a Cys 325 330 335 Ser Phe Arg G u Arg Leu Leu G u Asp Gy Tyr Asn Val Tyr G n Ser 340 345 350 G u Al a Hi s Gy Leu Pr o Leu Hi s Leu Pr o Gy Asn Lys Ser Pr o Hi s 355 360 365 Arg Asp Pr o Al a Pr o Arg Gy Pr o Al a Arg Phe Leu Pr o Leu Pr o Gy 370 375 380 Leu Pr o Pr o Al a Pr o Pr o G u Pr o Pr o Gy I I e Leu Al a Pr o G n Pr o 385 390 395 400 Pr o Asp Val Gy Ser Ser Asp Pr o Leu Ser IVbt Val Gy Gy Ser G n 405 410 415 Gy Arg Ser Pr o Ser Tyr Al a Ser

<210> 37 <211> 1274

420

Page 19

2016204968 15 Jul2016 <212> DNA <213> Ar t i f i ci al <220>

<223> recorrbiant fusion protein <400> 37

A- 1429- W> PCT_ST25

at ggacaaaa ct cacacat g t ccacct t gt ccagct ccgg aact cct ggg gggaccgt ca 60 gt ct t cct ct t ccccccaaa acccaaggac accct cat ga t ct cccgt ac ccct gaggt c 120 acat gcgt gg t ggt ggacgt gagccacgaa gaccct gagg t caagt t caa ct ggt aegt g 180 gacggcgt gg aggt gcat aa t gccaagaca aagccgcgt g aggagcagt a caacagcacg 240 t accgt gt gg t cagcgt cct caccgt cct g caccaggact gget gaat gg caaggagt ac 300 aagt gcaagg t ct ccaacaa agccct ccca gcccccat eg agaaaaccat ct ccaaagcc 360 aaagggcagc cccgagaacc acaggt gt ac accct gcccc cat cccgt ga t gaget gacc 420 aagaaccagg t cagcct gac ct gcct ggt c aaagget t ct at cccagcga cat egeegt g 480 gagt gggaga gcaat gggca gccggagaac aact acaaga ccacgcct cc cgt get ggac 540 t ccgacggct cct t ct t cct ct acagcaag ct caccgt gg acaagagccg 11 ggcagcag 600 gggaacgt ct t ct cat get c cgt gat gcat gagget ct gc acaaccact a cacgcagaag 660 agcct ct ccc t gt ct ccggg t aaaggt gga ggt ggt ggt t ctggtggtgg t ageggt ggt 720 ggt ggat ccc at ccaat t cc agat t ct t ct ccat t at t ac aat t cggggg ccaagt ccgg 780 cagcggt acc t ct acacaga t gat gcccag cagacagaag cccacct gga gat cagggag 840 gat gggacgg tggggggcgc t get gaccag agccccgaaa gt ct cct gca get gaaagee 900 11 gaagccgg gagt t at t ca aat ct t ggga gt caagacat ccaggt t cct gt gccagcgg 960 ccagat gggg ccct gt at gg at eget ccac 111 gaccct g aggcct gcag ct t ccgggag 1020 cgt ct t ct t g aggaeggat a caat gt 11 ac cagt ccgaag cccacggcct cccgct gcac 1080 ct gccaggga acaagt cccc acaccgggac cct gcacccc gaggaccagc t eget t cct g 1140 ccact accag gcct gccccc cgcacccccg gagccacccg gaat cct ggc cccccagccc 1200 cccgat gt gg get cct egga ccct ct gage at ggt gggag gt t cccaggg ccgaagcccc 1260 agct acgct t cct a 1274

Page 20